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ABSTRACT 
ACUTE ENDOMYOCARDIAL DISEASE IN INFANTS AND CHILDREN. 
The relationship between acute myocarditis and 
endocardial fibroelastosis. 
This prospective study of acute myocarditis (AM) and endocardial fibroelastosis 
(EFE) was prompted by their common occurrence in infants and children in Cape 
Town, and by the persisting controversy regarding the possible relationship of 
these two conditions to each other, and to idiopathic, chronic, congestive 
cardiomyopathy (COCM). Patients with AM and EFE were analysed concurrently 
and over the long-term. 
The following hypotheses were investigated: 
A) that AM and EFE represent different phases of a common disease process, and 
B) that either AM or EFE evolves into COCM. 
From 1st June 1970 to 31st December 1976 (a study period of 6 years 7 months), 
140 consecutive patients with AM or EFE were evaluated, and continually observed 
until 31st March 1979 (a total observation period of 8 years 10 months). Be-
cause there is no definitive, non-invasive, in-vivo diagnostic test for AM or 
EFE, an inclusive diagnosis of acute endomyocardial disease (EMD) was made in 
123 patients who fulfilled all 4 rigid clinical criteria, i.e. a short history 
(< l month), clinical evidence of myocardial involvement (heart failure, gallop 
rhythm or shock), radiological cardiomegaly (CTR > 0.55), and ST/T wave changes 
on electrocardiogram (ECG). Acute EMD was confirmed in all 20 patients who 
came to autopsy. A further 17 patients with insufficient clinical data had 
EMD at post-mortem. 
In the clinical seri.es, patients were separated into AM or EFE categories 
\ VI 
according to the absence or presence of LVH on ECG CSVl and/ or RV6 > normal for 
age). Classification depended on LVH status on admission (92 patients without, 
31 with LVH) ; at any stage of the course (71 without, 52 with) ; or at the end 
of the study-p~riod or death, i.e. terminally (96 without, 27 with). These 
LVH negative and positive groups were compared statistically in terms of patient 
data, epide~iological factors, clinical presentation (mode of onset, · symptoms 
and signs), results of investigations (haematological, biochemical, radiological, 
electrocardiographic, enzymatic arid virological), natural history, mortality and 
pathological findings. 
The following results were observed. 
Both AM and EFE occurred predominantly in Cape coloured patients. Patients 
with EFE were ·younger (mean age !sEM of 12!2.7 months) than those with AM 
+ 
-(22-2. 6 months), p< 0. 05. 
. . . 
Epidemiologically, AM manifested seasonal peaks in winter/spring, whereas 
EFE was non-seasonal, but relatively more common in the ensuing summer months. 
A marked rise in incidence of EFE occurred in early 1974 following a minor 
epidemic of AM in 1973, and concurrent with an increased conversion rate from 
LVH negative to LVH positive status(21 instances throughout the study). 
Symptoms, predominantly respiratory, were in keeping with a viral infection, 
and were remarkably similar in AM and EFE. 
Sigµs of heart failure were more common in AM. This included tachycardia 
(p<0.05), elevated JVP (p<0.01), oedema (p<0.025) and two or more features 
~ 
(p<0.025). Conversely, radiological cardiomegaly· on admission was more marked 
in EFE (p<0.005).· Gallop rhythm was equally prevalent in both conditions, 
and severe shock almost exclusive to AM. Grunting respiration occurred mainly 
in EFE (p<0.05) ·,and CNS abnormalities due to shock and/or viraemia predominantly . 
in AM (p<0,05). 
VII . 
Routine investigations revealed more severe anaemia in AM (p<0.025), and 
evidence of renal involvement - uraemia (31%) and urinary abnormalities (11%) -
in both conditions. Evidence of concurrent (viral) infection was equally 
prevalent in AM and EFE. 
Detailed review of ECG's on admission and throughout the course, revealed 
similar incidences in AM and EFE of arrhythmias (11%), conduction abnormalities 
(19%), left (21%) and · right (34%) axis deviation, P wave abnormalities (69%) and 
pathological Q waves (16%) and infarct patterns~ ST segment depression and deep 
T wave inversion were more frequent in EFE, in keeping with severe LVH. 
Serum lactate dehydrogenase (LDH) and hydroxybutyrate dehydrogenase (HBDH) 
levels were initially higher in AM (means of 1157!147 and 678!114 u/L) than in 
EFE (850!128 and ~99!128 u/1), but differences were not significant. Serum 
creatine kinase (CPK) elevation was less frequent. 
progressively towards normal levels over 3 weeks. 
All 3 enzymes decreased 
The yield of virus by direct culture and serology (31% of patients tested) 
was similar in both conditions. Enteroviruses occurred almost exclusively in 
AM, whereas a wide range of viruses was detected in both AM and EFE. 
Overall mortality was similar in both conditions over the long-term, though 
AM patients ran a more fulminant course in the first month, as exemplified by 
actuarial survival rates at 48 hours, 1 month, 3 months and 1 year of 86%, 79%, 
757. and 71% respectively in AM, and 96%, 89%, ·697. and 63% in EFE patients. 
Incidence of readmissions was greater in EFE than AM (p<0.05). 
Of the 123 patients with clinical EMD, 40 (32%) died - all during the first 
13 months, 61 (50%) recovered completely, and 22 (18%) have residual clinical, 
radiological or electrocardiographic abnormalities (including patients lost to 
follow-up). After observation of all parameters for at least 1 year, only 
11 (9%) have residua, and all are improving. 
and EFE. 
This outcome was similar in AM 
VIII 
Autopsy data in 37 patients revealed features of AM in 22, of EFE in 7, 
and of both coexisting in 8, with a histological gradation from extensive 
inflammatory cell infiltration and gross myocardial cell destruction in 
patients with severe AM, through milder inflammation and myocardial cell 
degeneration in ~hose with AM+EFE, to occasional degenerative changes only 
in patients with EFE. Viral pneumonitis and bronchiolitis (78%) and lymphoid 
hyperreaction (76%) were equally prevalent in AM and EFE. Despite the paucity 
of confirmed cases at autopsy (15), the incidence of pathological EFE was 
significantly greater in LVH positive patients, preterminally, than in LVH 
negative patients. (p< 0.05). 
These findings favoured the concept that AM and EFE are phases of a common 
disease process. Both conditions were prevalent in socio-economically deprived 
communities, were related epidemiologically, and simulated each other in 
symptomatology, clinical manifestations, evidence of infection, cardiac size 
and ECG abnormalities - at presentation and throughout the course - serum enzyme 
responses, yield of viruses, mortality rate and natural history; and pathological 
features coexisted in over 20%. 
Most significant differences favoured a bimodal form of presenii.tion, with 
AM being an immediate, often fulminating, expression of a concurrent (causative) 
viral infection, and EFE a delayed manifestation of a previous sub-clinical 
infection, often made clinically apparent by a subsequent (precipitating) viral 
infection. Differences in degree of anaemia and frequency of grunting res-
piration were probably age-related, as was the special propensity of young infants 
to develop EFE. Although largely circumstantial, this evidence strongly 
supports Hypothesis A. Serial endomyocardial biopsy would be required to prove 
the dynamic nature of EFE. 
IX 
By contrast, Hypothesis Bis rejected because of the very favourable long-
term outcome for both AM and EFE, after the high mortality rate in the first 
year. Complete resolution occurred in most survivors, and not a single 
patient evolved into COCM. 
Although AM is a coIIllilon precursor of EFE, it is speculated that many other 
conditions can provoke the fibroelastotic response, pre- or post-natally, 
through the mechanism of severe dilatation and high mural tension in rela-
tively thin-walled (mainly left-sided) cardiac chambers. 
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CHAPTER 1. 
INTRODUCTION. 
During the late 1960's, the author noted a relatively high incidence of acute 
myocarditis (AM) and endocardial fibroelastosis (EFE) in Cape Town. As re-
166, 195,225,430 . . . · · h ported by others, , the clinical manifestations int e acute 
/' 
phase and the response to therapy in these two conditions were remarkably 
similar and suggested a common disease process. 
A possible relationship between AM and EFE has been a vexed question since 
these conditions were first described in 1899 148 and 1740 447 respectively. 
1 . . 11 d b . d · 1 · f · 43 , A though AM itself is genera y accepte as eing ue to vira in ection, 
197, 187, 457, 528 h . l f . . l 157. d d t e aetio ogy o EFE remains controversia an suggeste 
467 
causes abound. Yet it appears that AM and EFE have not been evaluated 
together, prospectively and simultaneously, in a comprehensive clinical, 
natural history and pathological study over the lon&-term. 
These factors prompted this prospective study of 140 consecutive patients 
with AM and EFE, i.e. acute onset endomyocardial disease (EMD), presenting 
to the wards of the Department of Paediatrics and Child Health, University 
of Cape Town, from June 1970 to December 1976, and observed until March 1979. 
2 
The study was designed to test the foll~wing hypotheses, 
(i) that AM and EFE represent different phases of the same disease 
process, and 
(ii) that eit~er AM or EFE evolves into so-called idiopathic chroni~ 
congestive cardiomyopathy (COCM) in children. 
These aims were investigated by a detailed comparison of patients with clinical 
AM and EFE, in terms of 
(i) patient data, 
(ii) epidemiological factors, 
(iii) clinical presentation, i.e. mode of onset, symptomatology and signs, 
(iv) results of investigations, i.e. radiological~ electrocardiographic, 
enzymatic and virological, 
(v) the natural history, and 
(vi) pathological findings. 
It was anticipated that similarities and differences would thus be identified 
and that the relationship, if any, between AM and EFE would be clarified. It 
was also reasoned that a long-term follow-up of almost 9 years would permit an 
assessment of the significance, if any, of AM and EFE in the aetiology of COCM. 
Although not the primary purpose of the study, it was expected that these 
investigations would furnish additional information regarding the racial inci-
dence, socio-economic milieu, age and sex distribution, clinical course, 
radiological, electrocardiographic and enzymatic changes with time, incidence 
and type of viral infections, prognosis, mortality rate, and cardiac and non-
cardiac pathology, in both AM and EFE in Cape Town. 
., 
CHAPTER 2. 
HISTORICAL REVIEW OF THE LITERATURE 
Acute myocarditis (AM) and endocardial fibroelastosis (EFE) have been regarded 
as distinctive entities by most authorities. They are discussed in separate 
h d . . . b d. . d. 1 293 ' c apters by ifferent authors in maJor text oaks on pae iatric car io ogy 
379, 549 . . . 166, 195, 255, 225, 467 d. 
and, with few exceptions, reported as isparate 
conditions in the medical literature. AM and EFE are thus reviewed independent-
ly in this section. 
1. ACUTE MYOCARDITIS 
The different terms used for this condition from the first description by 
Fiedler in 1899 148 until the present 563 exemplify the confusion and doubt 
regarding its aetiology. Most authors have agreed that the histological 
features reflect an acute event, 94 • 123 • 148 , 194 • 218 , 235 , 229 , 471 though 
subacute 334 and chronic varieties 287 have been reported. Other terms have 
been purely descriptive, i.e. "interstitial" to describe the presence of in-
fl 11 b h f .b 23, 163, 148, 194, 248, 229, 345, 336, annnatory ce s etween t e myo ires, 
519
• 
524 
"diffuse" to emphasise its distribution throughout the myocardium, 5o, 
248, 524 ~ 
though the pathology is frequently patchy and focal, and "isolated" 
4 
. 50, 
to denote inflammation in the heart only, and not in other organs or tissues, 
6 142 94, 89, 123, 218, 235, 266, 471, 461,551, 5 3 also referred to as "primary". 
"Pernicious" myocq.rditis 54 appears to represent a condition in adults with a 
more prolonged course, and "giant-cell" myocarditis is a different entity. 
514
, 
563 h · d rt; ·d;opa· th;c", 
334
' 
564 or "non-spec;f;c1155 Other authors have emp asise the LL L LL 
9 
nature of the disease, or the "non-bacterial, aseptic" aetiology. 
More recently, however, there has been widespread acceptance that the 
d;sease · 11 · 1 · . . 187, 457,
 528, 562, 558, 43, 197 
L is usua y vira in origin, even 
though isolation of the virus and a cause-and-effect relationship have been 
164 163, 310, 43 difficult to confirm. ' Experimental -induction of myocarditis 
225 303 
has been achieved with the Coxsackievirus postnatally, but not prenatally. 
Myocarditis has been identified as part of generalised acute viral infectious 
diseases, 149, 365, 338, 411, 416, 441, 457, 462, 542, 524, 171 and EGG ab-
normalities have been demonstrated in as many as 10 to 337. of patients with 
common childhood infections. 443 , 47 o, 5l6, 553 A wide range of viruses 
h b . 1 · d . h . f . 1 416, 425 b 11 as een imp icate int e causation o AM, e.g. in meas es, rue a, 
10, 11, 160 38, 434 . . l . 152, 240, 428, 552 
mumps, infectious mononuc eosis, . 
. 11 112, 147, 210, 373, 374 1· 1· . 237, 267, 391, 520 
varice a, po iomye itis, 
;nfect;ous h . . 108, 462 . fl 3, 88, 150, 411, · 399 b" 83, 442 
L L epatitis, in uenza, ra ies, 
and . . 261, 542 . h 3
6, 85, 280, 316, 355, 371, 360, 464, 449 
psittacosis; in ec o-, 
d 233 l 569, 73 b 398 h . l 
576, 558 
a eno-, cytomega o-, ar or-, erpes simp ex and 
. . . l 175 . . f . d · .. 11 452, 304 respiratory syncitia virus in ections; an post-vaccinia y. 
The likelihood of developing myocarditis in these situations appears to 
1 . h h . f h · f · 
391 corre ate wit t e severity o t e in ection. 
The coxsackie viruses, mainly group B, appear to be particularly cardio-
5 
. . . . . . . 60, 230, 262, 372, 386, 501, tropic and have been incriminated in epidemics 
534, 171, 283, 506, 482 d .· d" 35, 69, llO, 155, 196, 186, 
an in spora ic cases, 
219, 246, 224, 280, 309, 396, 420, 339, 486, 542, 570, 575, 197, 485, 454, 
507 . h h ,t b . . · . . 60, llO, 170, 168, 262, 258, 
wit t e neonate eing highly susceptible. 
279, 277, 372, 386, 435, 527, 534, 171, 283, 506, 482 (Further examples 
in infants and children are referred to in the paper by Burch et al. 69 ) 
Apart from viruses, virtually every infective agent has been identified 
as a cause of acute myocarditis, including bacteria, fungi, Rickettsia, 
· h d . 187, 222, 461, 558 
spiroc etes an parasites. 
It has been suggested that myocardial cells may be destroyed in the 
457 initial infectious phase , or be sensitised, with signs of cardiac in-
volvement occurring after a latent period of 7 to 10 days following auto-
209, 547, 558 482 immunisation, the so-called "infectious-allergic" mechanism. ' 
366, 418 
69 In routine autopsies in children under 4 years, Burch et al detected 
histological evidence of myocarditis in 587. and antibodies to coxsackie B 
viruses by immunofluorescent techniques in 24% ; the latter method yielded 
positive results in 50% of children aged 1 month to 15 years~ 68 This 
suggests that viral myocarditis (and valvulitis) are more common than 
previously recognised. 
Comment 
For purposes of this study, AM refers to cases of sporadic or non-
epidemic myocarditis with an acute-onse_t, characteristic clinical picture, 
and typical pathology (where possible) of diffuse, patchy or focal, inter-
6 
stitial and peri-vascular, mononuclear, inflannnatory cell infiltration. 
2. ENDOCARDIAL FIBROELASTOSIS 
Endocardial fibroe.lastosis was first described by Lancusi in· 1740 (quoted by 
Rossi 447 ) and by Morgagni in 1765, 375 but remains a'n enigma to pathologists 
/ 
d 1 . . . 1·k 157 an c 1n1c1ans a 1 e. 
2.1 TERMINOLOGY 
As with AM, EFE has been reported under a multiplicity of titles, i.e. 
"foetal endocarditis" by Kreysig in 1816 
292 (quoted by Gross in 1941 203 and 
b h 295, 416, 555, 177 . 1 cardi· ac 
h h 41, 228, 359, 557, 
y ot ers, congenita ypertrop y, 
469 idiopathic cardiac hypertrophy, 41, 99, 295, 317, 359, 423, $44, 557, 
177, 502 d d. l f.b . en ocar 1a 1 rosis, 34 idiopathic hypertrophy with endocardial 
fibrosis, 259 ' 335 elastic tissue hyp~rplasia of endocardium, 
459 diffuse 
d d . 1 h 0 k . 326 d d
0 1 h 1 . 422 d d d 0 1 en ocar 1a t 1c ening, en ocar 1a yperp asia, . an en ocar 1a 
sclerosis. 95, 93, 124, 242, 543,52, 53 
Endocardial fibroelastosis, the term generally accepted today, was 
introduced by Weinberg and Hinnnelfarb in 1943. 
555 In 1956, Andersen and 
Kelly. 16, 274 . d d h f . d d f 
f intro uce t e concept o primary an secon ary arms o EFE 
for those without and with other congenital cardiac anomalies. This was 
d b h 417, 572 b . d b . l . supporte y some aut ors ut reJecte y many as imp ying unproven 
· 1 · l · .f. · · 49, 48,28, 165, 367, 368 aet10 ogica s1gn1 1cance. The differentiation 
into contracted and dilated forms has also proved unhelpful, since the 
former is rare without associated congenital obstructive anomalies of the 
1 f h 115, 137 . f d·1 
274, 476 
et eart, is o ten non- 1 ated rather than contracted, 
. 226 521 
and has a totally different clinical presentation. ' 
7 
2.2 AETIOLOGY AND PATHOGENESIS 
The aetioiogy and pathogenesis of EFE 159 ' 308 remains "in a state of 
467 
utter confusion as reflected in innumerable past and present hypotheses". 
(a) Inherited, ~amilial, congenital. 
· . 307 (of di"zyg' ous 274, 422, 532, 342 Several reports of EFE 1n both twins 
d 166, 191, 174, 306, 501 .. ) . h 1 an monozygous or1g1n, 1n t e monozygous pair on y 
in the case of triplets, 523 and in a parent and child, 39o' 559 ' 369 
suggested an inherited disorder. However, others reported EFE 1n only 
160 "f 84, 275, 376 
one of twins, even 1 monozygous. 
Fam1·11·a1 EFE has b d d f 1 253 (" 26, 49, 84, 121, 125, een recor e requent y 1n two, . 
139, 159, 239, 415, 439, 429, 426, 483, 476, 554, 572, · 583 h 244, 468, 84, 
· tree, 
390 d · "bl" 351 ) h 11 . "d . "bl" . f an six s1 1ngs , t e overa 1nc1 ence 1n s1 1ngs varying ram 
"negligible" 467 to 47. 9f 120 cases 125 and 87. of 119 families. 
1 . d 1 · k d . 323 . h . d · Autosoma recessive an X- 1n e recessive 1n er1tance an genetic 
. 567 306 340 532 572 heterogeneity ' ' ' ' have been proposed, but the familial 
pattern does not generally coincide with these or with multifactorial modes 
f . h . 84 o ::..n er1tance. 
A congenital factor causing endocardial (and myocardial) elastin hyper-
1 . 48, 113, 203, 367, 332, 422, 33 l"f . 118, 424 endocardi"al p as1a or pro 1 erat1on, or 
. 95 93 128 
sclerosis, ' ' has been suggested, but there is little supportive 
evidence for this. 99 EFE in association with congenital metabolic defects 
274 has been recorded in isolated cases only, e.g. with . 117 189 glycogenos1s, ' ' 
234, 450, 447, 536, 568 l . . 145 d ·1 . - 96 
euc1nos1s, an ep1 01a. Congenital non-cardiac 
174 239 572, 583 defects have been observed, ' ' but there has been no increased 
. 
incidence· of associated anomalies,in patients with EFE or 1n their siblings. 84 ,27 4 
8 
Hence, although an inherited disorder appears unlikely, a non-genetic 
prenatal factor cannot be excluded. 
(b) Mechanical and haemodynamic. 
The association of EFE with congenital cardiac an0malies has prompted 
various mechanical and haemodynamic theories. Increased intra--cavitary 
pressure or stagnation due to mechanical obstruction to outflow, mainly 
158 159 114 
of the left heart, ' was proposed by Dewitski in 1912 and 
supported by others, 49 , 48 • 28 • 78 • 118 ' 135 • 
459 but these same anomalies 
are usually found without EFE, 63 • 76 , 408 , 4
47 
and EFE also occurs in 
. . . . 
. 78, 166, 165, 214 
association with decompressing ventricular septal defects. 
368 
Coexisting mitral incompetence has been assigned a causative role, but 
is usually considered to be secondary to EFE. Hypoxia of the endocardium 
49, 59 , 164 , 245 , 263 , 343 , 440 following limitation of flow of relatively 
well oxygenated blood has been incriminated, especially in the left heart 
37 129 214 348 
following premature closure of the patent foramen ovale. ' ' ' ' 
532 But most patients do not have a closed foramen ovale, and none of these 
theories account for cases of EFE extending into the right atrium and/or 
. l 48, 95, 116, 126, 164, 165, 214, 239, 259, 297, 301 . . 
ventric e or being iso-
lated to the right heart. 49, 113, · 159, 214, 239, 447 
The mechanical stimuli known to produce focal EFE, such as the jet effect 130 
or lift effect (due to changes in blood velocity 226 • 354 ) do not apply in 
most cases, but chamber distention with increased eridocardial (mural or wall) 
. 72 · . . · 249 329 65 
tension and consequent elastic tissue proliferation ' ' would be a 
mechanism common to most of the above situations. 
48
• 
255
, 
254 (see pagel81 ) . 
• (c) Myo~ardial ischaemia. 
Myocardial ischaemia has been implicated by the presence of EFE in isolated 
9 
1 212, 393, cases of anomalous left coronary artery from the pu monary artery, 
456
, 
581 d f d · d d · 1 · f · in chi" ldren. 545 an . o coronary isease an myocar ia in a_rction 
Furthermore, the myocardial lesion of EFE resembles the bland infarct in 
adults. 203, 254 A recent report suggests that coronary insufficiency . 
. h 0 d d 137 h . . ff" . 0 d f may cause rig t si e EFE, butt ere is insu icient evi ence o coronary 
involvement in left sided EFE. 
(d) Other theories. 
Interference with lymph drainage of the heart was shown experimentally 
to result in EFE. 288 , 362 This has not been demonstrated in humans but 
b d ff f h . d. . 288, 362 may ea secon ary e ect o c ronic myocar itis. 
272 Other poorly substantiated theories include hyperoxia, collagen 
238 151 251 disease, transfer. of maternal toxins or antibodies, and status 
thymo-lymphaticus. 82 
-(e) Myocardi tis 
During recent years, interest in the historic theory of foetal endocarditis 
148, 203, 292, 427, 571 d d" . 276 h b · d h h the an myocar itis as een revive . t roug out 
world. 5, 136, 166, 164, 165, 173, · 170, 248, 220, 260, 410, 414, 501, 500, 550 
Supportive evidence has come from clinical and pathological studies. The 
clinical cou~se and evolution of the ECG in EFE has been claimed to be in-
distinguishable from AM in many cases. 195 , 226 , 225 Coexistence of histo-
logical features of acute or chronic inflammation and EFE has been demonstrated 
· .. . 166 
at post-mortem by Fruhling et al in almost all their 28 cases studied 
h . 1 . 11 . 41 f 64 b h' d . 255 20% f 106 isto ogica y, in o cases y Hutc ins an Vie, in • o cases 
in Ontario and approximately half of 729 cases collected from the literature 
by Sh and K h ' 467 d. h 43, 132, 126, 140, 248, c rye~ arnauc ow, an in ot er reports. 
259, 336, 349, 529, 466, 512 Similar pathological features were noted in the 
10 
II , k 394, 490 
naturally occurring cardi?myopathy, "round heart disease , in tur eys. 
These findings tend to negate earlier rejection of this theory on the grounds 
' ff' . 'd f ' fl . 4 , 203 , 439 h h fai'l t of insu icient evi ence o in ammation, t oug o prove a 
1 . . 325, 390 prenata origin. Recent evidence, demonstrating the physical 
132 
fusion of the endocardial and myocardial process and the presence of 
126 · 
myocardial scarring subjace~t to the EFE, confirmed the close relationship 
between the myocardial and endocardial elements of the disease. 
(£) Viral infection 
According to Hastreiter and Fisher, 
226 
a viral aetiology is supported by 
h h . 'b' . f b 1 h . · · f · 
498 
t e igh suscepti ility o em ryona eart tissue to virus in ection, 
h . 1 . . . . 13 f 28 . f . h 
166 h 
t e iso ation of coxsackie B viruses in o in ants wit EFE, t e 
widespread acceptance of the viral origin of AM, 
372 the experimental pro-
duction of EFE in animals by inoculation with viruses, 
67
, 
496 
and the 
correlation of EFE with coxsackie B epidemics. 
41
, 
46
, 
166
, 
5oi, 5oo The 
367 
latter was also noted by Mitchell et al in a review of 199 cases from 
54 reports in the literature (including many referred to above, and others . 
296, 268, 289, 270, 312, 356, 518, 499, 582, 207, 188, 154, 179, 503). Viral 
infections in pregnancy have been implicated in the aetiology of congenital 
h d . · 67, 62, 42, 98
, 143,227, 311, 504, 566 1 . 'd eart isease, and a seasona inci ence 
of EFE has been reported. 
80 
The viral theory has been rejected on the grounds that only one of twins 
or triplets may be .affected; 
241
' 
5oo that there is no consistent association 
between the incidence of maternal antibodies to coxsackieviruses, or of viral 
infections in the pregnant mother, and EFE her child; 
367 
and that neither in 
congenital anomalies no~ EFE could be induced in the progeny 
198, 303 
of preg-
nant animals experimentally infected with coxsackieviruses. 
.11 
Counter-arguments assert that all cases of AM are unlikely to lead to 
EFE, 387 , 4o9 , 447 and that a short· interval between onset of AM and death 
may preclude the evolution of EFE. 44 
., 
(g) Mumps virus 
h 1 f · h . l 380 Tero e o mµmps virus in uman EFE remains controversia. Noren 
et al demonstrated a high inc_idence of skin reactivity to the mumps antigen 
. h. ld . h 3 92 b h k. . . 1 1 . b 1 24 7 inc i ren wit EFE, ut t es in test is notorious y unre ia e 
172, 352 
and these results were not confirmed by others. Some investigators 
did find a higher than normal rate of skin test positivity in patients, but 
· h 1 · f · d · h "b d" 'n maternal 3
92
' wit out materna mumps in ection an wit out mumps anti o ies. 
492 . I 392, 476, 481, 541 
or patients sera. These results raised the possi-
b · 1 · f . . h k. 4
81 f d. . . h d . i ity o cross-reactivity totes in·test, or o iminis e responsive-
f h f h 
. 180 
ness d t e oetus tote antigen. Nonetheless, a mumps virus aetiology 
was supported by several authors, 492 ' 481 • 493 , 541 and in 1971, St. Geme 
et al 495 experimentally produced mumps virus embryopathy in the chick, with 
disappearance of signs of inflammation one week after delivery and persistence 
of neutralising antibodies for a year, at which stage pathological EFE was 
identified in 4 of 5 chicks. 496 • 497 In the human, however, no instance 
of EFE was found in the off-spring of 18 mothers with mumps infection in 
( . h . ) 291 1 h . pregnancy wit sere-conversion, or in severa ot er prospective 
studies, 201 , 243 , 478 • 561 • 560 though other cardiac anomalies were ob-
45 
served in one instance. Furthermore, there is no relationship of EFE 
. h 1 1 . 84 1 f to mumps int e genera popu ation, there are on y scanty reports o 
d . h . . h 1 · 79 ' 434 d . f . h d mumps car iopat yin t e iterature, an one in ant wit EFE an a 
1 h . f h d . . k. 84 materna istory o mumps a a ·negative sin test. 
(h) Immunological mechanism 
The above factors suggested the existence of a non-autoimmune, delayed 
\ 
. 12 
. . . h . 494 . . h 11 . t hypersensitivity mec anism operating e!t er as an a ergic response o 
. . 297, 302, 457 b 1 . · · · · h EFE b · current infection or year ier sensitization, wit eing 
. . . . f . 99 precipitated by subsequent minor in ections. The hypersensitivity 
mechanism has been' opposed because of the lack of similar lesions in other 
467 
endothelial or mesenchymal structures. 
(i) Idiopathic 
• 11• • • II 441, 463, Other authors believe that the etiology remains idiopathic , 
563 
or that EFE is a "non-specific structural change rather than a disease 
• II 96 
entity. 
Comment 
For purposes of this study, EFE refers to cases of the so-called dilated 
variety, without evidence of congenital cardiac anomalies, manifesting post-
natally with a short history, characteristic clinical and electrocardiographic 
criteria, and with typic.al pathological features (where possible) of endo-
cardial thickening due to excessive fibrous and elastic tissue. 
3. THE RELATIONSHIP OF AM/EFE AND IDIOPATHIC CONGESTIVE CARDIOMYOPATHY. 
Like AM and EFE, chronic cardiomyopathy has been the subject of much con-
fusion and debate, as is evident from terms previously used to describe this 
. . . . . 
d. . 287 . . . 
condition, e.g. chronic pernicious myocar itis, idiopathic myocardial 
hypertrophy, 489 idiopathic cardiomegaly, 315
 
and obscure cardiopathy. 138 
Most authors agree that myocardial disease in adults 397 , 
421 
and children 
164 195 222 * · · 
' ' can be separated into an idiopathic (or primary) group if the 
* etymologically i r:orrect usage: "primary" myocardial disease should mean 
originating in the myocardium, whether the disease remains localised or not 
and whether the cause is known or not. 
\ 13 
aetiology is unknown and a secondary group for those with a recognised cause. 
The idiopathic group has been classified by Goodwin into hypertrophic 
· · c bl. . ) d . d. h. 184, 185, 182, restrictive o iterative an congestive car iomyopat ies. 
183, 181 The rote of AM or EFE in the evolution of the latter, i.e. 
idiopathic, chronic, congestive cardiomyopathy (COCM) remains conjectural. 
Under the umbrella term "primary myocardial disease of infants and 
children", Freundlich et al 164 402 106 . . and others ' included patients with 
a common clinical picture, i.e. congestive failure, cardiac enlargement, 
absence of significant murmurs, myocardial damage on ECG, and no primary 
disease elsewhere. However, this approach led to AM and EFE being in-
eluded in this grouping together with entities of known cause, e.g. glycogen 
storage disease, anomalous left coronary artery from pulmonary artery, medial 
· ' f . 440 d 1 . f. . f . necrosis o coronary arteries, an ca ci ication o coronary arteries, 
22 · 302 
-and with idiopathic myocardial hypertrophy. ' More recently, Harris 
d h · 222 · 1 d d . 1 d. . . h d d E an Ng iem inc u e vira myocar itis int e secon ary group, an EF 
together with idiopathic (or non-obstructive) cardiomyopathy in the primary 
group. Greenwood et al 195 classified AM in the secondary group if known 
to be viral, and in the primary g~oup if idiopathic, together with EFE and 
non-obstructive cardiomyopathy (isolated or familial). 
classification of AM and EFE remains confused. 
Hence, the precise 
In the copious literature on cardiomyopathy in adults, EFE receives scant 
attention, except to be included in the category of COCM 250 , 256 , 401 or 
"systolic pump failure". 397 Viral myocarditis, however, was suggested as 
a cause of COCM by Corvisant in 1811 92 (quoted by Somerville 488) ·and is 
· d d b f · 1 · l · . 45 7, 488, 513, consi ere to e o aet~o ogica importance in some cases. 
298, 310, 366, 70, ~6, 199 Histological "mark-bodies" 58 and virus·-like 
14 
particles 2?6 have been described in hearts of patients with COCM: An 
immunological reaction has beenin..vokec:L as the likely pathogenetic mechanism, 
71, 70, 56, 102, 208, 271, 403, 402, 305 b h' · · 11 ut tis is not universa y suppor-
d 77, 156 te. 
., 
Permanent myocardial injury has been demonstrated~ months after coxsackie-
567 
virus myocarditis in laboratory mice. However, in the long-term follow-
up of patients with AM, although 30% showed signs of cardiac involvement 
(mostly sub-clinical), no patient with progressive hypertrophy or dilatation 
.d .f. d 40, 453, 39 
was i enti ie . In a symposium on cardiomyopathy in 1972, 
several discussants mentioned the rarity of the transi~ion of myocarditis 
to myopathy (noted again recently by Waterson),
548 
and Olsen described 
404 
differences in the distribution of fibrosis in these two conditions. 
57, 472 
In South Africa COCM is a common form of heart disease, accounting 
for 62% of cardiomyopathy 
31 
and 37.5% of heart disease in urban Bantu adults.
32 
The literature on COCM in children is sparse. The condition was first 
d 'b · · · · 
. 14 491 
escri ed in children in this country bv Stein and colleagues in 1956, • and 
b 1 . h USA 269, 221 d l
 h 154, 20, 100, 122; 516, 257, 169 
su sequent yin t e an e sew ere. 
· d k 222 • 223 d' 'bl · 1 · f h'ldh d coc Harris an co-war ers iscuss possi e aetio ogies o c i oo M, . 
436 437 . 75 
including infective agents, ' magnesium and potassium deficiency, 
. f 30 l . . 176 h 222 genetic actors, ma nutrition, and ot ers. 
Comment 
In order to observe the possible evolution of acute endomyocardial 
, 225 
disease (EMD), i.e. the AM/EFE syndrome, into idiopathic, chronic, con-
gestive cardiomyopathy (COCM), patients with long-standing or established 
15 
heart muscle disease were excluded from this study at presentation as far 
as possible. Also excluded from consideration were patients with hyper-
trophic cardiomyopathy (idiopathic hypertrophic sub aortic stenosis or 
asymmetric septa! hypertrophy) and endomyocardial fibrosis (EMF) which is 
. . 19 90 104 105 127 479 522 . 400 
common in Central Africa, ' ' ' ' ' ' occurs in North 
d S th Af , 32 S h E A . 86, 103, 455, 535, 299, 384 J 
401, 
an ou rica, out ast sia, · apan 
578 d S h Am . 18, 91, 141, 205, an out erica, 
31 · America, and also in Cape Town. 
144 
and is rare in Europe and 
., 
CHAPTER 3. 
CASE SELECTION 
1. METHODS 
1.1 CLINICAL, RADIOLOGICAL AND ELECTROCARDIOGRAPHIC 
B~cause there is no definitive, non-invasive, pre-mortem diagnostic test 
for AM or EFE, the in-vivo diagnosis of either condition depends entirely 
on non-specific clinical, radiological and electrocardiographic features. 
For this reason, the diagnostic criteria laid down for inclusion of patients 
in this study were made stringent and strictly applied, in similar fashion 
to the Jones's criteria for acute rheumatic fever. 
It has been claimed that there is considerable clinical overlap between 
AM and EFE, with no definitive way of differentiating the two conditions 
195
• 
430 short of d d. 1 b. 195, 226, 255 en omyocar ia iopsy. Other authors believe that 
the clinical presentation of EFE is characteristic and distinctive, 
113
• 
322
• 
352 h h . l d d l d. h. LVH 164, 222, 302, 368, 353, t oug main y epen ent one ectrocar iograp ic 
538 
and earlier onset. 368 • 339 In this study, th·e same criteria were used 
for both conditions on fhe assumption that they reflected two phases of one 
disease process. The patients were then divided on the basis of electro-
cardiographic LVH for comparative purposes. 
17 
Overdiagnosis is a major problem, especially in patients without LVH on 
ECG, and in infants and young children - the age-group most susceptible to 
both AM and EFE . For instance, congestive heart failure may be simulated 
. by primary respiratory disease, such as pneumonia or bronchiolitis. These 
patients present with tachypnoea, tachycardia due to pyrexia, hypoxia or 
respiratory failure, and apparent hepatomegaly from depression of the liver 
edge by excessive ventilatory excursion. The chest x-ray and ECG, however, 
would show cardiac normality in these circumstances. 
Cardiac failure without significant cardiac murmurs may be caused or 
simulated by volume overloading in acute glomerulonephritis, the nephrotic 
syndrome, or nutritional oedema, or by severe anaemia. · However, the ECG 
is usually normal, though associated electrolyte disturbances may produce 
T wave .changes, and LVH alone may occur in longstanding chronic anaemia. 
On ECG, non-specific T wave changes may occur with electrolyte disorders, 
. f . · 508, 509 d " 510, 511 1 . · 111, 510 . 285 i.e. o potassium, so ium, ca cium, and magnesium, 
and with metabolic acidosis or alkalosis, 333 , 43 i, 5io, 511 hypothermia, 511 
h . 511 d d h d . 510 h . ypoxia an e y ration, but the eart is usually normal in other 
respects. On chest x-ray, pseudocardiomegaly may be due to thymic enlarge-
ment in infants, elevated diaphragms from ascites or visceral organomegaly, 
or to x-rays being exposed during expiration - a common event in crying 
children. 
To avoid false positive diagnoses, patients were admitted to the study 
only if there was evidence of cardiac involvement at all three levels of 
assessment, i.e. clinical, radiological and electrocardiographic. It is 
common cause that this would exclude patients with milder degrees of acute 
18 
myocarditis and preclude an accurate estimate of incidence, but a firm 
diagnosis of AM was considered essential to validate the comparison between 
AM and EFE. 
1.2 OTHER INVESTIGATIONS 
There appear to be no reports 1n the literature regarding the value of 
serum enzymes in differentiating AM and EFE. Serum lactate dehydrogenase 
(LDH), hydroxybutyrate dehydrogenase (HBDH) and creatinine kinase (CPK) 
values were measured in this study to investigate this possibility. 
Haemodynamic and angiocardiographic findings in EFE have been comprehen-
. l d 12, 15, 4, 27, 190, 195, 226, 302, 294, 329, 321, 353, 368, 
s1ve y reporte , 
352 , 532 , 363 , 539 , 533 are non-specific, and do not discriminate between 
EFE d .. 195, 226 and d" h 182, 183,
216,419,580 
, myocar 1t1s car 1omyopat y. 
Furthermore, these results do not influence therapy, which is identical 1n 
AM and EFE anyway. 226, 225, 339 An invasive procedure like cardiac 
I 
catheterisation was therefore considered unjustified in our patients unless 
195 226, 476 
anomalous left coronary artery from the pulmonary artery ' or 
other specific entities were suspected on clinical grounds. 
h 1 f d d . lb" 61, 290
, 344, 474, 405, 406, 407, 480 
Tero e o en omyocar 1a 1opsy 
in establishing the precise histological diagnosis in acute endornyocardial 
disease in children is still highly contentious 146 ~ 167 , l9S, 226, 330, 331 
(see page 182 ) • Because histological diagnosis confers no therapeutic 
advantage, and patients with EFE and especially AM are prone to arrythrnias 
and sudden demise, endomyocardial biopsy was not undertaken in this study. 
The value of echocardiography, a non-i~vasive technique, was not widely 
recognised in paediatric practice when this study commenced in 1970. This 
., 19 
procedure should be helpful in monitoring cardiac function over the long-term 
but was considered incapable of differentiating AM from EFE. However, a 
recent report indicates that the thickened endocardium of EFE can be demon-
579 
strated by both conventional and two-dimensional echocardiography. 
Th . 1 f . . h l.. • d . 505 ere is on y one report o scintigrap y ~eing use in EFE. 
2. DIAGNOSTIC CRITERIA - next page. 
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2. DIAGNOSTIC CRITERIA 
Based on the above considerations the following diagnostic criteria were 
regarded as essential for entry of a patient into the study: 
., 
· · Clinical 
i) A short history, 
ii) + clinical signs of significant myocardial involvement, i.e. any one 
of the following, 
a) elevated heart rate in the absence of fever, 
b) obvious cardiomegaly on palpation, 
c) systemic or pulmonary venous congestion, 
d) obvious gallop rhythm, or 
e) cardiogenic shock, 
iii) + ST/T wave changes on ECG, with or without LVH, · 
iv) + cardiomegaly on chest x-ray. 
Autopsy 
Pathological features of either AM or EFE in patients with insufficient 
clinical data. 
2.1 SHORT HISTORY 
The duration of symptoms was limited in order to exclude patients with long-
standing disease or congestive cardiomyopathy. However, in view of the concept 
that certain cases of acute rnyocarditis may develop as an autoimmune process 
k f h . . . l . l .· f . 120, 
297, 325, 457 . d f 
wees a ter t e initia vira in ection, a perio o up to 
one month was acce~ted. 
2.2 CLINICAL SIGNS 
a) Elevated heart rate: A heart rate greater than the 95th percentile for 
b) 
c) 
d) 
e) 
21 
age was considered excessive, using values modified from the normal 
. 319 ( . ) 
ranges reported by Liebman and Plonsey see Key to Appendix D . 
Cardiomegaly on examination: This was considered positive when the 
left ventricular apex was displaced laterally aqd/"or downwards from 
the normal position for age. Because radiological cardiomegaly may 
be simulated by pseudocardiomegaly (see page 152 ) or pericardial 
effusion, clinical cardiomegaly is a significant pointer to true 
cardiac enlargement and was therefore included as a separate sign. 
Systemic or pulmonary venous congestion: Because of the difficulties 
in detection and interpretation of these signs in small children, left 
and right sided decompensation were combined into a single sign, which 
was considered positive if 
(i) two of the following features were present; 
oedema, 
elevated JVP, 
hepar>2 ems below the costal margin at the mid-
clavicular level, 
crepitations in one or .both lung fields (or diffuse 
wheeze),or 
(ii) the hepar was >3 ems below the costal margin. 
Gallop rhythm: A physiological 3rd heart sound is common in young 
children, especially with tachycardia. A pathological gallop rhythm 
was diagnosed if the diastolic sound was a prominent feature, i.e. of 
equal or greater intensity than the 1st and 2nd heart sounds, and coastant, 
i.e. not disappearing during expiration. 
Cardiogenic shock was diagnosed if 
(i) there was obvious circufatory collapse, with absent pulses, 
22 
unrecordable blood pressure, and poor heart beat, or 
(ii) peripheral vasoconstriction with thready pulses, low BP, 
generalised pallor and clammy, cold skin. 
2.3 ECG CHANGES 
T wave flattening (< 1 mm) or inversion (to any depth) in leads VS and V6 
and/or significant ST segment elevation or depression in any leads were re-
garded as essential features. 
(i) T wave alterations in VS and V6: 
Definite 
Suggestive 
any combination of inverted, flattened or biphasic T waves 
in both leads. 
normal in VS and inverted, flattened or biphasic in V6, 
inverted, flattened or biphasic in VS, and normal in V6. 
(ii) Significant ST segment alterations in children have been defined as 
follows, though original data has not been pre~ented in any of these 
references. 
"Elevation or depression of ST segment of greater than 1. S mm are 
383 probably pathologic" 
"(Normal) ST segment change is rarely greater than 1 mm and never 
greater than 2 mm in standard leads ; may be greater than 4 mm in 
· ht d · 1 leads" 273 rig praecor ia 
"Elevation or depression of ST segment ·of greater than 2 mm in any 
293 lead is always abnormal" 
"ST segment change greater than 1 mm in limb leads unusual ; 2 mm 
change within normal limits in left chest leads and even 3 mm change 
may be seen in lead V4" 44o 
Criteria used in this study were: 
. 
ST segment elevation or depression, 
a) greater than 2 mm in the standard leads and/or 3 ·mm in the chest 
23 
l~ads, in an otherwise normal ECG, or 
b) greater· than 1 mm associated with a coved ST-T wave segment, 
and/or greater than 2 mm in the chest leads, in the presence 
of othe~ ECG abnormalities (e.g. T wave changes). 
(iii) . . . . . . 222, 368, In view of the importance of LVH in differentiating AM from EFE, 
476 
voltage criteria for LVH were distilled from several sources which are referred 
to in Table 2.1. 
The values used for LVH in this study were, 
for RV6 under 1 month >20 mm, 
1 to under 6 months >- 25 mm, 
6 months to 12 years 7 30 mm, 
for SVl 0 t'o under 6 months > 20 mm, 
6 months to 12 years )'- 25 mm. 
These values are more stringent than the 20 mm limit for RV6 and SVl accepted 
by Sellers et al 476 for under 2 year olds and by Hastreiter and Fisher 
226 for 
all ages. Other criteria for LVH, such as the R/S ratio in Vl, left axis de-
viation, size of Q wave in lead V6, QRS-T vector angle, ST-T wave depression, 
intrinsicoid deflection, and o~her voltage changes, were omitted from considera-
tion because of lack of agreement regarding their validity or levels of signifi-
cance, or because they conflicted with the indices of myocardial involvement in 
this study (see Chapter 9). 
2.4 RADIOLOGICAL CARDIOMEGALY 
This was considered an essential criterion because . the chest x-ray affords 
an objective, reliable and easily measured parameter of cardiac enlargement. 
For inclusion into the study, a cardio-thoracic ratio (maximum transverse 
diameter of the heart : , diameter of the chest at the height of the diaphragms) 
of greater than 0.55 was considered positive. Because the normal cardio-
I AGE 319+ 
' 
' months 
I 0 to <..1 22 I 
0 to <3 25 
3 to <6 26 
6 to <.9 28 
6 to <12 
9 to< 24 30 
years 
1 to< 3 
2 to (6 28 
3 to <.6 
6 to 12 33 
AGE 
l 319+ 
TABLE 2.1. Voltage criteria for LVH 1n leads Vl and V6 
extracted from literature, and values used in present 
study (final column). 
RV6 (mm) 
REFERENCE NUMBER · 
206d, 385° 13+ 383° 81° 293° 
I 
. 
21 20 
25 
20 
24 
-
30 30 35 
30 
24 
28 
33 
SVl (mm) 
REFERENCE NUMBER 
206d, - 13+ 383° 81° 293° 
· months 
I 
i 
! 
' 
I 
0 to< 1 15 20 
1 to< 3 22 18 
3 to<6 17 
6 to< 9 30 
6 to< 12 16 
9 to< 24 
years 
1 to< 3 25 27 
2 
3 
6 
to< 6 
to< 6 30 
to 12 36 26 
+ - maximum normal values 
di - upper . limits of nor~al 
o - recommended values for hypertrophy 
23 
20 
25 20 
22 1; 
25 
25 
27 
Study 
20 
25 
30 
Study 
20 
25 
I 
25 
thoracic ratio is somewhat larger in infants than older children, and because 
films were not always exposed during inspiration, a more stringent requirement 
was set than the usual 0.50 ratio. 93 
2.5 PATHOLOGY 
The criteria for inclusion of patients in the autopsy series are defined 
and detailed in Chapter 13. 
Comment 
These diagnostic criteria are similar to those recommended in the literature. 
223 The clinical diagnosis of overt AM depends mainly on acute-onset .and signs 
43 
of heart failure, radiological cardiomegaly, or ST-T changes on ECG. These 
features plus LVH "with strain" 476 ' 352 are required for the diagnosis of EFE, 
. 1 d. h f h d 2 476 · bl inc u ingot er actors sue as onset un er years, no or varia e murmurs 
f . l 352 d/ . o mitra an or aortic 476 valve involvement, and the . exclusion of other 
specific conditions such as rheumatic carditis, glycogen storage disease, anoma-
lous origin of the left coronary artery and acute myocarditis. 352 Only Green-
wood et al have recommended common criteria for so-called primary myocardial 
disease in children (AM, EFE ~ non-obstructive cardiomyopathy), including 
195 
radiological cardiomegaly, ST-T changes and no murmurs louder than grade 3/6 • 
• 
{. 
\ 
CHAPTER 4. 
PATIENT MATERIAL. 
A total of 140 patients was prospectively admitted to the study from 1st 
June 1970 to 31st December 1976, a period of 6 years 7 months. The presence 
or absence of diagnostic criteria for each patient is indicated in Appendix A, 
together with the initials; race, sex and date of presentation in each case. 
The patients are numbered consecutively in order of increasing age at presen-
tation within each of the following groups. 
number for the entire study. 
Each case retains this index 
1. CLASSIFICATION TOTAL SERIES. 
A CLINICAL SERIES 
123 patients complying with the clinical diagnostic criteria, and sub-divided into 
GROUP 1 
GROUP 2 
92 patients with ST-T wave changes, but no LVH on ECG, and 
31 patients with ST-T wave change~ plus LVH on ECG, and 
B AUTOPSY SERIES 
17 patients with insufficient data for inclusion into section A, but with autopsy-
confirmed AM or EFE, and divided into 
GROUP 3 
GROUP 4 
13 patients with acute-onset (comparable with Groups 1 and 2 
,.n this respect), and 
4 patients with a long history. 
(: 
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1.1 COMPLIANCE WITH DIAGNOSTIC CRITERIA 
The 17 patient& in Groups 3 and 4 were included on the basis of post~mortem 
findings. Of the li3 patients in the clinical seri~s (Groups 1 and 2), all but 
7 complied with the strict criteria of short history, ST-T wave changes on ECG, 
cardiomegaly on chest x-ray, plus 1 or more clinical signs of cardiac involvement 
(Table 4.1). Each of these 7 patients failed to comply with one criterion only, 
but were included in the study for the reasons mentioned below. 
(i) Patient no. 9 did not have ST-T wave changes on ECG, but presented 
with frequent episodes of supraventricular tachycardia, and AM was proved 
at autopsy. 
(ii) Patient no. 111 had LVH on ECG at presentation but no ST-T wave changes. 
However, the latter appeared on a subsequent ECG 12 days later, and both 
features persisted till his death 5 weeks later. (No post-mortem was 
performed). 
(iii) Patient no. 117 presented wi~hout ST-T wave changes but with evidence 
of biventricular hypertrophy on ECG (Katz-Wachtel phenomenon), which 
persisted till her death 10 weeks later. 
were demonstrated at autopsy. 
Features of both AM and EFE 
(iv) Patient no. 39 died within hours of admission before a chest x-ray 
was performed, but gross cardiomegaly was observed at autopsy, which 
also confirmed AM. Because all other criteria were met, this patient 
was included in clinical Group 1 rather than in autopsy Group 3. 
(v) Patient no. 95 presented with a characteristic ECG (LVH with T wave 
inversion in leads VS and V6) which persisted for 3 years, cardio-
megaly on x-ray, and a 2 cm hepatomegaly, but with no obvious 
clinical cardiomegaly or evidence of heart failure. However, one 
day after admission, a gallop rhythm and signs of cardiac decompen-
sation appeared. 
In the following two patients the long-term course favoured a diagnosis of AM 
TABLE 4.1 Patient Compliance with diagnostic criteria - clinical series. 
Number of patients with (Group 1) and without (Group 2) LVH on ECG. 
NO. OF PATIENTS 
DIAGNOSTIC GROUP l GROUP 2 TOTAL 
CRITERION (92) (31) (123) 
ECG 91 29 120 
RADIOLOGICAL 91 31 122 
CLINICAL 92 28 120 
1 sign 8 4 12 
2 signs 22 4 26 
3 signs 25 11 36 
4 signs 28 9 37 
5 signs 9 0 9 
· Total number of patients in each group appears in parentheses. 
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or EFE, and they were therefore included · in the clinical series (Group 2). 
(vi) Patient no. 98 presented with LVH and T-wave inversion on ECG 
and radiological cardiomegaly, but with no features of heart 
failure except for pulmonary crepitations (without pneumonia· ; 
on chest x-ray). Although the ECG change~ resolved within 
12 days of admission, the radiological cardiomegaly persisted 
for over 3 years. 
(vii) Patient no. 103 presented without clinical signs of cardiac 
involvement but with radiological cardiomegaly and LVH and 
T-wave changes on ECG which persisted for over 10 months. 
2. CLASSIFICATION CLINICAL SERIES. 
2.1 THE NEED FOR FURTHER CLASSIFICATION 
In reviewing the evolutionary changes in the ECG's of patients entered into 
the clinical series, it became apparent that the use of LVH on admission to 
identify EFE as distinct from AM may be erroneous. As many as 32 of the 123 
patients (26%) changed status at a later stage from LVH positive to LVH 
negative or visa versa (detailed in Appendix D). 
The proponents of the view that LVH is equated with EFE do not point out 
whether· the LVH must be present on admission or terminally, or whether 
LVH must be a constant feature throughout the course of the illness, or may 
fluctuate in its presence or degree of severity at different times. Indeed, 
the variation of the ECG with time is a major argument in this study for the 
proposal that AM and EFE are inter-related (see Chapter 14 ). 
So as to enable ~omparison of LVH negative patients (Group 1) with LVH 
30 
positive patients (Group 2) in this .study, it was decided to allocate 
. I 
patients to these two groups accordini to 
course, 
the timing of LVH in each patient's 
pre ent 
I 
i.e. whether LVH was absent or 
(i) on admission (Groups lA and 
(ii) at any stage of the course, 
2A respectively), 
i~c luding at the onset, during or at the 
end, and whether intermittently or continually (Groups lC and 2C), or 
(iii) at the end of the study period or at death, whether LVH was present 
before this or not, i.e. terminally (Groups lT and 2T). 
The patients were categorised at the end of the study period 
(31st December, 1976). 
2.2 RESULTS 
Figure 4.1 indicates the number of patients changing status and the resultant 
numbers in each group 
appears in Table 4.2. 
the complete ~ist of all patients in each category 
Of the 92 patients allocated to Group 1 according to the ECG on admission 
(Group lA), 71 remained in category 1 (without LVH) throughout the duration 
of the study, i.e. lA-+lC-+lT. 
In like manner, 20 of the 31 patients in Group 2 on admission (Group 2A) 
remained in category 2 (with LVH on EC) throughout the study period, i.e. 
2A-.2C~2T. 
The remaining 32 patients (21+11) c anged status after admission, as follows: 
15 patients started without LVH n admission (lA), developed LVH 
subsequently (2C), but lost the VH prior to the end of the study . 
e GROUP NUMBER 
- WITHOUT LVH ON ECG 
+ WITH LVH ON ECG 
•1A 
•1T 71-
2Ao 
11- 20+ 2C e 
FIG. 4.1 Patient grouping - Clinical sen.es. Number of patients in 
each group according to absence (Group 1) or presence (Group 2) of LVH 
on ECG on admission (lA and 2A), at any time during the course (lC and 2C), 
and at the end of the study or death, i.e. terminally (lT and 2T). 
-TABLE 4.2 CLASSIFICATION - CLINICAL SERIES. 
Index numbers of patients allocated to Group 1 or Group 2 according to the 
absence pr presence of LVH on ECG at different stages of the illness, i.e. 
Groups lA and 2A - on admission, 
lC and 2C - at any stage during the patient's course, 
lT and 2T - at the end of the study, or death (terminally). 
. 
., 
INDEX NUMBERS OF PATIENTS IN EACH GROUP 
lA 2A lC 2C lT 2T 
(92) (31) (71) (52) (96) (27) 
I 32 63 93 I 32 63 93 I 32 63 93 
2 33 64 94 2 64 33 94 2 33 64 94 
3 34 65 95 3 34 65 95 3 34 65 95 
4 35 66 96 35 66 4 96 35 66 4 96 
5 36 67 97 5 36 67 97 5 36 67 97 
6 37 68 98 6 37 68 98 6 37 68 98 
7 38 69 99 7 38 69 99 7 38 69 99 
8 39 70 100 8 39 70 - . I 00 8 39 70 100 
9 40 71 I 01 40 71 9 IO I ·9 40 71 IOI 
10 41 72 102 10 41 72 102 10 41 72 102 
11 42 73 103 11 42 73 103 11 42 73 103 
12 43 74 10~ 43 74 12 104 12 43 74 104 
13 44 75 105 13 44 75 105 13 44 75 105 
14 45 76 106 14 76 45 106 14 45 76 106 
15- 46 77 107 15 77 46 107 15 46 77 107 
16 47 78 108 16 78 47 108 16 78 47 
17 48 79 109 17 48 79 109 17 48 79 109 
18 49 80 110 80 18 49 110 80 18 49 110 
' 19 50 81 111 19 50 81 111 19 50 81 111 20 51 82 112 20 51 82 112 20 51 82 112 
21 52 83 113 21 52 83 113 21 52 83 113 
22 53 84 114 53 84 22 114 22 53 84 114 
23 54 85 115 23 54 85 115 23 85 115 54 
24 55 86 116 24 55 86 . 116 24 55 86 116 
25 56 87 117 25 56 87 117 25 56 87 117 
26 57 88 118 26 57 88 118 26 57 88 118 
27 58 89 119 27 89 58 119 27 89 58 119 
28 59 90 120 28 59 90 120 28 59 90 120 
29 60 91 121 29 60 91 121 29 60 91 121 
30 61 92 122 . 30 92 61 122 30 61 92 122 
31 62 123 31 62 123 31 62 123 
Total number of patients . in each group appears in parentheses. 
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period or death (lT), 
i.e. lA~2C~lT (Patient no's 5, 9, 12, 22, 23, 33, 36, 45, 46, 58, 
61, 67, 85, 87, 91). 
6 patients started without LVH at presentation (lA), developed LVH 
during the course (2C), which persisted till the end of the study 
period or death (2T), 
i.e. lA~2C~lT (Patient no's 4, 18, 47, 49, 54, 62). 
11 patients started with LVH (2A and 2C) which resolved prior to the 
end of the study period (iT), 
i.e. 2A-+2C---;>1T 
Comment 
(Patient no's 93, 95, 98, 100, 105, 106, 113, 114, 
115, 120, 122). 
Since the fluctuation of LVH has not previously been taken into account 
in differentiating EFE from AM, all three methods of classifying LVH negative 
and LVH positive patients were used whenever appropriate to compare suspected 
AM and EFE. 
3. RACE DISTRIBUTION. 
There was a consistent and marked predominance of Cape coloured patients 
over black and over white patients in Groups 1, 2 and 3 (Table 4.3), with 
ratios of 102:27 and 102:11 respectively, for the total series. The 
difference was even more striking when comparing the combined Cape coloured 
and black group with whites (129:11). 
There ~as no statistlcally significant difference in race distribution 
between LVH negative and LVH positive pati~nts in all 3 modes of classification 
TABLE 4.3 Race distribution in the Clinical (Groups 1 and 2) 
and Autopsy (Groups 3 and 4) series • ., 
GROUP RACE TOTAL C B w 
lA 71 14 7 92 
2A 20 9 2 31 
lC 56 9 6 71 
2C 35 14 3 52 
lT 74 14 8 96 
2T 17 9 1 27 
CLINICAL SERIES 91 23 9 123 
3 10 2 1 13 
4 1 2 1 4 
AUTOPSY SERIES 11 4 2 17 
· - · 
TOTAL SERIES 102 27 11 140 
C = Cape coloureds; B = blacks; W = whites 
TABLE 4.4 Distribution of sexes in the Clinical (Groups 1 and 2) 
and Auto.psy (Groups 3 and 4) series. 
GROUP MALE FEMALE TOTAL 
lA 46 46 92 
2A 18 13 31 
lC 37 34 71 
2C 27 25 52 
lT 51 45 96 
2T 13 14 27 
CLINICAL SERIES 64 59 123 
3 4 9 13 
4 3 1 4 
AUTOPSY SERIES 7 10 17 
TOTAL SERIES , 71 69 140 
/ 
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2 (X = 0.034, 1.528 and 1.511 ; p~0.80, 0.20 and 0.20, respectively), or 
2 . between the clinical and autopsy series (X = 0.266, p>0.60). 
Comment 
It is known th_.at the admission rate in relation to population totals is 
higher in blacks and Cape coloured than whites, who ·tend to be treated 
privately in institutions other than . those of the Department of Paediatrics 
and Child Health. A questionnaire was therefore sent to the nine private 
paediatricians in Cape Town (all responded), which revealed that since 1970 
only one had encountered 2 white patients with AM or EFE fulfilling the 
strict clinical criteria of this study. Several paediatricians intimated 
that patients as severely affected as this would have been referred to the 
Department anyway for intensive care. 
Furthermore, the percentage distribution of Cape coloured/black to white 
patients with AM and EFE in this series was 92:8, whereas the percentage 
racial distribution for all admissions to the paediatric wards during the 
same time-period was 80:20. Hence, the frequency of AM and EFE was signi~ 
ficantly greater in the black groups than in white patients (X2 = 5.025, p<I).025). 
These findings support the conclusion that acute EMD is particularly 
prevalent in Cape coloured and black children. 
• 
There is little information in the literature regarding racial distribution 
362 in acute EMD~ Miller et al reported no racial predominance in EFE. 
Mitchell et a1 367 .detected EFE in 5 coloured and 2 white infants in a large 
perinatal study, but this ratio was within expecte~ limits. However, Hutchins 
and Vie255 reported an 82% incidence of post-mortem AM and EFE in blacks 
relative. to whites, compared with a 30% incidence of blacks in a~l autopsies, 
and Mcloughlin et a1 352 found that 75% of patients with clinical EFE were 
36 
negroes compared with an overall admission rate in negroes of only 25%. 
The latter concluded that "hereditary, environmental and socio-econo~ic 
factors may play an aetiological or a modifying role'in the expression" of 
EFE, and the former that there was "a propensity for fatal myocarditis and 
fibroelastosis in the socio-economically depressed". Since the vast 
majority of black/coloured patients in the present study belong to the 
socio-economically deprived segment of society, these views are supported. 
The evidence suggests, firstly, that impoverished children are more prone 
to contracting acute viral myocarditis, as suggested by Whitehead 562 in 
relation to enteroviruses, and found experimentally with coxsackieviruses 
. d . h d . . 574 in un ernouris e mice. Secondly, because EFE occurs in patients 
with the same socio-economic background, a possible relationship between AM 
and EFE is strengthened, in compliance with the stated hypothesis. 
4. DISTRIBUTION OF SEXES. 
The male:female ratio was approximately equal in LVH negative and LVH 
positive patients (Groups 1 and 2), however classified, and in the autopsy 
series. (Table 4.4) 
Connnent 
195 255, 352 An equal male:female ratio in EFE has been recorded by others, ' 
but a female predominance ranging from slight 476 to 1:6:1 84 , 274 and 2:1 368 
has also been reported. An equal sex distribution has been reported in autopsy-
confirmed cases of AM as well. 255 
. , 
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5. AGE DISTRIBUTION. 
Statistical comparison of the mean ages in Groups 1, 2 and 3 showed 
that patients in Group lA were significantly older than those in Group zA. 
(Table 4.5) 
Although this conclusion may be invalid for the t-test, since the degree 
of variance of the standard deviations suggests that the samples were drawn 
f 1 1 . 378 ( 2 725 0 0 ) . . rom two unequa popu ations _ F = • , p<" : 1 , a valid difference 
between the 2 samples (both greater than 30) was indicated by the fact that 
the observed difference (9.9 months) was greater than twice the standard 
error of the difference of the means (3.69). 
There were no statistically significant differences in mean age between 
the cl_inical Groups lC and 2C, or lT and 2T ; nor between Group lA or 
2A (without and with LVH on admission)and Group 3 (deaths soon 
after admission). 
The age difference may also be demonstrated by the fact that the number 
of patients in the younger age groups was significantly greater in LVH positive 
than LVH negative patients, i.e. Group 2A)Group lA (p-(0.05 for patients under 
6 and 18 months, p<0.005 under 12 months) ; _ Group 2C>Group lC (p<0,05 for 
patients under 6, 12 and 24 months) ; and Group 2T>Group lT (p<0.05 under 24 
months). (Table 4.6) 
Furthermore, 1n the graphic display of the number of patients (Figures 
4.2, 4.3 and 4.4) in different age brackets in each group, it is apparent 
that LVH positive patients by any method of classification had earlier peak 
ages than LVH negative patients. The ·peak age for Group 1 was 12 to 14 
months, and for Group 2 approximately 6 months. Group 3 appeared to have 
t \ 
TABLE 4.5 Age at presentation (mean !sEM) in patients without (Group 1) 
and with (Group 2) 1.Y!i. on ECG, on admission (Type A), at any stage (Type C) 
and terminally (Type T), and in the autopsy series (Group 3). 
AGE (months) 
TYPE OF GROUP t . ., 
CLASSIFICATION 1 2 3 1 cf 2 1 cf 3 2 cf 3 
A 21. 7 11. 8 +12.5 2.095* 1.273 -0.144 
!2.57 + . -2.65 -2.70 
C +21.5 16.1 - 1.289 -
-2.67 !3.23 
T 21.1 +12.6 - 1. 742 
!2.49 -2.85 
t = statistical evaluation by Student's t-test for unpaired samples. 
*=difference significant at p<0.05. 
-
TABLE 4.6 Age at presentation. Number of patients in different age-ranges 
at presentation according to absence (Group 1) or presence (Group 2) of LVH 
on ECG on admission (A), at any stage of the course (C), and at the end~ 
the study or death, i.e. terminally (T). 
NUMBER OF PATIENTS 
AGE GROUP 
x2 
GROUP 
x2 (months) lA 2A lC 2C 
(92) (31) (71) (52) 
0 to <6 12 10 4. 594 * 8 14 3.999* 
6 to < 12 18 11 2.437 15 14 0.248 
12 to < 18 27 5 1.474 20 12 0.183 
18 to < 24 14 3 0.223 10 7 0.027 
24 to <36 6 0 'f 6 0 'f 36 to < 48 6 1 'f 6 l 'F 48 to <60 2 0 'f 1 1 'f 60 to <72 4 0 'f 3 1 'f 
72 to <.108 1 1 'f 1 1 'f 108 to 152 2 0 'f 1 1 'F 
UNDER 12 30 - 21 10.389d) 23 28 4.842* 
UNDER 18 57 26 4.125* 43 40 2.953 UNDER 24 71 29 3.083 53 47 3.909* 
Total number of patients in each group appears in parentheses. 
x
2 Statistical evaluation. by Chi-square analysis. 
* Significant difference at p<. 0.05 
d) II II II P< 0. 005 
'f numbers too small for statistical analysis. 
GROUP 
x2 lT 2T 
(96) (27) 
15 7 0.902 
20 9 1.200 
26 6 0.068 
13 4 0.021 
6 0 'f 
7 0 'f 
,., 0 'f ~ 
4 0 'f 
1 1 'f 
2 0 'f 
35 16 3.623 
61 22 2.327 
74 26 3.931* 
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peaks at both these ages, in keeping with a mixed group. (Figure 4.2) 
It is concluded that patients with LVH on admission, at any stage of the 
., 
illness, or terminally, present at a younger age than those without LVH. 
This is statistically significant in the type A and C classifications when 
comparing the relative frequency of younger patients, and in the type A 
classification in respect of mean age. 
Comment 
This result coincides with previous findings that EFE occurs mainly in 
47 195 226 342 476 . . . early infancy, ' ' ' ' while acute myocarditis, other than 
the epidemic neonatal form is reported to occur sporadically at any age. 
476, 564, 573, 288, 353 The peak prevalence of 12 to 14 months for 
sporadic AM noted in this study has not been reported previously. 
If EFE coincides with the presence of LVH on ECG and is a response to AM, 
as claimed, then an explanation must be sought to account for its seemingly 
paradoxical prevalence in younger patients. The possibility of a special 
predilection for EFE in the first few months of life is consid~red in Chapter 
14. 
It is noteworthy in the figures that, of the three groups with LVH, only 
Group 2C had a second peak age which coincided with the peak age seen in all 
three groups without LVH (Groups lA, lC and lT). (Figure 4.3) This is in 
keeping with the suggestion that a certain number of patients in Group 2C 
were primarily cases of AM on admission who developed LVH at a later stage 
which then tended to re,,solve. In the _patients who have LVH from the time 
of presentation it is postulated that an earlier bout of AM occurred that was 
mild and unrecognised, or sub-clinical, but sufficient to initiate the de-
ve lopmen t of EFE. ( see nage 17 9 ) 
CHAPTER 5. 
EPIDEMIOLOGY. 
If AM is due to a viral infection and EFE is an independent non-viral 
condition, the former would be expected to show seasonal variations in inci-
dence with fluctuations from year to year, while the latter should have a 
consistent pattern over the long-term. 
On the other hand, if AM and EFE are rel.ated and viral-induced, these 
variations in incidence should be discerned in both conditions. 
1. METHODS. 
To this end, patient admissions were plotted chronologically on an annual 
and 3-monthly time-scale encompassing the 6! year duration of the study period. 
" (Figures 5.1 to 5.7) Total admissions for each calendar month throughout this 
period are depicted graphically in Figure 5.8. 
Patients were divided into LVH negative and LVH positive groups (Chapter 4) 
as based on the initial ECG's (Groups lA and 2A), on tracings from throughout 
the study (Groups lC and 2C), or on ECG's assessed at the end of the study or 
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(Group 1) 
Fig. 5.1 
Fig. 5.2 
Fig. 5. 3 
patients presenting per 3 month period according to absence 
or pr~sence (Group 2) of LVH: 
- on admission (Groups lA and 2A) 
- at any stage (Groups lC and 2C) 
- at end of· study or terminally (Groups lT and 2T). 
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just prior to death (Groups lT and 2T), to...examine which classification would 
facilitate differentiation between AM and EFE. 
2. RESULTS. 
2.1 THREE MONTHLY DISTRIBUTION. 
In the 3-monthly distribution of patient admissions for Groups lA and 2A 
(Figure 5.1), both groups had concurrent peaks from 1970 to 1973. The maximal 
peak for Group lA in July to September, 1973 and a subsequent peak in July to 
September, 1974 were followed, respectively,by the maximal Group 2A peak in 
January to March, 1974 and a second peak in 1974, in October to December. 
Thereafter, the two curves did not coincide with each other. Group lA peaks 
all occurred in the second half of each year except for 1972 when this group 
had two peaks (April to June and October to November). 
In the graph for Groups lC and 2C (Figure 5.2), a similar pattern is evident 
with peaks for the two groups coinciding prior to, but not after, 1973 and with 
the maximum group 2C peak in January to March 1974 occurring approximately 6 
months after the maximum peak for Group lC in June to September, 1973. 
A similar pattern is also seen in the Group lT and 2T graph (Figure 5.3), 
with the two dominant peaks in Group 2T (January to March and October to 
December 1974) occurring approximately 6 and 3 months, respectively, after 
the two dominant peaks of Group lT (July to September, 1973 and 1974). 
2.2 ANNUAL DISTRIBUTION. 
The annual distribution of patients (Figures 5.4 to 5.6)revealed that the 
number of LVH negative patients, however classified, reached minor epidemic 
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proportions in 1973, with the maximal annual incidence of LVH positive cases 
occurring in the following year (1974) in each case. This effect is most 
clearly demonstrated when comparing Groups lC and 2C where the two sets of 
patients were equ~l in numbers (Figure 5.5). 
2.3 PERCENTAGE ANNUAL DISTRIBUTION. 
The number of patient admissions per annum as a percentage of the total 
admissions for each group is depicted in Figure 5.7. The percentage dis-
tribution of patients in each year was similar for Groups lA, lC and lT, and 
also for Groups 2A, 2C and 2T. The percentage of Group 1 cases, by any 
classification, was similar to or greater than the percentage of Group 2 cases 
in each year except for 1974, when the Group 2 percentage was higher. The 
peak incidence of Group 2 cases (1974) followed the peak incidence of Group 
1 cases (1973), as previously noted. · 
2.4 CUMULATIVE MONTHLY DISTRIBUTION. 
The cumulative number of patients for each month of the year throughout 
the study period is diagrammatically represented in Figure 5.8. The distri-
bution shows that the majority of ~atients presented between the months of 
July and October (58 patients), compared with either of the other 4-month 
periods (34 patients in November to February and 31 patients from March to 
. June). This occurred with LVH negative and LVH positive patients, but was 
more striking in the former. 
Despite their relative paucity, LVH positive cases (Groups 2A, 2C and 2T) _ 
equalled or exceeded the number of LVH negative cases in January and February 
and to a lesser extent ,in December and March. Further analysis revealed that 
the increase in LVH positive cases during the early months of the year occurred 
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FIG. 5.8 CUMULATIVE MONTHLY DISTRIBUTION of patients without (Group 1} 
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admission (Groups lA and 2A), 
any stage of the course (Groups lC and 2C) and 
the end of the study or death (Gr oups lT and 2T). 
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mainly in 1974, after the maximal frequeQcy of LVH negative patients in the 
second half of 1973. 
DISCUSSION. 
The type C classification (with or without LVH at any stage) appeared to 
differentiate the incidence trends between AM and EFE most clearly, but similar 
conclusions could be drawn from all 3 classifications. 
Assuming that LVH negativity correlates with AM and LVH positivity with the 
presence of EFE, the factors that support an infective aetiology for AM include 
(i) the seasonal variation (peak incidence in late winter and early 
spring), and 
(ii) the annual fluctuations in incidence, with a sudden rise to minor 
epidemic proportions in 1973. 
The association of EFE with infection is less convincing. Although there 
was a rapid increase in incidence of EFE in 1974, the incidence from year to 
year and throughout each year was more uniform than in AM. 
However, a relationship between AM and EFE is supported by 
(i) the concurrence of peaks of incidence of both conditions before 1973, 
(ii) the higher ratio of EFE to AM in the surmner months following Ju~ peaks 
in the preceding winter and spring, 
(iii) the particularly marked increase in incidence of EFE (with LVH at 
presentation) in 1974 approximately 6 months after the minor epidemic 
of AM in 1973, and 
(iv) the increased frequency of conversions from LVH negative to LVH posi-
tive status (Group lA to 2C) pari passuwith the increased incidence 
of AM (1973). , 
Hence, it may be concluded that AM is of infective origin and that EFE is related 
to, and probably a consequence of, prior outbreaks of overt AM in the community. 
' ~ 
\ 51 
The absence of a previous history of AM ip patients presenting with EFE (LVH 
positive) ab initio, suggests that these cases follow sub-clinical episodes of 
myocarditis. 
Th 1 . 1 . d . h 1. . h f 80 . 84 ere is itt e evi ence int e iterature eit er or or against a 
seasonal variation in EFE, but an increased frequency of deaths due to EFE 
has been noted following epidemics of viral disease. 367 ,SOl,SOO The de-
creasing incidence of EFE in Western countries over the yea~s,
84
,
195 probably 
d b . . d. . 226 b . d. . ue to etter socio-economic con itions, may e in irect evidence of an 
infective· (viral) aetiology for EFE. 
Chen et a184 found an increased incidence of EFE in later births and a 
gr~atly increased incidence of EFE (3.8%), but not of other congenital anomalies, 
i"Q. siblings. The latter favoured a post-natal acquired condition. These 
factors were not evaluated in this study. 
CHAPTER 6. 
EVALUATION OF DIAGNOSTIC CRITERIA. 
The diagnostic criteria are compared in Groups 1 and 2 in all three modes 
of classification to identify which, if any, permits differentiation between 
AM and EFE~ 
1. DURATION OF HISTORY. 
The mean duration of history for patients in Group 2A was significantly 
longer than for Group lA patients (p<(0.05). (Table 6.1) 
378 The Variance-Ratio test (Snedecor's F test) makes this statistic un-
tenable (F = 4.28, p< 0.01), despite the fact that by definition histories 
were under 1 month in both populations. Furthermore, in contrast to the 
position regarding age, (page 37) the observed difference between the means 
(2.3 days) is less than twice the standard error of the difference of means 
(1.55)," so that the conclusion that Group lA patients have more acute ill-
nesses is probably not valid. 
There was no significant difference between Groups lC and 2C, or Groups 
lT and 2T (Student's t-test valid : F = 1.398, p')0.05 ; and F = 1.203, 
p)0.05, respectively). 
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2. CLINICAL CRITERIA. 
2.1 HEART RATE 
There was no significant difference in the mean heart rate between Groups 
~ 
1 and 2 patients, whatever the method of classification. (Table 6.1) (Student's 
t-test valid in each case; F = 1.274, 1.245 and 1.123, respectively; p>0.05 
in all). However, there was a significantly larger number of patients with a 
heart rate above the 95th percentile for age among those LVH negative at any 
stage (1C>2C, p<'0.05). (Table 6.2) 
Comment 
The latter coincides with the concept that AM represents a more acute 
condition than EFE. 
2.2 CARDIOMEGALY 
The frequency of cardiomegaly detected on clinical examination was not 
significantly different in Groups 1 and 2 patients, by any mode of classification. 
(Table 6.2) 
2.3 SYSTEMIC VENOUS CONGESTION 
a) Hepatomegaly 
There was no significant difference in the frequency of hepatomegaly (>2 ems 
below the costal margin) between Groups 1 and 2 patients, by any method of 
classification. (Table 6.2) 
was 80.5%. 
b) Elevated JVP 
The overall incidence of hepatomegaly in the series 
Venous pressure elevation was signi~icantly more prevalent in Group lA than 
2A (p<0.01) and in Group lC than 2C (p<'..0.05), but there was no significant 
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difference between Groups lT and 2T. (Table _6.2) 
34.2% of the series. 
This sign was detected in 
c) Oedema was significantly more frequent in Group lC than 2C (p<:0.0~5) but 
there was no statistically significant difference in.the two other methods of 
classification. (Table 6.2) The overall incidence in the series was 29.3%. 
A single abnormality indicating systemic venous congestion was significantly 
more connnon in patients positive for LVH on admission (Group 2A>lA, p<.0.025), 
and at any stage (Group 2C >lC, p< 0.025), but not terminally. On the other 
hand, two or more abnormalities were significantly more prevalent in patients 
negative for LVH on admission (Group lA> 2A, p< 0.025) ~ and at any stage 
(1C>2C, p<0.025), but not terminally. 
Corrunent 
These apparently contradictory results may indicate that features of more 
acute or severe right heart failure, especially elevated JVP, oedema and two 
or more signs in combination, occur in patients with AM, whereas the predominance 
of any single isolated abnormality in patients with EFE reflects a low-grade, 
chronic cardiac involvement. 
As in this series, hepatomegaly is reported to be common in EFE, with oedema 
. f'f h f ' 226 occurring in one it o p2tients. 
2.4 PULMONARY VENOUS CONGESTION 
Clinical evidence of pulmonary venous congestion was similar in frequency 
in LVH negative and LVH positive patients in all 3 forms of classification. 
(Table 6.2) 
\ 
57 
Comment 
The incidence of 53% in this series ·is greater than the 36% quoted for 
radiological pulmonary venous congestion in primary myocardial disease (PMD) 
in children. 195 ~the high incidence in EFE in this study also differs from 
h 1 . 164 ot er ow estimates. 
2.5 GALLOP RHYTHM 
Gallop rhythm was very common (over 77% in the series) but there was no 
significant difference in incidence between Groups 1 and 2 patients. (Table 6.2) 
Comment 
The reported incidence of gallop rhythm varies between 39.8% in PMD195 and 
almost universal in EFE. 226 
2.6 SHOCK 
Shock was rare in Groups 2A (1/31) and 2T (1/27), but was not significantly 
different in frequency from Groups lA (p >O .10), and lT( )0. 05) ,respectively 
(Table 6.2). However, a highly significant predominance of shock occurred 
in patients LVH negative at any stage (lC > 2C, p< 0. 01). 
Comment 
This result supports the proposal that patients without LVH (AM) have a more 
acute onset than those with LVH (EFE). 
A state of shock has been well described in the neonatal epidemic form of 
AM, 506,527,534 . . . . 64,195,395 but is not mentioned as a feature in sporadic cases. 
In this series shock occurred in 19.6% of patients without LVH on admission 
(AM), and affected the outcome adversely. 
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2.7 APICAL SYSTOLIC MURMUR 
A murmur compatible with mitral regurgitation was heard in only 8 patients 
was 
in the entire clinical series. Only one-graded 3/6 in intensity, while two 
were graded 2/6 aqd three were just audible (1/6). There was no significant 
difference in the frequency of mitral murmurs between patients with and those 
without LVH, defined in any manner. 
Comment 
The reported incidence of. mitral murmurs varies widely from 6% in PMD 195 
to 40% in EFE 226 and 66% in AM, 43 but these murmurs were soft and often 
transient. Grade 3/6 or louder apical systolic murmurs were heard in EFE 
by McLaughlin et al in 5 of 24 cases, 352 by Moller et al in 16 of 23 patients, 368 
476 
and by others. Moller et al noted that the presence of mitral murmurs was 
age-dependent. A rela~ionship to duration of pathology seems more appropriate. 
In this series, the paucity of mitral murmurs suggests that the cardiac 
involvement was indeed acute or of short duration in the vast majority of 
cases, i.e. before chronic dilatation in AM or fibroelastotic encroachment in 
EFE resulted in established mitral incompetence. 
3. ECG CRITERIA 
No statistically significant differences were demonstrated between Group 1 
and 2 patients, by any mode of classification, in respect of ST segment or T 
wave abnormalities, independently or together. (Table 6.3) 
4. RADIOLOGICAL CARDIOMEGALY 
All but 3 of the 123 patients in the clinical series had a cardio-thoracic 
ratio (CTR%) of greater · than 55% on admission (Appendix 1). Two patients 
were regarded as being positive for cardi~megaly since the CTR fell into the 
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abnormal range later during the first admission, i.e. increasing from 54.3% 
on admission to 63.3% after 10 days in patient no. 6, and from 51.5% on ad-
mission to 56.8% after 17 days in patient no. 57. (No chest x-ray was available 
in patient no. 39 but he was included in the clinical series for reasons given 
on page 27 ). 
On statistical analysis, the presenting CTR% was significantly greater in 
LVH positive than LVH negative patients as classified on admission (Group 2A)>lA, 
p<0.02), and at any stage (Group 2C>"lC, p<(0.005), but not terminally(Table 6.1). 
However, the wide overlapping range of 51.5% to 84.7% in Groups lA and lC, and 
55.1% to 79.3% in Groups 2A and 2C, limited the value of this finding in the 
individual case. 
Comment 
The more marked cardiomegaly in LVH positive patients at presentation is in 
keeping with more prolonged cardiac involvement in EFE than AM despite their 
younger age. 
The reported incidence of cardiomegaly in EFE is 30% for a CTR between 0.55 
226 
and 0.65, 50% between 0.65 and 0.75 and 20% for a CTR over 0.75. . In the 
present series as a whole the comparable incidences for the same CTR ranges 
were 50%, 45% and 57.lrespectively. The lower incidence o( marked cardiomegaly 
probably reflects the inclusion of more acute cases (AM) in this material. 
There appear to be no detailed reports in the literature of heart size in AM. 
5. AUTOPSY FINDINGS 
Pathological features are discussed in Chapter 13. 
The clinical diagnosis of acute EMD (AM or EFE) was confirmed in all 23 
2 patients from Groups 1 and 2 who came t~ autopsy (X = 42.087, p<.0,0005). 
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Limited clinical data was available ~n 10 of the 13 patients in Group 3. 
It is noteworthy that the incidence of shock in Group 3 (9/10) was very sig-
nificantly greater than in Group lA (18/92, p<0.005) and Group 2A (1/31, 
., 
p<0.0005). 
Comment 
This finding was not unexpected, since these patients were put into Group 3 
because of insufficient data, which was mainly due to their fulminant course 
and early demise within hours of admission. 
6. CONCLUSIONS 
From the clinical and radiological findings it may be concluded that AM is 
a more acute illness than EFE. · In particular, the state of shock in these 
sp~radic cases of AM, well recognised in the epidemic form, emphasize the 
·immediacy of the pathological insult. In contrast, the less dramatic onset 
of EFE supports the belief that the fibroelastotic thickening of the endocardium 
is not an immediate response but a more insidious and protracted process. 
Clinical differences between AM and EFE were demonstrated equally with the 
type A and C, but not at all with the type T,classifications. 
The strict clinical diagnostic criteria used in this study proved highly 
accurate in diagnosing acute EMD. 
( . 
\ 
CHAPTER 7. 
CLINICAL PRESENTATION. 
The initial presentation of patients 1n the clinical series 1s reviewed 1n 
terms of 
(i) pre-admission symptomatology, 
"(ii) clinical features, other than diagnostic criteria, 
(iii) routine investigations, excluding radiological (Chapters 6 and 12), 
electrocardiographic (Chapters 6 and 9), serum enzyme (Chapter 10), 
and virological (Chapter 11) examinations, 
(iv) treatment, and 
(v) duration and outcome of first admission. 
The appropriate information for each case is tabulated 1n Appendix B. 
These findings are again compared in patients with and without LVH on ECG, 
classified as in Chapter 4, so as to evaluate which classification, if any, 
permits differentiation between these 2 groups. 
1. PRE-ADMISSION SYMPTOMATOLOGY 
The duration of history has already been analysed (page 52 ). 
( ' 
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1.1 RELATIVE FREQUENCY OF SYMPTOMS 
In the clinical series as a whole, respiratory symptoms were most common 
with 82.9% (102/123) being affected, fever occurred in 42.3% (52/123), oedema 
in 18.7% (23/123), general malaise in 13.0% (16/123), gastrointestinal symptoms 
., 
in 11.4% (14/123), a history of measles in 5.7% (7/12-3) and convulsions in 4.9% 
(6/123). 
Comment 
The predominance of respiratory symptoms is in agreement with reported 
f . d. . . . h 43 352 d . d. l d. 195 in ings in patients wit AM, EFE an primary myocar ia isease. 
0 d d b . . 352 d f . 43 e ema is reporte to e prominent in EFE an ever in AM. 
1.2 COMPARISON OF LVH NEGATIVE AND LVH POSITIVE PATIENTS 
The frequency of symptoms in each group appears in Table 7.1. 
There was no significant difference in the frequency of any symptom between 
Group~ and Group 2 patients, however classified, except that a history of 
pneumonic or grunting respiration was significantly more frequent in LVH posi-
tive patients on admission (Group 2A> lA, p< 0.05). 
1.3 RESPIRATORY SYMPTOMS 
The respiratory symptoms could be divided into mild, i.e. features of upper 
respiratory tract infections, such as coughing and coryza; and severe, i.e. 
dyspnoea (including shortness of breath, tight chest, wheezing, and respiratory 
distress), pneumonic or grunting respiration, and apnoea or cyanosis (one case 
each). 
The milder symptoms were relatively more frequent in Group 1 patients, but 
the differences were not statistically significant. Severe symptoms occurred 
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equally in all groups, except for features_ suggesting pneumonia, as mentioned 
above. 
., 
Comment 
The significantly higher incidence of grunting respiration in Group 2A 
compared with lA patients may indicate that concomitant pneumonia is more 
frequent in EFE, or may simply reflect the greater propensity for grunting 
in younger patients, whether due to pneumonia or pulmonary congestion. Mc-
Loughlin et al also noted a high incidence of severe respiratory symptoms in 
EFE (15 of 24 patients) compared with symptoms of upper respiratory tract 
infections (2 of 24). 352 
1.4 OEDEMA 
Swelling of the feet, face or body, is usually only noticed by parents 
when advanced, so that a frequency of 18.7% is high. However, a diagnosis 
of cardiac oedema was questionable in several cases who had evidence of 
protein-calorie malnutrition or renal involvement. 
1.5 FEVER, MALAISE AND GASTROINTESTINAL SYMPTOMS 
These symptoms were all more common in Group 1 patients, but not signifi-
cantly so. ) , 
1.6 CONVULSIONS 
A history of convulsions was obtained in 6 patients, all of whom were LVH 
negative on admission (Group lA) and terminally (Group lT), though two developed 
LVH transiently (Group 2C). Numbers were too small for statistical evaluation. 
Comment 
Although a history of convulsions was relatively infrequent, its occurrence 
66 
is important since it points to cerebral invplvement and is evidence of a 
generalised viraemic state (or of shock). 
1.7 MEASLES 
In 2 of the 7 patients (no's 57 and 88) a characteristic illness and rash 
was observed more than 14 days before presentation with EMD, while in the 
remaining 5 (no's 21, 58, 59, 70 and 97) measles was noted less than 4 days 
before. 
Comment 
This condition is so common among the Cape coloured and black populations 
attending Red Cross War Memorial Children's Hospital that a recent history 
of this condition may well be coincidental. However, in those patients who 
manifested full-blown measles and acute EMD concurrentlY, a real association 
was possible. 
1.8 MISCELLANEOUS 
Other symptoms were uncommon and included a non-specific rash (one case), 
pallor (2), weakness of limb (2), chest pain (1), arthralgia (1) and a history 
of recent general anaesthesia (1). 
1.9 CONCLUSION 
Most initial symptoms appeared to be related to infection, probably viral, 
followed days to weeks later by the cardiotropic effect, and a neurotropic 
effect in some cases. This is in keeping with a diphasic course described in 
AM. 171 , 468 , 527 , 534 Although mild respiratory symptoms, fever, malaise, 
gastrointestinal and Cefebral symptoms were more frequent in LVH negative 
patients (AM) in concurrence with this concept, the difference from LVH posi-
tive patients (EFE) was not conclusive in any classification mode. 
67 
2. OTHER CLINICAL FINDINGS. 
Apart from the clinical diagnostic criteria,features which were .observed at the 
time of presentation or developed as complications during the initial admission, 
are tabulated in Table 7.2 with their frequency in each group. 
2.1 ELEVATED TEMPERATURE 
A temperature above normal was measured in 26% (32/123) of all patients, 
and the frequency was similar in each group. Elevated temperature as evi-
dence of infection is discussed later (page 83 ). 
2.2 PNEUMONIA 
The incidence of radiological pneumonia was higher in LVH negative than 
LVH positive patients, but the differenc-e was not statistically significant. 
Comment 
Although pulmonary adventitious sounds were common, a diagnosis of pneumonia 
on clinical examination often proved difficult because of the co-existence of 
pulmonary venous congestion in many cases. Hence, only unequivocal features 
of consolidation on chest x-ray were accepted in this category. 
2.3 CENTRAL NERVOUS SYSTEM (CNS) ABNORMALITIES 
Included in this category were 5 patients with neurological deficit (signs 
of mid brain and pontine lesion in case no. 30, who also had convulsions~ 
hemiparesis in case no's 64 and 71; bulbar palsy in case no's 76 and 78, with 
sixth cranial nerve and peripheral neuropathy in the latter): 5 patients with 
change in level of consciousness (coma in case no's 63 and 59, both with abnormal 
cerebra-spinal fluid; depressed level of consciousness in case no's 44 and 
81, both with abnormal CSF; and hyper-irritability in case no 46) 
patient with convulsions only (case no 29). 
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These CNS abnormalities occurred exclusively in LVH negative patients in 
all three classifications except for 1 patient who developed LVH transiently. 
The predominance in LVH negative patients was statistically significant in the 
C-classification (eroup 2C>1C, p<0,05). (Table 7.2) 
If one includes 4 of the 6 patients with a history of ·convulsions, i.e. 
case no's 17, 19, 61 and 77 (case no's 63 and 64 were already included above), 
then the number of patients with CNS involvement in each group is 15 in Group lA 
and O in 2A 13 in lC and 2 in 2C 15 in lT and O in 2T. 
The Chi-square statistic for the three comparisons are 4.334, 4.591 and 3.456, 
respectively. Hence, abnormal CNS features occurred significantly more fre-
quently in patients LVH negative on admission and at any stage of the illness 
(Gr·oup 1A>2A and 1C>2C, p< 0.05 in both cases). 
Comment 
In this situation, the most likely causes for CNS abnormalities are 
(i) a direct inflammatory effect of a disseminated (probably viral) 
infection on the brain as well as the heart, or 
(ii) severe cardiogenic shock with low cardiac output and secondary 
hypoxia of the brain. 
Although these CNS events occurred relatively more commonly in shocked (6/19) 
than in non-shocked patients (9/104), a difference which is statistically 
significant (X2 = 5.889, p<0,025;, the fact that over half the patients with 
CNS .conditions were not associated with shock strongly suggests that dissemi-
nated viraemia does play a role in some cases. The predominance of CNS ab-
normalities among LVH negative patients,therefore;emphasises the occurrence 
of viraemia as well as shock'in AM as compared with EFE. 
\ 70 
Aseptic meningitis is known to accompany AM in Coxsackievirus epidemics 
230 527 534 in the newborn ' ' and has been reported in isolated cases in the 
110 277 
neonate. ' b 1 . . 226 b d . 9% CNS a norma 1t1es are rare 1n EFE ut occurre 1n • 
of patients with PMD. 195 
2.4 ASSOCIATED VIRAL INFECTIONS 
In patient no 15 measles intervened 15 days after presentation, 1n patient 
no 72 chicken-pox developed 4 days after admission, and in patient no 45 chicken-
pox and measles developed 20 and 36 days after presentation, respectively, so 
that these episodes are coincidental to the underlying AM. 
On the other hand, florid clinical measles was a presenting feature in case 
no. 58 (who also had a positive serum complement fixation test for measles), 
as was varicella in case no. 88. Both patients with Herpes infections (case 
no. 52 with H. hominis and no. 81 with H. simplex) had typical skin lesions on 
admission. 
Hence, 4 patients had convincing evidence of viral infection simultaneous 
with presentation of endomyocardi~l disease. All 4 were in Group lA, and 3 
in Groups lC and lT, but the numbers were too small for statistical analysis. 
2.5 KWASHIORKOR 
Only one patient presented with characteristic clinical features of kwashiorkor, 
but oedema was connnon in this study (page 56) and was probably due to incipient 
kwashiorkor in some cases. 
2.6 NEPHRITIS 
Clinical featurL3 of nephritis (systemic hypertension, an elevated blood urea 
71 
of 97 mgs/100 ml and hyaline and granular casts in the urine, as well -as con-
gestive cardiac failure)was noted in 1 patient (no 72). However, the inci-
dence of urinary abnormalities and elevated blood urea was suprisingly high 
(see section 3). ~ 
2.7 RESPIRATORY ARREST 
Respiratory arrest occurred after admission in only 1 patient (no 41) but 
was a more frequent sign at presentation (see page 79 ). 
3. ROUTINE INVESTIGATIONS 
All positive or abnormal results of investigations, apart from the electro-
cardiographic (Chapters 6 and 9), radiological (Chapters 6 and 12), serum 
enzyme (Chapter 10), and virological (Chapter 11) findings, are recorded in 
Table 7.3. There were no statistically significant differences in frequency 
of abnormalities between LVH negative (lA, -lC and lT) and LVH positive groups 
(2A, 2C and 2T) for any of the routine investigations. 
3.1 HAEMOGLOBIN 
Because of the high incidence of iron-deficiency anaemia in the patient 
population attending this hospital, and the preponderance of young children 
in this series, a relatively low haemoglobin of 11 gms/100 ml was arbitrarily 
selected as the lower limit of normal for all ages. 
Haemoglobin values were available in 110 of the 123 patients (89%) in the 
clinical series. Of these, 65% (72/110) with values below 11 gms/100 ml were 
regarded as having anaemia, including 18% (20/110) with values below 8 gms/ 
100 ml, i.e. with severe anaemia. 
+ The mean haemoglobin values -SEM (gms/100 ml) were as follows: 
TA
BL
E 
7,
3 
R
ou
ti
ne
 i
nv
es
ti
ga
ti
on
s.
 
C
om
pa
ri
so
n 
o
f 
n
u
m
be
r 
o
f 
pa
ti
en
ts
 w
it
h 
a
bn
or
m
al
 f
in
di
ng
s 
in
 t
ho
se
 w
it
ho
ut
 
(G
ro
up
 1
) 
an
d 
w
it
h 
(G
ro
up
 2
) 
LV
H 
o
n
 
EC
G 
o
n
 
a
dm
is
si
on
 (
A)
, 
a
t 
a
n
y 
s
ta
ge
 d
ur
in
g 
th
e 
c
o
u
rs
e
 
(C
), 
a
n
d 
a
t 
th
e 
e
n
d 
'o
f 
th
e 
s
tu
dy
 o
r 
de
at
h,
 
i.
e.
 
te
rm
T
na
ll
y 
(T
). 
NU
M
BE
.R
 
OF
 
PA
T,
IE
N
TS
 
W
I,T
H 
AB
NO
RM
AL
 
R
ES
U
ilT
S 
GR
OU
P 
x
2 
GR
OU
P 
x
2 
GR
OU
P 
x
2 
IN
V
ES
TI
G
A
TI
O
N
 
lA
 
2A
 
lC
 
2C
 
lT
 
2T
 
(9
2)
 
(3
1)
 
(7
1)
 
(5
2)
 
(9
6)
 
(2
7)
 
HA
EJ
-iO
GL
OB
IN
 
(8
2)
 
(2
8)
 
(6
3)
 
(4
7)
 
(8
4)
 
(2
6)
 
<
 1
1G
/1
00
m
l 
57
 
15
 
1.
69
4 
43
 
29
 
0.
26
2 
55
 
17
 
0.
05
2 
<
 
8G
/1
00
m
l 
17
 
3 
0.
81
5 
14
 
6 
1.
04
5 
15
 
5 
0.
01
8 
WB
C 
3 
(6
9)
 
(2
4)
 
(5
1)
 
(4
2)
 
(7
0)
 
(2
3)
 
( >
 12
00
0 
c
e
ll
s/
m
l 
) 
37
 
9 
1.
26
3 
28
 
18
 
0.
89
8 
34
 
12
 
0.
00
4 
BL
OO
D 
UR
EA
 
( >
30
rn
g/
10
0m
l) 
30
 
8 
0.
23
4 
25
 
13
 
1.
02
7 
29
 
9 
0.
00
6 
UR
IN
E 
12
 
3 
0.
03
2 
9 
6 
0.
00
8 
13
 
2 
0.
27
9 
a
)r
bc
's,
ca
st
s 
o
r 
pr
ot
ei
n 
7 
2 
'f 
6 
3 
'f 
8 
1 
'f 
b)
cu
ltu
re
 
5 
1 
'f 
3 
3 
'f 
5 
1 
'f 
UR
T 
CU
LT
UR
E 
.
 
10
 
4 
0.
00
03
 
8 
6 
0.
05
8 
12
 
2 
0.
15
5 
a
) 
T
hr
oa
t 
sw
ab
 
3 
1 
'f 
2 
2 
'f 
4 
0 
'f 
b)
 S
pu
tu
m
 
6 
3 
'f 
5 
4 
'f 
7 
2 
'f 
c
) 
T
ra
ch
ea
l 
a
s
pi
ra
te
 
1 
0 
'f 
1 
0 
'f 
1 
·
O
 
'f 
ST
OO
L 
CU
LT
UR
E 
4 
0 
'f 
4 
0 
'f 
4 
0 
'f 
EA
R 
CU
LT
UR
E 
1 
1 
'f 
1 
1 
'f 
1 
1 
I 
AL
L 
BA
CT
ER
IA
L 
CU
LT
UR
ES
 
20
 
6 
0.
00
1 
16
 
10
 
0.
04
8 
22
 
4 
0.
41
5 
CS
F 
3 
0 
,
.
 
3 
0 
'f 
3 
0 
'f 
BR
AI
N 
SC
AN
 
1 
0 
'f 
0 
1 
'f 
1 
0 
'f 
T
ot
al
 n
u
m
be
r 
o
f 
pa
ti
en
ts
 i
n 
e
a
c
h 
gr
ou
p 
in
di
ca
te
d 
in
 p
ar
en
th
es
es
. 
2r
bc
's
 =
 
re
d 
bl
oo
d 
c
e
ll
s;
 C
UL
TU
RE
= 
B
ac
te
ri
al
 c
u
lt
ur
e;
 U
RT
 =
 
u
pp
er
 r
e
s
pi
ra
to
ry
 t
ra
c
t;
 
CS
F 
=
 
c
e
re
br
a-
sp
in
al
 f
lu
id
. 
X
 
S
ta
ti
st
ic
al
 e
v
a
lu
at
io
n 
by
 C
hi
-s
qu
ar
e 
a
n
a
ly
si
s.
 
No
 
s
ig
ni
fi
ca
nt
 d
if
fe
re
nc
es
 d
et
ec
te
d.
 
'f 
n
u
m
be
rs
 t
oo
 
sm
a
ll
 f
or
 a
n
a
ly
si
s.
 
-
_
_
.
:;;
:;=
- .
 
-
C 
\ 73 
+ + Group lA - 9.7-0.25; 
~ 
Group 2A - 10.8-0.41 
lC - + 9.6-0.30; 2C - + 10.4-0.30 
lT - + 9.9-0.25 .2T - + 10.1-0.41 
Statistical evalu~tion by Student's t-test for unpaired samples was carried out. 
The mean haemoglobin value for LVH negative patients was significantly lower 
than for LVH positive patients on admission (1A>2A; t = -2.310, p<(0.025), but 
not at any stage or terminally (t = -1.699 and -0.318, respectively, p)>0,05 in 
both). 
Comment 
The prevalence of anaemia is further evidence of the sub-optimal nutritional 
status of the population sample in this study. The lower mean haemoglobin 
level in patients with AM is probably age-dependent (see page 37 ), since these 
patients present after longer periods of iron deficiency. Anaemia is 
, . 226 
.reported to be common in EFE. 
3.2 ELEVATED WHITE BLOOD CELL COUNT (WBC) 
White blood cell estimations were available in 93 of the 123 cases (76%). 
Of these, 49% (46/93) exceeded the generally accepted upper limit of aormal 
of 12,000 white cells/ml3 , but there were no significant differences in fre-
quency between Group 1 and Group 2 patients. 
of infection is discussed in section 4. 
An elevated WBC as an index 
Statistical Comment 
The total number of patients in each group who were subjected to the 
following investigations is not known, since only positive or abnormal results 
were recorded in the protocols of each patient (Appendix B). However, it is 
argued that the ra . io of the number of Group 1 to Group 2 patients tested would 
( : 
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be approximately proportional to the ratio of the total number of Group 1 
-to Group 2 patients. Use of the Group totals as the denominators would 
therefore not invalidate the Chi-square analysis. 
3.3 BLOOD UREA 
Blood urea estimations were abnormally elevated (over 30 mgs/100 ml) in 
as many as 31% of patients (38/123). The increased values ranged from 34 
+ i + 
to 116 mgs/100 ml with a mean -SEM of 57.4-3.21 mgs/100 ml. There was 
no significant differences in the frequency of abnormal results between 
Group 1 and Group 2 patients (Table 7.3). 
+ The mean elevated blood urea values -SEM (in mg/lOO ·ml) for each group 
were: 
+ + Group lA - 59.0-3.89; Group 2A - 51.3-4.22 
lC - + 59.2-4.58; 2C + - 50.8-3.37 
lT - + 58.8-4.10; 2T + - 48.3-2.89 
Statistical analysis resulted in the following t-values for each comparison 
of Group 1 and 2 : 0.987, 1.239, and 1.383, respectively; p:;>0.05 in each case. 
Comment 
The high incidence of uraemia may be due to intrinsic nephropathy or to a 
pre-renal state secondary to cardiogenic shock. Further statistical analysis 
revealed that uraemia did occur significantly more frequently in patients with 
. 2 
shock (10/19) than in those without shock (28/104) - X = 3.842, p<0.05. 
However, in the group of uraemic patients without shock, it is likely that the 
virus causing myocarditis produced renal damage as well. 
Mesangial hyper~lasia of glomeruli was recently demonstrated in 2 patients 
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with EFE, 412 who had urinary manifesta;ions simulating glomerulonephritis, and 
h . . . d . h AM 1 413 reports of glomerulonep ritis associate wit are a so rare. 
3.4 URINARY ABNORMALITIES 
Abnormal urinary findings were detected in 11.4% of the clinical series 
(14/123). Examination of the urine revealed red blood cells and granular 
casts in 2 patients (no's 6 and 122), red cells and hyaline casts in 1 
(no 40), red cells alone in 1 (no 28), hyaline and granular casts in 1 (no 
72), granular casts and proteinuria++ in 1 (no 69) and 2+ proteinuria alone 
in 3 (no's 39, 85 and 116). 
Evidence of a probable bacterial infection of the genito-urinary-tract 
(positive urine culture) was detected in 6 patients; Klebsiella aerogenes 
in ·3 (no's 10, 49 and 93), Escherichia coli in 2 (no's 20 and 85), and E. 
~oli + Candida albicans in 1 (no 14). 
Comment 
Although a mild proteinuria can occur in severe congestive heart failure, 
the presence of formed elements, especially red blood cells and casts, strongly 
supports an inflammatory process of the renal cortex. Only one of these 
patients (no 85) was associated with a positive urinary bacterial culture, so 
that nephritis was probably due to disseminated virus infection in the remaining 
412 8 patients, though an association with EFE has been reported. 
patients had an increased blood urea (without shock). 
Four of these 
Considering all evidence of renal involvement (sections 3.3 and 3.4), a total 
of 32 patients had either uraemia (24) or changes in the urine (4) or both (4), 
not attributable t shock or bacterial urinary tract infection, and thus probably 
due to a disseminated virus which is nephrotropic as well as cardiotropic. 
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It is of interest that there was no 9verlap between this group of 32 
patients and the 10 patients with CNS abnormalities (without shock). This 
suggests infection by two groups of viruses, one essentially cardio- and 
nephrotropic, the~other mainly cardio- and neurotropic. 
3.5 UPPER RESPIRATORY TRACT (URT) INFECTION 
Bacterial organisms were grown from URT specimens in 14 patients. Throat 
swabs were positive in 4 patients (all with beta-haemolytic streptococci) ; 
sputa in 9 (Klebsiella aerogenes, Haemophilus influenza, and Escherichia coli 
in 2 patients each; Enterobacter aerogenes and Pseudomonas aer1g1nosa in 1 
patient each; and Enterobacter, Pseudomonas aeriginosa and Klebsiella aero-
genes together in 1 patient) ; and tracheal aspirate in 1 patient (Pseudomonas 
aeriginosa). 
OTHER CULTURES 
Stool cultures were positive for bacteria in 4 patients (Salmonella Bin 
2, Salmonella Cl in 1 and Salmonella C of unknown type 1n 1). Ear culture 
1n 2 patients with otitis media grew Proteus mirabilis 1n 1 and Staphylococcus 
and Diplococcus pneumon1ae 1n the other. 
Because the numbers of cultures from each site were too small for statis-
tical evaluation, all positive bacterial cultures were summed for each group 
(Table 7.3). No significant difference between Group 1 and 2 patients, by 
any method of clas_sification, was demonstrated. 
3.7 CEREBROSPINAL FLUID (CSF) AND BRAIN SCAN 
A lumbar puncture was performed on 25 occasions 1n 21 patients. 
. 
Abnormal 
findings were det£~ ted in 3 patients. The CSF contained 7 polymorphs and 1 
lymphocyte in case no 44, and 5 lymphocytes in case no 81. Patient no 59, 
\ 77 
with clinical measles two days earlier and loss of consciousness, had an 
elevated CSF protein (50 mgs/100 ml), positive globulin test, slightly 
reduced sugar, and 1 lymphocyte in the first CSF specimen, 12 polymorphs 
in the second CSF~specimen 18 hours later, and a normal CSF 3 days later. 
· A brain scan showed infarction of the left middle cerebral artery region 
in patient no 46. 
Comment 
The large number of lumbar punctures performed reflects the high index 
of suspicion of cerebral involvement such as meningitis or encephalitis in 
the study population. However, positive confirmation· of cerebral pathology 
was found in only 4 cases. 
4. TREATMENT 
No statistically significant differences were demonstrated between Groups 
1 and 2 patients, however classified, in respect of the number of patients 
undergoing various forms of treatment. (Table 7.4) 
4.1 DIGOXIN 
Digoxin was administered routinely in all but 2 cases. Patient no 39 
presented in extremis with severe shock and the diagnosis of AM was not 
immediately reco.gnised. The major clinical problem in patient no 59 was 
neurological (see above) and digoxin treatment was inadvertently omitted. 
4.2 DIURETICS 
~ 
A diuretic was administered if heart failure was clinically obvious. 
Furosemide (Lasix) _was used exclusively in this study as the diuretic of 
. .. 
first choice, though Spironolactone or Moduretic was added in isolated cases. 
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The fact that 75% of patients (92/123) were treated with Furosemide testifies 
to the severity of heart failure in the majority of patients. 
4, 3 ANTIBIOTICS ., 
Various antibiotics were administered either singiy or in combination, and 
by the intravenous, intramuscular or oral route, depending on the assessment 
of severity of the accompanying infection. The antibiotics selected was the 
responsibility of the medical officer in charge of the patient's overall 
management and is noted for each patient in Appendix B. A large proportion 
of patients (65% - 80/123) received antibiotics though the majority of in-
fections were probably viral in origin. 
4.4 INTERMITTENT POSITIVE PRESSURE VENTILATION (IPPV) 
-Assisted ventilation was required in 7.4% of patients (11/123), either for 
_neurological apnoea (case no's 76 and 78), respiratory failure (no's 11, 14 
and 29), cardiogenic shock (no 63), or acute cardio-respiratory arrest on 
admission (no's 19, 37, 39 and 96) or terminally (no 62). Only 4 patients 
survived (case no's 11, 29, 76 and 78). 
respiratory arrest all succumbed. 
Those requiring IPPV for cardio-
IPPV was more frequently required in Group 1 than Group 2 patients, but the 
numbers· were too small to reveal statistically significant differences. 
Comment 
These cases emphasize the acute onset and fulminant course in some patients 
with AM. 
4.5 BLOOD TRANSFPSION 
A blood transfusion was given to 5 patients for severe anaemia in 2 
80 
(case no's 47 and 79) and for moderate anaemia and presumed infection in 3 
(no's 11, 14 and 97) . 
4.6 STEROIDS ., 
Hydrocortisone was administered to patient no's 59 (see section 4.1) and 
30, both for suspected cerebral oedema. 
Comment 
Th Of Steroi'ds i'n AM h' hl · . 1-B,9,2,195,211,346,473 e use remains ig y controversia 
because of the demonstration in animals of fatal viral dissemination and ex-
. 281 282 tensive myocardial necrosis, ' though some authors have reported beneficial 
effects in humans. 112 ' 244 ' 224 ' 466 
this study. 
Steroids were not employed for AM per se in 
5. DURATION AND OUTCOME OF FIRST ADMISSION 
A total of 121 patients was admitted to the wards for treatment. Two 
patients (no's 23 and 67) were managed as outpatients and are therefore ex-
cluded from further analysis in this section. 
5.1 MORTALITY RATE 
There were no statistically significant differences in the mortality rates 
between Groups 1 and 2 patients, however classified (Table 7.5). The overall 
mortality rate during the initial admission was 19% (23/121). All deaths in 
the clinical series (Groups 1 and 2), including those- occurring after the first 
admission, are discussed in Chapter 12 and, together with the autopsy series 
(Groups 3 and 4), in Chapter 13. 
5.2 DURATION 
The duration of first admission ranged between 2 and 142.days in survivors 
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and 1 and 72 days in patients dying. Tbere were no statistically significant 
differences in the mean duration in hospital between Groups 1 and 2 patients 
in survivors and in the total group. Among patients dying, however, duration 
in hospital was significantly shorter in patients LVH negative at any stage 
than in LVH positive patients (lc<2c, p<0.01). 
Comment 
The significantly earlier deaths in LVH negative patients reflect the more 
acute illness and rapid progression in AM than EFE. 
CHAPTER 8. 
EVIDENCE OF INFECTION 
If the assumption is correct that AM has a viral aetiology and that EFE is 
either non-viral or a late consequence of earlier viral infection, patients with 
AM would be expected at presentation to have signs of infection more frequently 
than E'FE patients. Several features likely to be due to an infective process 
were assessed in LVH negative and LVH positive patients to test this observation. 
The selected parameters and their absence or presence in each patient are 
tabulated in Appendix C. An attempt was .made to limit positive results to 
viral rather than bacterial infections where possible. 
1. CRITERIA FOR INFECTION 
1.1 PYREXIA 
A history of fever was accepted as an index of infection, as well as an 
elevated temperature C>37°C) on admission, since it was recognised that the 
pyrexia of infection may have subsided by the time the patient was brought to 
hospital with the more alarming features of heart failure or shock. 
terial aetiology could not be excluded, however. 
A bac-
84 
1.2 ELEVATED WHITE BLOOD COUNT (WBC) 
3 A WBC of over 12,000 cells/ml was regarded as significant, although it is 
known that a leucopenia is not unusual with viral infections. Unfortunately, 
a differential count was not regularly performed so that the polymorph:!ymphocyte 
ratio was not available to assist in differentiating 'viral from bacterial infec-
tions. However, an elevated WBC on its own has been used as evidence of viral 
171,230,506 infection in previous reports. 
1.3 PNEUMONIA 
Because of the difficulty in differentiating pneumonia from pulmonary venous 
congestion clinically, only clear-cut radiol~gical lobar consolidation or broncho-
pneumonia were accepted as positive. 
tiated from a viral, however. 
1.4 CNS ABNORMALITY 
A bacterial aetiology could not be differen-
As previously no~ed (page 69 ), convulsions or neurological disorders were 
highly suggestive of an associated neurotropic effect of the virus causing the 
cardiopathy, if shock could be excluded. 
1.5 URAEMIA 
Similarly, uraemia occurred commonly in the absence of shock, and could be 
ascribed to a nephrotropic effect of the virus (see page 74 ). 
1.6 URINARY ABNORMALITY 
Jhe presence of protein, red blood cells and/or casts in the urine was 
accepted as indicating an inflammatory process in the upper renal tract, i.e. 
due to concomitant nephritis. If bacterial organisms were identified in the 
urine (with or without the above features) a diagnosis of viral-induced 
nephritis was rejected. 
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1.7 POSITIVE VIROLOGY 
Although viral identification did not establish a cause and effect relation-
ship, its detection was regarded as a valid index of infection for comparison 
J 
of LVH negative and LVH positive patients. (see Chapter 11). 
Evidence of bacterial infection, such as a positive culture in the sputum 
or stool, was excluded from this a~sessment. 
2. RESULTS. 
The number of patients with positive results for the above criteria in LVH 
negative and LVH positive groups, as defined in the three ways previously 
described, appears in Table 8.1. 
2.1 INCIDENCE 
The overall incidence of one or more of these criieria in the entire series 
was 83.7% (103/123). A history of fever was encountered in 32.5% (40/123) of 
patients an elevated temperature in 28.5% (33/123) ; an elevated WBC in 35.8% 
(44/123) pneumonia in 28.5% (35/123) ; CNS abnormalities in 12.2% _ (15/123), 
_9.6% (10/104) in patients without shock; uraemia in 30.1% (37/123), 26.9% 
(28/104) in patients without shock; urinary abnormalities in 7.3% (9/123) 
and positive virology in 18.7% (23/123), or 30.7% (23/75) of patients actually 
tested. 
2.2 COMPARISON OF LVH NEGATIVE AND LVH POSITIVE PATIENTS 
Since patients with clinical shock have a high incidence of CNS abnormalities 
and uraemia, which may not be due to infection, they have been excluded from the 
total number of positiv~s for statistical analysis (see Appendix C). 
TABLE 8.1 Evidence of Infection. Comparison of number of affected patients 
without (Group 1) and--;ith (Group 2) LVH on ECG on admission (A), at any stage 
of the course (C), or at the end of the study or death, i.e. terminally (T) • 
., 
NUMBER OF PATIENTS 
EVIDENCE OF GROUP GROUP GROUP lA 2A x2 lC 2C x2 lT 2T INFECTION (92) (31) (71) (52) (96) (27) 
ISOLATED 
HIST. OF FEVER 3 1 'f 2 2 'f 4 0 
TEMP. ELEVATION 4 2 'f 2 4 . 'f 4 2 
WBC ELEVATION 5 0 'f 4 1 'f 4 1 
PNEUMONIA 2 1 'f 2 1 'f 2 1 
CNS ABNORMALITY 2 0 'f 2 0 'f 2 0 
URAEMIA 3 1 'f 2 2 'f 3 1 
URIN. ABNORMALITY 0 0 'f 0 0 'f 0 0 
POS. VIROLOGY 2 2 'f 2 2 'f 2 2 
TOTAL WITH 
FEVER 32 8 0.491 24 16 0.026 34 6 
TEMP. ELEVATION 25 8 0.007 19 14 0.035 25 8 
WBC ELEVATION 35 9 0.474 26 18 0.002 32 12 
PNEUMONIA 30 5 2.337 24 11 1. 779 31 4 
CNS ABNORMALITY 10 0 2.357 9 1 3.319 10 0 
URAEMIA 20 8 0.048 15 13 0.083 19 9 
URIN. ABNORMALITY 7 2 0.034 6 3 0.046 8 1 
VIROLOGY 16 7 0.140 11 12 0.692 14 9 
0 ABNORMALITY 11 9 3.790 8 12 2.268 15 5 
ANY 1 ABNORMALITY 21 7 0.048 16 12 0.083 21 7 
II 2 II 29 8 0.140 23 14 0.207 30 7 
II 3 II 20 5 0.171 16 9 0.235 19 6 
II 4 II 9 1 0.601 7 3 0.236 10 0 
II 5 II 2 I 1 'f 1 2 'f 1 2 
Total number of patients in each group appears in parentheses. 
x2 
'f 
'f 
I 
'f 
'f 
'f 
'f 
'f 
'f 
1.125 
0.016 
o. 700 
2.362 
1.826 
1.495 
0.158 · 
3.718 
0.004 
0.034 
0.087 
0 
1.826 
'f 
HIST. - history; TEMP. - temperature; WBC - white blood cell count; CNS - central nervous 
system; URIN. - urinary; POS. - positive 
x
2 
- statistical evaluation by Chi-square · analysis 
'f - numbers too small for statistical analysis 
No significant difference~ demonstrated. 
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L.. . 
There were no statistically significant differences, between LVH negative 
and LVH positive patients, ·by any classification, in the frequency of a history 
of fever, elevated temperature, elevated WBC, pneumonia, CNS abnormalities, 
uraemia, urinary abnormalities or positive virology . 
.; 
Nor were there any statistically significant differences between Group 1 and 
2, by any classification, for any single abnormality, or any combination of two, 
three, or four abnormalities. The frequency of one or more signs of infection 
was greater in LVH negative than LVH positive patients on admission - 88.0% 
(81/92) compared with 71.0% (22/31) - but this difference was also not statis-
tically significant (Group 1A>2A, x2 = 3.790, p<:O.l0>0.05). 
The only two indices of infection which were predominant in LVH negative 
patients in each classification, but not at statistically significant levels, 
were pneumonia and CNS abnormalities." In contrast, there was a preponderance 
of positive virology in LVH positive patients terminally, but the difference 
is short of statistical significance (Group 2T>-1T, p<:O.l0>-0.05). 
3. DISCUSSION. 
A high incidence (83.7%) of infection was demonstrated rn the study sample 
as a whole, but there was no statistically significant difference between 
LVH negative and LVH positive patients, however classified. Assuming that 
the absence or presence of LVH effectively differentiates AM and EFE, both 
conditions manifested features of infection to a similar degree, contrary to 
the expectation stated at the beginning of this chapter. 
One possible explanation is that AM is associated with a viral infection, 
and EFE with a bacteri~l infection. This is unlikely since the selection of 
parameters favoured a viral infection, e_yen though the data did not permit a 
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clear separation of viral and bacterial origins. Furthermore, identification 
of a virus was actually more frequent in LVH positive patients, which tends 
to contradict this possibility. 
A more cogent explanation is that both AM and EFE are associated with viral 
infections. It would be appropriate to regard the viral infection as the 
causative agent in AM, but difficult to ascribe the fully developed fibro-
j 
elastotic endocardium seen at autopsy soon after admission in some cases of 
EFE (see Chapter 13) to an acute infection lasting only days or weeks. It 
seems more likely that the viral infection acts as the initiating factor . in 
AM, and a precipitating factor in EFE. 
The latter would comply with the overall hypothesis that EFE is initiated 
at an earlier stage by a sub-clinical . or mild viral illness, which then pro-
gresses slowly with the development of the typical pathological changes in the 
endocardium, and which becomes clinically manifest through a second viral infec-
tion acting as a booster or precipitating agent. 
Although an antecedent viral infection has been gaining popularity as a 
cause for EFE (see page 10 ) there are few reports on the frequency of signs 
of infection concurrent with the clinical presentation of EFE. Greenwood et 
a1 195 reported the presence of fever in 76.9% of patients with AM but also in 
27.8% with EFE, and emphasised that fever was common (33%) in patients without 
AM at autopsy. - . d . h 226 f d h . . d b Hastreiter an Fis er oun tat EFE was precipitate y 
an infection in approximately half their cases, in whom fever and an elevated 
WBC were common. In no other series was the evidence of infection as common 
as in the present one, probably because particular attention was not directed 
to this aspect. 
., 
CHAPTER 9 
ELECTROCARDIOGRAPHY. 
· · · h d' . f AM341,438 d EFE 476 The ECG is of maJor importance int e iagnosis o an . 
ST/T wave changes occur in both conditions, whereas LVH is the most valuable 
sign for differentiating EFE from AM and is used as such in this study. 
However, the fact that LVH fluctuated during the course necessitated 3 alter-
. native modes of classification to separate AM and EFE clinically (Chapter 4). 
In this chapter, the variability of LVH is examined more fully, and other 
ECG abnormalities are evaluated and compared in LVH negative and LVH positive 
patients. The C-type classification was selected for this purpose since ECG 
abnormalities were themselves observed at various stages during the course. 
METHODS 
An attempt was made to obtain ECG's in all patients on admission, daily for 
3 days, on alternate days for 1 week, biweekly thereafter till discharge, and 
3 to 6 monthly during the remainder of the study period which ended in December 
1976 a final ECG was obtained in long-term survivors during the patient's 
last visit up to March 1979 (observation period). Additional tracings were 
obtained as determined .by the clinical conditiun of the patient. The com-
plete protocol could not be achieved during the first admission in 33 patients 
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who died early (under 2 months), in 20 pa~ients who had to be admitted to the 
paediatric wards at Groote Schuur Hospital or New Somerset Hospital because of 
the lack of beds at Red Cross Children's Hospital, in 32 long-term survivors 
who failed to attend regularly or were transferred to home centres far from 
Cape Town, and th;ough complete non-compliance in 5 patients • 
. Despite these difficulties a total of 1,050 ECG's were available and 
suitable for detailed analysis, i.e. an average of 8.5 tracings/patient. 
(This included 176 ECG's from 40 patients who died - 4.4 tracings/patient 
and 874 ECG's from the 83 survivors - 10.5/patient). 
The timing of ECG's following presentation and the abnormalities detected 
in each tracing for each patient, are tabulated in Appendix D. The criteria 
used for these selected ECG abnormalities are indicated in the key to Appendix D. 
RESULTS 
The 10 ECG abnormalities evaluated appear in rank order of frequency in 
Table 9.1. The frequency of each ECG sign in LVH negative and LVH positive 
patients (Groups lC and 2C), and in survivors and deaths, is depicted in 
Tables 9.2 to 9.5. These ECG features will be discussed under the . following 
headings: 
i) Heart rate 
ii) Arrhythmias 
iii) Conduction abnormalities 
iv) QRS vector 
v) P wave 
vi) Left ventricular hypertrophy 
vii) Q wave 
viii) ST segment 
ix) T wave 
., 
TABLE 9.1 ECG Abnormalities. Frequency ~nd Rank order 
in the clinical series during the entire study-.~ 
NUMBER OF 
RANK ECG ABNORMALITY PATIENTS % 
(123) 
1 T WAVE 119 96.8 
2 P WAVE 85 69.1 
3 SINUS TACHYCARDIA 62 50.4 
4 ST SEGMENT 59 48.0 
5 MEAN QRS AXIS 58 47.2 
6 R/S RATIO (Vl) 56 45.5 
7 LVH BY VOLTAGE 52 42.3 
8 1ST DEGREE HEART BLOCK 23 18.7 
9 Q WAVE 20 16.3 
10 ARRHYTHMIAS 14 11.4 
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1. HEART RATE 
Sinus tachycardia (ST) on ECG (>95th percentile for age) occurred in 62 
of 123 patients. Tachycardia appeared within 3 days in 47 of the 62 patients, 
and was usually of short duration, i.e. 1 day only in 37 of the 62 patients 
and 2 days to 3.5 months in 22 patients. (ST lasted 8 months in 1, 18 months 
in 1 and intermittently for 65 months in 1 patient). 
In survivors persistence of ST was no more frequent in those with late-
onset (after 3 days - 5/11) than in those with early-onset ST (under 3 days -
5/11). 
There was no statistically significant difference in frequency of ST 
between Group lC and 2C patients, or between survivors and deaths (Table 9.2) • 
. Comment 
Although regarded as a very reliable clinical sign of myocardial involve-
ment, ST was observed in only half the series. The value of ST as an index 
of acute-onset EMD was further reduced by its late onset and short duration 
in many patients. 
2. ARRHYTHMIAS 
Arrhythmias were detected in 11.4% of cases (14/123) and were least frequent 
of all the ECG abnormalities (Table 9.1). 
arrhythmias appears in Table 9.2. 
A break-down of the different 
Atrial extrasystoles were observed in 6 patients, i.e. no's 44 (atrial 
bigeminy), 82, 94 and 122 (all day 1 to 3), 115 (day 11 and 13), and 48 (day 
. 
21 with ventricule: extrasystoles at 4 months). Patient no 47 had ventricular 
\ 
TABLE 9.2 ECG Abnormalities : Rhythm and Conduction Disturbances. 
Comparison o"I""f"requency in patients without and with LVH at any stage of 
the course (Groups lC and 2C, respectively), and----rn-survivors and deaths. 
NUMBER OF PATIENTS 
· GROUP GROUP 
ECG ABNORMALITY lC 2C x2 ALIVE DEAD 
(71) (52) (83) ,,. (40) 
SINUS TACHYCARDIA 34 28 0.135 40 
ATRIAL EXTRASYSTOLES 2+ 4 'f 5+ 
SUPRAVENTRICULAR 1 0 'f 1 
TACHYCARDIA 
WANDERING PACEMAKER 2 0 'f 1 
JUNCTIONAL TACHYCARDIA 0 3 'f 1 
WITH A-V DISSOCIATION 
WPW SYNDROME 0 1 'f 1 
VENTRICULAR EXTRA- l+ 1 'f l+ 
SYSTOLES 
TOTAL ARRHYTHMIAS 5 9 2.201 9 
1ST DEGREE HEART BLOCK 12 11 0.132 18 
Total number of patients in each group indicated in parentheses. 
+l patient (No. 48) had both atrial and ventricular extrasystoles. 
x2 - statistical evaluation by Chi-square analysis. 
# - numbers too small for statistical analysis. 
No .statistically significant differences demonstrated. 
1 
0 
1 
2 
0 
1 
22 
5 
5 
x2 
0.265 
'f 
'f 
'f 
'f 
'f 
'f 
0.001 
0.999 
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extrasystoles on day 9 and 16, and no 11 had a wandering pacemaker with inter-
mittent junctional extrasystoles between admission and day 5, but not there-
after. Patient no 17 developed the same arrhythmia with aberration pre-
terminally, at 9 months. Supraventricular tachycardia (SVT) was noted in 
patient no 59 from admission to day 30. 
syndrome was seen in 1 patient. 
The Wolff-Parkinson-White (WPW) 
Episodes of junctional tachycardia with ventricular aberration alternating 
with atrio-ventricular (AV) dissociation were observed in 3 patients ; for a 
period of 28 months in patient no 5, , who is alive and well after 43 months 
for 39 days in patient no 9 and for 35 days in patient no 49, both of whom 
succumbed. 
Assessing these patients as a group, there was no 
difference in frequency between survivors or deaths, 
2C patients (Table 9.2). 
Comment 
Arrhythmias were relatively uncommon and mild. 
statistically signi, icant 
or between Group lC and 
However, the pattern of 
junctional tachycardia and aberration alternating with AV dissociation w s 
long lasting and had a poor prognosis. 
A similar .incidence of arrhythmias has been reported in both AM (SVT8 , 253 , 
528 . 43 373 517 . 147 355 . 
supraventricular ' ' and ventricular ' arrhythmias) and E 
(SVT195,226,368 WPW d 195,226,306 AV d" . . 226,368 tr~-' syn rome, issociation, suprave L 
252 368 . 195 368 537 . 
cular ' and ventricular ' ' arrhythmias). 1~5 Greenwood et al I found 
arrhythmias in 16% of c~ses which were no more frequent in AM than in other 
categories of primary myocar4ial disease. Pathological changes in the onduction 
( '. 
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system have been demonstrated in EFE 6 (and infantile COCM269 ). 
3. CONDUCTION ABNORMALITIES 
Apart from the patients with junctional rhythm an~ AV dissociation me tioned 
above, the only conduction disturbance noted was first degree heart bloc in 
18.77. (23/123) of patients. The prolonged PR interval for age endured 
under 1 month in 17 patients (observed once only in 9 patients nd twice in 
6), and for periods of 5-38 months in 6 patients. 
There was no statistically significant difference in frequency betwee 
Groups lC and 2C, or between survivors and deaths (Table 9.2). 
It is likely that first degree heart block was due to digitalis treat ent 
· 
226 
· · d d d 1 d 2 . 1 2 . d in most cases, since it was etecte on ay an in on y patient an 
after 8 days of treatment in the other 21 patients. 
Comment 
Conduction disturbances have been reported in .AJ.~280 (including second 
24 43 264 43 428 320 . 195 degree ' and complete ' ' ' heart block) and in EFE (inclu ing 
f . d 368 d d 226 d l t 166,226,217,415 h bl ) irst egree, secon egree an comp e e eart oc . 
4. QRS VECTOR 
Although vectorcardiograms were not performed,the mean frontal plane RS 
axis could readily be derived from the standard leads of the ECG's. Th 
mean vector deviated from the normal range (see key to Appendix D) in 47 2% 
(58/123) of patients ;26 % (32/123) having right axis deviation (RAD) al ne, 
13 7. (16/123) left axis deviation (LAD) alone, and 8 % (10/123) RAD at one 
time and LAD at another (RAD . initially in 7, and LAD initially in 3). 
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There was no statistically significanc difference between Group lC and 2C 
patients in frequency of RAD alone, LAD alone, or RAD+ LAD, or in the 
number of patients with RAD, with LAD, or with either vector deviation 
., 
9.3). 
However, the frequency of axis deviation was greater among survivors 
deaths, the difference being almost signif1cant in respect of the total 
of patients with LAD (p<0.10 >0.05); significant for the total number o 
al 
ble 
an 
patients with RAD (p<:0.05), and highly significant for the total number f 
patients with either vector shift (p<0.01). 
Comment 
An explanation for the latter finding is not readily apparent. One 
expect patients with LAD or RAD to have more severe right or left heart 
and, hence, to have a higher MR, but this is contradicted by 
Mean QRS axis deviation was suprisingly common in this series and 
5th position in order of frequency of ECG abnormalities (Table 9.1). 
occurred in 34 % (42/123) and LAD in 21 % (26/123) which are similar to the 
f . f 38 6% d 10 7% ' 1 d b G d 1195 · igures o • • an • • , respective y, quote y reenwoo et a in 
primary myocardial disease. LAD is thought to be uncommon in EFE~76 but 
ilure 
ults. 
H. . d . h 226 h . . . astreiter an Fis er noted tat the mean QRS axis in EFE shifted towa ds 
the left with treatment and towards the right with time. Only 1 report 
mentions a high incidence of RAD in AM. 164 In the present study RAD and 
LAD were equally common in both AM and EFE. 
5. P WAVE 
P wave abnormalities occurred in 69.1% (85/123) of the series, second nly 
to T wave changes in order of frequency (Table 9.1). 
TABLE 9.3 ECG Abnormalities : Mean frontal plane QRS Axis Deviations , 
Comparison o"'f"frequency in patients without and with LVH at any stage 
of the course (Groups lC and 2C, respectively), and in survivors and 
deaths. 
NUMBER OF PATIENTS 
GROUP 
x2 
GROUP 
ECG lC 2C ALIVE DEAD 
ABNORMALITY (71) (52) (83) (40). 
LAD ALONE 7 9 0.887 13 3 . 
RAD ALONE 20 12 0.183 25 7 
LAD + RADO 6 4 0.033 9 1 
TOTAL LAD 13 13 0.455 22 4 
TOTAL RAD 26 16 0.234 34 8 
TOTAL AXIS 33 25 0.0001 47 11 
DEVIATION 
Total number of patients in each group indicated in parentheses. 
LAD - left axis deviation of mean frontal plane QRS vector 
RAD - right axis deviation of mean frontal plane QRS vector 
o - at different times 
x
2 
- statistical evaluation by Chi-square analysis 
* - significant difference at p <. 0. 05 
$ - 11 II II p(0.005 
) 
X 
0.9 ,o 
1.6 '6 
1.5 '3 
3.4 , 7 
4.314: 8 .o ,8 
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5.1 CRITERIA FOR ATRIAL ENLARGEMENT 
Criteria for right atrial hypertrophy or enlargement (Pra) in children are 
well established, i.e. a tall peaked P wave of greater than 2.5 mm (or 3 mm293 ) 
. l d 319 ... l d 13 in ea II or In any ea. Criteria for this study are noted in the 
key to Appendix D. 
Identification of left atrial enlargement depends more on descriptive 
criteria such as , 
"flat-topped P _waves of normal height in leads I and II with prolonged 
. + . . 29 . duration (normal being 0.06-0.02 mm in standard leads ) and with two 
383 
notches at least 0.05 seconds apart " 
"broad, notched or prolonged P waves in leads I, II~ VS and V6, or bi 
phasic P waves in V3R or Vl with negative portion slurred and of greater 
d . h d. . . . 293,, · uration tan prece ing positive portion ; or 
"prolonged terminal vector to the left and posterior, the latter usually 
319 being the larger". 
In this study, negative, bifid or notched P waves were frequently seed , 
either alone or in combination. Although these patterns did not comply with 
recommended quantitative indices for left atrial enlargement, such as the 
MaCruz index or those mentioned above, the characteristic shapes favoure a 
left atrial origin. The regularity with which these features appeared in 
the early phase and disappeared on treatment after a variable time, strongly 
suggested that they were caused by an acute but reversible event. The term 
"left atrial stress" (Pla) is therefore used, in preference to left atrial 
hypertrophy. 
It has been cla ·med that a distinct notch can always be seen in the normal 
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p wave, coincident with the change from a_predominantly anterior to a 
· · 319,l92 b h' d' th ECG t d bl orientation, ut tis pre-supposes recor ing e a ou e 
po9terior 
speed 
1 d d . . 193,319 and daub e stan ar isation. The presence of such notching is distinct-
ly unusual in standard ECG's of normal children. 
5.2 FREQUENCY OF ATRIAL ABNORMALITIES 
Of the total of 85 affected patients, only 7 had evidence of Pra alone, 
whereas 63 had features of Pla alone and 15 had both, either in the same ECG 
(in different leads) or in separate ECG's at different times (Table 9.4) J 
Hence, the overall incidence of Plain the series was 63.4% (78/123) and of 
Pra, 17.9% (22/123). 
There were no statistically significant differences in frequency of attrial 
abnormalities between Group lC and 2C patients or between survivors and 
.patients dying (Table 9.4). 
5.3 MORPHOLOGY OF ATRIAL ABNORMALITIES 
A bifid P wave was the conunonest sign of left atrial stress, occurrin1 
in 71 patients, while a notched P wave was noted in 33 patients and a ne1ative 
P wave in 17. The bifid Pas an isolated feature was seen in 28 patien ,s, 
and an isolated negative or notched Pin 7. The remaining patients had a 
combination of 2 (19 cases) or 3 (9 cases) abnormalities. 
of right atrial enlargement was found in 22 patients. 
5.4 EXTENT OF P WAVE ABNORMALITIES 
A peaked P wave 
The features of Pla were observed in lead Vl in every affected patient, 
with extension to lead V2 in 10, to V3 in 13 and to V4, VS or V6 in 9 cases. 
Involvement of the standard leads was unusual (7 patients), with lead II 
affected in each case. Evidence of Pra was characteristically observed in 
TABLE 9.4 ECG Abnormalities Atrial and Ventricular Enlargement. 
Comparison of ;frequency in patients without and with LVH at any stage 
of the course (Groups lC and 2C, respectively), and in survivors and 
deaths. 
NUMBER OF PATIENTS 
ECG 
ABNORMALITY 
Pla ALONE 
~ra ALONE 
Pla + Pra 
TOTAL Pla 
TOTAL Pra 
TOTAL ATRIAL 
ABNORMALITIES 
SVl ALONE 
RV6 ALONE 
SVl + RV6 
"TOTAL SVl 
TOTAL RV6 
TOTAL LVH 
R/S Vl 
lC 
(71) 
35 
4 
6 
41 
10 
45 
0 
0 
0 
0 
0 
0 
29 
GROUP 
2C 
(52) 
28 
3 
9 
37 
12 
40 
22 
8 
22 
44 
30 
52 
27 
x2 
0.100 
'f 
1.450 
1.784 
1.097 
1.983 
1.072 
ALIVE 
(83) 
44 
4 
10 
54 
14 
58 
15 
5 
13 
28 
18 
33 
40 
GROUP 
DEAD 
(40) 
19 
3 
5 
24 
8 
27 
7 
3 
9 
16 
12 
19 
16 
Total number of patients in each group indicated in parentheses. 
Pla = P wave features of left atrial stress 
Pra = P wave features of right atrial enlargement 
SVl = LVH by S wave voltage in lead Vl 
RV6 = LVH by R wave voltage in lead V6 
R/SVl = R to S wave racio in lead Vl 
x2 = statistical evaluation by Chi-square analysis 
I = numbers too small for statistical analysis 
No significant differences demonstrated. 
- patient distribution by definition. 
x? 
I 
0 .1145 
:/-
0.030 
0 .1120 
0.030 
0.004 
0.030 
0 .0106 
0.4?7 
0. 2 29 
0.611 
0.384 
0.438 
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lead II in 95.0% of cases, with involvemen~ of the right chest leads in nly 
2 patients. 
• 
5.5 TIME OF ONSET AND DURATION 
The majority of P wave abnormalities was present within the first 48 ours 
(53/85), or developed during the first week (75/85). In no patient did 
these features commence after 3 months. 
The abnormalities persisted for under 48 hours in 19 patients, 2 to 7 days 
in 16, 8 to 31 days in 17, 1 to 3 months in 15, and over 4 months in 18 
patients. 
Connnent 
The reported incidence of left atrial overwork in EFE varies between 0%, 368 
226 352 . 368 226 
·SO% and 58% ; of right atrial overwork between 25% and 33% ; and of 
biatrial enlargement, up to 45%. 368 There is no equivalent data in AM, but 
195 Greenwood et al report a 55.7% incidence of left, right or biatrial e large-
ment in primary myocardial disease in children. 
Strict quantitative criteria are not necessary to identify 
reversible left atrial stress. Having excluded artefact, even 
transient nd 
1 . . 11 as ignt 
notched or small bifid or negative P wave appears to represent an acute, 
dynamic event different from persistent left atrial hypertrophy, e.g. p-
mitrale of mitral stenosis. 
In this series, P wave abnormalities occurred with equal frequency in 
patients with AM and EFfi, and neither the morphology, extent, duration n r 
time of onset infl~enced the mortality rate. The high incidence of P 
abnormalities makes this a valuable diagnostic sign. 
f: 
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6. LEFT VENTRICULAR HYPERTROPHY 
6.1 CRITERIA FOR LVH 
Several indices of LVH were ruled out for the following reasons. The 
., 
pattern of deep Q waves with tall Rand T waves in the inferior and left 
chest leads74 is excluded by virtue of the tall T waves. LAD of the mea 
1 ' ' f ' h ' ld 319 d 11 d fronta QRS vector is a poor sign o LVH inc i ren, an is usua y e 
d . d f 318 to a con uction e ect. The wide variation in QRS width in normal 
children negated its use as a dependable index of LVH. 319 The fact that 
T wave flattening or depression was interpreted as an index of myocardial 
involvement in this study, precluded its use as a sign of LV strain161 , 2
3 
or of LVH by virtue of a widened QRS-T angle. 43 , 438 
According to Liebman and Plonsey, 319 increased voltage of the R wave i 
lead AVF, reflecting increased magnitude of the inferior vector, is 
in normal children. Increased magnitude of the leftward vector is 
as more dependable, and of the posterior vector as probably the 
ed 
criterion for LVH. Although these are best measured on the standard EC by 
the R voltage in VS and the S voltage in V2, respectively, the R voltage 
319 V6 and S voltage in Vl approximate these vectors closely. Age-relate 
SVl and RV6 voltages were therefQre used as the sole criteria of LVH int is 
study (.see key to Appendix D) . • 
Because a larger posterior vector will reduce th~ relative contributio of 
the anterior vector, the R to S ratio in Vl (R/SVl) would be expected to 
decrease significantly. This feature was evaluated but not adopted as 
index of LVH because of lack of consistent norms (see key to Appendix D). 
I ( ' 
\ 
6.2 FREQUENCY OF LVH 
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LVH was identified in 25.2% (31/123) of patients at presentation in 42.3% 
(52/123) at some stage of the illness, i.e. initially, intercurrently, o 
terminally; and in 22.0% (27/123) at the end of the study period (December 
1976). (see Chapter 4) 
A break-down of the indices of LVH appears in Table 9.4. An increase in 
posterior forces (SVl) was the dominant finding, occurring in 84.6% (44/5 ), 
compared with an increase in leftward forces (RV6) in 57.7% (30/52). 
There was no statistically significant difference in frequency of LVH 
between survivors and deaths. 
6.3 TIME OF ONSET 
LVH was present on admission in 31 patients. In the remaining 21 ents, 
LVH began early in the course in most, i.e. during the first week in 9, b tween 
1 and 4 weeks in 6, and between 1 and 6 months in 5. In only 1 patient id 
transient LVH develop later, i.e. at 26 months in patient number 67. 
The MR was similar whether LVH was present on admission (11/31) or dev loped 
subsequently (8/21). 
6.4 DURATION 
The duration of LVH and mortality are illustrated . in Figure 9.1. 
Of the 32 survivors, LVH resolved in 29 and possibly resolved in 2 (L 
present on last ECG after 20 days in patient no 97 and after 1 month in p tient 
no 108, both of whom were completely well clinically at 47 and 32 months, res-
pectively). Hence, only 1 patient (no 123) was known to have persistent LVH 
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FIG. 9.1 DURATION OF LVH ON ECG in the 52 patients with LVH at any sage 
of the course (Group 2C). 
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after 55 months duration. (This patient was 81 months old at presentation and 
may have had undetected long-standing myocardial disease at the time). 
Resolution of lJ,TH occurred within 6 months in 26 survivors, but was ~t 11 
possible after 18, 34 and 38 months (patient no's llo, 121 and 114, respe tively). 
All but 2 of the 20 patients who died still had LVH at the time of dea h. 
Patient no's 9 and 91 died 6 days and 1 month after losing their LVH. 
The MR appeared to be uninfluenced by the duration of LVH, except that 
there were no deaths in patients with LVH for more than 1 year. 
6.5 R/S RATIO IN LEAD Vl (R/SVl) 
A small R/SVl ratio for age was observed in 45.5% (56/123) of patients 
(Table 9.4) This sign was associated with an increased SVl and/or RV6 i 
27 cases, but was independent of ocher evidence of LVH in 29. Hence, if a 
diminished R/SVl was accepted as a criterion for LVH, the overall number , f 
patients with left ventricular overload would be 65.9% (81/123). 
There was no statistically significant difference in the number of patents 
with a diminished R/SVl between Group lC and . 2C, or between survivors and 
patients dying. (Table 9.4) 
Time of onset 
As with LVH, the decreased R/S ratio was present on admission in over alf 
the cases (30/56), and developed before 3 months in 21 of the remaining 2 . 
The MR was not significantly different whether the decreased R/SVl comrnen ed 
• . 2 
before (15/41) or after (1/15) one week (X = 3.462, p<0.10 >0.05). 
106 
Duration 
Decreased R/S ratios tended to be more protracted than other indices o 
LVH, persisting for over a year in 12 of the 56 patients compared with o 
4 of the 52 patients with definitive LVH. However, the decreased R/S r 
~ 
also resolved with time, persisting in only 3 of the ,40 survivors at the 
of the follow-up period (page 153) ; intermittently for 54 months in 
no 77, for 47 months in no 98, and 72 months in no 58. 
Comment 
476 In EFE, Sellers et al found the percentage frequency of 
alone to be 66% and 17% respectively in their autopsy group, and 26% 
in their clinical group, while SVl + RV6 together occurred in 10% in 
• J 
groups. In the present series (autopsy plus clinical cases), the perce 
frequ~ncy of SVl and RV6 alone was 43% and 15%, but the incidence of SVl + RV6 
was considerably higher (42%). 
476 Although the authors stated that LVH is reliable in differentiatin AM 
from EFE, their finding of a 17% incidence of RV6 or SVl + RV6 in 23 cas s 
of autopsy-proved AM emphasizes the overlap that exists between these 2 on-
ditions. 
The reported 83% incidence of a prominent posterior vector (diminishe R/SVl) 
in AM, relative to 17% in clinical EFE and 7% in autopsy EFE, 476 implies that 
this sign is ·more selective of AM. In the present ·study, however, a de 
R/SVl was of similar frequency in clinical AM (29/71) and clinical EFE ( 7/52). 
The similarity of frequency, duration, mode of onset and resolution i this 
study between a diminiihed R/SVl and SVl and/or RV6 suggested that the 
could be a useful additional sign of LVH in EMD. 
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In terms of the objective of this study, the late onset of LVH in 40.4. 
(21/52) of positive cases and its resolution within 1 year in virtually a 1 
survivors, supports the concept that EFE is aphasic event in acute EMO. 
Hence, individual .cases of AM could manifest LVH at any stage depending·o 
the development and timing of the EFE process. 
7. Q WAVE 
Pathological Q waves (criteria in key to Appendix D) occurred in 16.3% 
(20/123) of patients (Table 9.1). There was no significant difference i 
frequency between Group lC and 2C patients, or between survivors and deat s 
(Table 9.5). 
Associated ST segment changes occurred in 16 of the 20 cases. Twelve 
had ST· segment elevation and depression in different leads (infarct patten), 
and 3 had ST segment depression alone (subendocardial ischaemia). Only ne 
patient had ST segment elevation alone, possibly due to pericarditis. 
Pathological Q waves were present within 48 hours in 13 and within 1 ek 
in 16 patients. Q waves persisted for under 48 hours in 8 patients and or 
periods of 4 days to 6 months in 11. In the remaining patient (no 121) this 
sign was continuously present from 2 months to 21 months. The MR was not 
significantly different whether pathological Q waves were present ab ini 
(6/13) or later (2/7), or whether they were short-lived (4/8) or persist 
(4/12). 
Comment 
An infarct pattern is well-recognised in AM in both adults 178 , 353 and 
h 'ld 64,119,195,202',402,527 . b · 10% f 476 b . c i ren, in a out • o cases, ut is rare in 
EFE:Ol,324,368,356,476 In this study pathological Q waves and infarct 
TABLE 9.5 ECG Abnormalities : Q wave, ST segment and T wave 
abnormalitieS:- Comparison of frequency--"fn patients with~and 
with LVH at any stage of the course (Groups lC and 2C, respectively), 
and in survivors and deaths. • 
NUMBER OF PATIENTS 
GROUP GROUP ECG 
ABNORMALITY lC (71) 
2C 
(52) x2 
ALIVE 
(83) 
DEAD 
(40) 
PATHOLOGICAL Q 
WAVES 
ST SEGMENT 
ST+ ALONE 
ST - ALONE 
ST+ AND ST-
TOTAL ST+ 
TOTAL ST-
TOTAL ST ABNOR-
MALITIES 
T WAVES 
NORMAL 
FLAT/SHALLOW 
DEEP 
10 
19 
4 
9 
28 
13 
32 
2 
66 
3 
10 
8 
4 
15 
23 
19 
27 
2 
42 
8 
0.267 
1.652 
0.008 
4. 021 * 
0.121 
4. 278 * 
0.324 
'f 
3.104 
3.322 
11 
18 
5 
12 
30 
17 
35 
1 
76 
6 
Total number of patients in each group indicated in parentheses. 
ST+ = ST segment elevation 
ST- = ST segment depression 
FLAT= upright T wave<(l mm in VS and V6 
SHALLOW = inverted T wave Z2 mm in VS and V6 
DEEP= inverted T wave )2 mm in VS and V6 
x2 = statistical evaluation by Chi-square analysis 
* Difference significant at p< 0.05 
All other differences not significant 
'f numbers too small for analysis 
9 
9 
3 
12 
21 
15 
24 
3 
32 
5 
x2 
1.084 
0.017 
0.006 
3.221 
2.189 
3.225 
2.761 
'f 
2.379 
0.387 
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patterns were more common (16%) and occurred with equal frequency in bot 
AM and EFE. . . . . h . f 101 The higher MR reported in EFE patients wit an in arct pat ern 
was not confirmed in this series • 
.. 
8. ST SEGMENT 
ST segment abnormalities were common, 48.0% (59/123) of patients bein 
affected (Table 9.1). ST segment elevation (51 cases) was more prevale t 
than ST depression (32 cases), occurring on its own in 27 patients and 
together with ST segment depression in different leads in 24. 
alone was observed in 8 patients (Table 9.5). 
ST depre sion 
The total number of patients with ST segment depression, or ST depres ion 
plus elevation, was significantly greater in LVH positive than LVH negat·ve 
patients. (Group 2C)lC, p<0.05 in both cases). (Table 9.5) 
There was no statistically significant difference between survivors ad 
deaths in respect of incidence of ST segment elevation or depression, or both 
together. 
Comment 
The predominance of ST depression in suspected EFE is explicable on t e 
basis of subendocardial ischaemia due to severe LVH, as seen in hypertro 
cardiomyopathy or severe aortic stenosis. 
' h" d f . . h 226 in two t ir so patients wit EFE. 
This pattern is reported to ccur 
ST segment elevation is more li ely 
to occur in AM, due to an acute current of injury from myocardial cell · 
necrosis, or to acute pericarditis from extension of the inflammatory pr cess. 
9. T WAVES 
T wave flattening or inversion in the left chest leads (VS and V6) is the 
• I 
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" . . . d 22,116,476,538 
"sine quanon of diagnosis in both AM a_!! EFE. 
was observed in 96.87. (119/123) of patients and was first in order of fr 
of ECG abnormalities (Table 9.1). (The remaining 4 patients had ST seg 
abnormalities witttout T wave changes). 
9.1 T WAVE MORPHOLOGY IN RELATION TO LVH (Table 9.5) 
Of the 4 patients with normal T waves 1 had LVH at presentation, 1 de 
LVH later, and 2 did not have LVH at any stage. 
(no 12) resolved completely. 
Three patients died an 1 
Flat ( ( 1 mm), mildly inverted (~ 2 mm) or bifid T waves were observe in 
108 patients. Associated LVH was not seen at any stage in 66 patients : 18 
succumbed, 2 were lost to follow-up (case no's 29 and 38), 2 had residua T 
wave abnormalities when last examined (case no's 48 and 52), and 44 reso ed 
completely. 
LVH was present in 42 patients, from presentation in 27 and later in 5. 
Fourteen patients died, 4 were lost to follow-up immediately after admis ion 
(case no's 93, 97, 107, 118), 5 had persistent abnormalities when lasts en 
- 3 with residual T wave flattening (case no's 85, 95 and 122), 1 with r si-
dual LVH (case no 123), and 1 with both (case no 108)-and 19 resolved co -
pletely. 
Deep T wave inversion ('>-2 mm) was unconnnon in this study, occurring only 
11 patients, 3 without LVH at any stage (all resolved) and 8 with LVH (3 from 
the onset and 5 later). 
completely. 
Of the latter, 5 patients died and 3 resolved 
Thus, of the 119 patients with T wave abnormalities, 37 succumbed, 6 ere 
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lost to follow-up after admission, 69 resolved completely (1 had residual LVH), 
. + + 
and only 6 had residual T wave flattening 22.6-9,2 months (mean -SEM) aft r 
presentation. 
There was a tendency for deep T wave inversion to occur in patients 
and normal or flat T waves in those without LVH, but the differences were not 
statistically significant (p< 0.10, )0.05 in both cases). (Table 9 .5). 
CoIIUI1ent 
Complete resolution of T wave abnormalities was the rule in survivors, whether 
LVH coexisted or not. Deep T wave inversion tended to be associated wit LVH. 
9.2 T WAVE MORPHOLOGY IN RELATION TO EFE 
·Despite the paucity of autopsy-proved EFE in the clinical series (see hapter , 
13), this pathology was significantly more frequent in patients with deep T 
inversion than in those with normal, flat or shallow T waves, whether rel ted 
fa the number of postmortems (p < 0. 05), deaths (p< 0. 025) or patients (p O. 005) 
in each group (Table 9.6). This finding was not significantly influence by 
the relative MR (5/11 and 35/112, respectively - x2 = 0.387, p>0.50), or number 
of PM's performed (3/11 and 17/112, respectively - x2 = 0.371, p)'0.50) ~ ich 
were similar in both groups. 
Comment 
Deep T wave inversion was a reliable index of underlying EFE, but occu red 
infrequently. The finding of deep T inversion in 3 patients in Group lC 
implies that EFE may be present in the absence of LVH. 
TABLE 9.6 P.athological endocardial fibroelastosis (EFE) in relation 
to number of postmortems, deaths and clinical cases in patients with 
different_!~ morphologies. 
NUMBER OF PATIENTS 
NORMAL/FLAT/ 
SHALLOW T WAVES DEEP T WAVES 
EFE 
RELATIVE TO: 
POSTMORTEMS 
DEATHS 
TOTAL 
3 
17 
35 
112 
Explanatory notes and abbreviations as in 
* Difference statistically significant at 
** 
cb 
II 
II 
II 
II 
II 
II 
II 
II 
Table 9.5 
P< 0.05 
p<0.025 
p<.0.005 
3 
3 
5 
11 
x2 
4. 781 * 
** 5.49P 
8.2915d, 
\ 
CHAPTER 10 
SERU}1 ENZYME ANALYSIS 
1. INTRODUCTION 
Serum enzymes are widely used for the diagnosis of acute myocardial i 
tion7 , 432 but little attention has been directed to enzyme levels in acu e 
myocarditis (AM), 402 endocardial fibroelastosis (EFE), or in their diffe 
tion. Theoretically, myocardial cellular destruction which accompanies the 
acute inflannnatory process in A..~ (see Chapter 13) should result in excessive 
release into the serum of enzymes active in cardiac muscle, such as crea ine 
kinase (CPK) and lactate dehydrogenase (LDH). If EFE is non-infective or a 
pathological response to inflannnation initiated at an earlier stage, seru 
enzymes should not be elevated at the time of presentation. 
ST segment abnormalities on ECG accompany AM in about 107. of cases 476 nd 
1 368,476 b . . k "f h h . d" 1 EFE rare y, ut it is not nown i t ese c anges are pericar ia o 
ischaemic in origin. Higher serum enzyme values in association with ST 
changes may indicate myocardial damage. Furthermore, if mortality in ients 
with acute-onset endomyocardial disease (EMD) is related to the extent of myo-
cardial damage, se,· ·Jm enzyme analysis may be prognostically valuable. 
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1.1 AIMS 
Serum enzymes were therefore measured to investigate 
(i) their behaviour pattern in acute-onset EMD, 
(ii) their vilue in differentiating EFE from AM, 
(iii) their response in patients with and without ST segment changes n 
ECG, and 
(iv) their prognostic value in survivors and in patients dying. 
1.2 SELECTION OF ENZYMES 
When this study commenced in 1970, CPK, LDH and especially alpha-hydr y-
butyrate dehydrogenase (HBDH), which reflects LDH1 isoenzyme activity ma'nly, 
were regarded as the most reliable enzymes for detecting myocardial cell 
damage, and were therefore selected for evaluation. Estimation of the 
isoenzyme of CPK has become the more definitive test for myocardial infa 
433,530,546 in rec.ent years. 
1.3 TIMING OF ENZYME ESTIMATIONS 
Because the onset of cardiac involvement could not be· accurately time 
(unlike acute myocardial infarction), and a history of variable duration (up 
to one month) was accepted for entry of the patient into the study, freq ent 
enzyme estimations in the first days after admission were not performed. Serum 
for LDH, HBDH and CPK estimations was obtained, subject to the constrains of 
the clinical situation, during the first 48 hours after admission, and a ain 
during the remainder of the first week, during the second and third week, and 
after 21 days if the patient was still in hospital. These five interva s 
were considered sufficient to indicate trends in enzyme behaviour and pa ,terns 
of response, and to permit comparisons. 
1.4 METHOD 
The serum LDH estimation was based on the conversion of pyruvate to 1 ctate 
. h h . f + d. 232 wit t e conversion o NADH 2 to NAD , accor ing to Henry. Serum HBD ac-
tivity was measured by the method of Ellis and Goldberg,
133 
and CPK byte 
tm 
"Calbiochem" method, using the Super-Stat-pac (Catalogue No. 869214). 
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1.5 NORMAL VALUES 
Enzyme values in normal infants and children are known to be high and ariable 
484,531 
and reach the adult range during the first 3 years. In this stud , the 
normal ranges for children were established in the Biochemistry laborator of 
the Department of Pathology in the Institute of Child Health, UCT. The pper 
limit of normal for LDH was set at 320 u/1 for HBDH 250 u/1 before Augu t 1975 
and 225 u/1 after this date; and for CPK, 50 u/1 before August 1975 and he same 
for females, but 80 u/1 for males, after this date. (The higher values ere 
selected to demonstrate the upper limit of normal in the Figures). 
2, RESULTS 
The detailed results for each enzyme in the five time-periods are tabu ated 
in Appendix E. When more than one estimate of an enzyme was obtained in any 
single time-period (on fifteen occasions in 14 patients), the highest vale 
was accepted for analysis. 
At least one enzyme was measured in 100 of the 123 patients in the cl' ical 
series. LDH values were obtained in 96 patients 
twice in 26, three times in 16, four times in 3 and five times in 2 pati ts. 
HBDH levels were measured in 87 patients once in 39, twice in 29, thre times 
in 15, four times in 3 and five times in 1 patient. CPK values · were ob 
in 78 patients ; once in 36, twice in 27, three times in 10, four times 'n 3 
and five times in 2 patients. 
2.1 FREQUENCY OF ABNORMAL RESULTS 
In the first 48 hours, LDH values were above normal in 92.6% (75/81) f 
patients, HBDH in 88.2% (60/73), and CPK in 40.3% (25/62). LDH was abn rmally 
elevated at some stage of the illness in 91.7% (88/96) of patients, HBDH in 
80.5% (70/87), and CPK .in 44.9% (35/78). 
The frequency of elevated LDH did not differ significantly from that f HBDH 
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initially or at any stage, but both were significantly greater than the f e-
quency of elevated CPK initially (X2 = 43.178 and 23.439, p<::0.005 and<O 001, 
2 
respectively) and at any stage (X = 43.251 and 20.998, J><:0.005 1, 
respectively). .. 
2.2 OVERALL TRENDS 
The mean values for the three enzymes in each of the five time-periods are 
tabulated in Table 10.1 and illustrated in Figure 10.1. The most striki g 
elevations were noted soon after admis·sion in respect of LDH (3. 4 times 
and HBDH (2.5 times normal), with a progressive fall during the ensuing 
but with higher than normal levels persisting after 3 weeks. The mean 
rmal) 
eks, 
K 
only because of very few grossly elevated results (case no's 11, 19, and 9). 
There was no statistically significant difference in the mean values any 
of the three enzymes between consecutive time-periods, or between the in"tial 
and subsequent time-periods (except for the difference between the first and 
final time-periods in respect of LDH). 
Comment 
Although not compared with a normal control group, LDH and HBDH value were 
so high in many cases that cellular damage could be confidently diagnose . 
· 465 
However, cells other than myocardial also release these enzymes. In 
face of concomitant viral pneumonitis and/or encephalitis, hepatic conge 
from heart failure, and shock, the specificity for cardiac involvement c 
not be confirmed. 
. 131 286 In shocked patients, CPK is released from non-cardiac sources, ' such 
as underperfused skeletal muscle. CPK levels were markedly elevated in a few 
• 
TABLE 10.1 ~Comparison of mean serum enzyme levels (u/L) at differ1 nt 
times after presentation. 
TIME-PERIOD 
(DAYS) 
LDH 
HBDH 
CPK 
CONSECUTIVE 
PERIODS 
LDH 
HBDH 
CPK 
INITIAL cf 
LATER PERIODS 
LDH 
HBDH 
CPK 
1-2 
(81) 
1077. 8 
:'::114.36 
(73) 
::~\~ 
(62) 
126.7 
:!:34 .18 
1.143 
0.597 
-0.122 
ENZYME VALUES (MEAN :!:sEM) 
3-7 8-14 
(34) 
855.4 
:!:125,43 
(33) 
:!:1~;:;; 
(30) 
+134. 7 
-62.54 
(23) 
727. 7 
:!:152,10 
(26) 
442.1 
:'::s3 .82 
(20) 
37.6 
:!:6 .51 
t - statistic 
0.647 
0.531 
1.261 
0.572 
0.576 
-1.104 
1.143 
0.597 
-0.122 
1.523 
1.156 
1.472 
15-21 
(19) 
624.4 
:!:74,03 
(15) 
+375.5 
-42.55 
(16) 
120.5 
:!:83.90 
1.892 
1. 249 
0.079 
Total number of patients in each group indicated in parentheses. 
21 
14) 
+' 55.9 
-, 9.14 
12) 
80.3 
+ 
- 5.01 
1. 751 
1.807 
0.822 
13) 
43.6 
6.00 
2. 245 * 
1.545 
1.107 
u/L = international units per litre; LDH = lactate dehydrogenase; HBDH = alpha 
hydroxybutyrate dehydrogenase; CPK = creatine kinase 
cf = compared with 
t = Statistical evaluation by Student's t-test for unpaired samples. 
* = difference between 1-2 day and >21 day periods significant at p< 0.05 
All other differences not significant. 
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FIG 10.1 SERUM ENZYME VALUES (mean ~SEM) at different times after 
presentation. 
(LDH = lactate dehydrogenase, HBDH = hydroxybutyrate dehydrogenase, 
CPK = creatine kinase. 
Dashed lines indicate upper limits of normal. 
*=significantly lower than initial LDH value at p(0.05 level). 
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FI&. 10.2 Correlation of serum HBDH with LDij values at different times 
after presentation. (Linear regression and correlation coefficients; 
A. 1-2 days (70) : y = 0.598 X - 42.6, r = 0.85 
B. 3-7 11 (32) . : y = 0.683 X - 113. 5, r = 0.92 
C • . 8-14 11 (22) y = 0.582 X + 1.1, r = 0.94 
D. 15-21 11 (15) : y = 0.404 X + 124.1, r = 0.76 
E. , 21 11 (11) : y = 0.266 X + 154.7, r = 0.56 
-
Number of patients indicated in pa!entheses). 
.. r 
;- . 
~ 
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non-shocked patients but not consistently enough to be helpful diagnostically. 
The CPK enzyme has a shorter half life than either LDH or HBDH465 and levels 
may already have decreased by the time the first samples were taken. 
2.3 CORRELATION OF ENZYME RESULTS 
Correlation between HBDH and LDH, HBDH and CPK, and LDH and CPK has been 
analysed statistically. The derived linear regression equations and graphs, 
and the correlation coefficients for each time-period, are demonstrated in 
Figures 10.2, 10.3 and 10.4 for each enzyme correlation. 
A high degree of correlation (r')0.75) was found between HBDH and LDH in 
each of the first four time-periods. Similar strong correlations were noted 
between HBDH and CPK in the second and fourth time-periods, and between LDH 
and CPK iri the second time-period only. The similarity in position and slope 
of the lines of identity between HBDH and LDH for each time-period is strikingly 
apparent in Figure 10.2, as compared with the scattered positions of the linear 
regression lines in relation to HBDH and CPK (Figure 10.3) and LDH and CPK 
(Figure 10.4). 
Comment 
The strong correlation between LDH and HBDH 1s not unexpected, since the 
latter reflects the activity of LDH1 1soenzyme mainly. However, it does 
suggest that the generally excessive LDH activity 1~ due essentially to the 
more cardiac-specific enzyme moiety. 
2.4 COMPARISON OF LVH NEGATIVE AND LVH POSITIVE PATIENTS 
The comparison was made between patients without and with LVH on admission 
(Groups lA and 2A), since this classificati~n was most closely associated with 
r 
~ 
700 l 
600 -
soo I 
-A 
":; 
::c 
Cl 300 -CD 
::i::: B 
200 -
100 l 
0 I I I I 
0 so 100 150 200 
C PK (ufl) 
FIG. 10.3 Correlation of serum HBDH with CPK values at different times 
after presentation. (Linear regression and correlation coefficients; 
·A, 1-2 days (58) 
B. 3-7 11 ( 2 6) 
C, 8-14 II (19) 
D. 15-21 11 (12) 
E. 21 11 (10) 
Number of patients 
=~ 
! I 
:c 4c» 
Q 
_, 
·, 
2Ql-
y = 1.092 X + 464.2, r = 0.39 
y = 1.590 x + 268.0, r = 0.95 
y = 4.762 X + 268.5, r = 0.29 
y = 0.356 X + 304.0, r = 0.82 
y =-1.505 X + 351.7, r = 0.31 
indicated in parentheses). 
• l 
ol----1~----1-----1---0 50 100 150 
CPK l~J 
FIG. 10.4 Correlation of serum LDH with CPK values, at different times 
after presentation. (Linear regression and correlation coefficients; 
A. 1-2 days (57) y = 1.329 X + 836.1, r = 0.39 
B. 3-7 II (28) y = 1.678 X + 63.9.5, r = 0. 77 
c. 8-14 II (17) y = ·6,570 X + 540.9, r = 0.24 
D. 15-21 II (16) y = 0.544 X + 518.2, r = 0.55 
E, 21 II (11) y = 1. 266 X + 391. 7, r = 0.18 
Number of patients indicated in parentheses). 
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the timing of enzyme analyses. The mean values 1n each time-period for LVH 
negative and LVH positive patients in respect of LDH, HBDH and CPK are 
tabulated in Tables 10.2, 10.3 and 10.4, respectively, and graphically demon-
., 
strated in Figures 10.5, 10.6 and 10.7, respectively. 
Patients without .LVH had higher mean values than those with LVH in all 
time-periods in respect of LDH; in the first, second, third and fifth time-
periods regarding HBDH; and in the first four time-periods in respect of 
CPK. However, none of these differences was statistically significant. 
The mean LDH and HBDH values were above the normal range 1n both LVH negative 
and LVH positive patients in all time-periods, except for a normal mean HBDH 
value in the LVH positive group 1n the last time-period. Mean CPK values were 
abnormally elevated in LVH negative p·atients in the first, second and fourth 
time-periods, but were normal in LVH positive patients 1n all time-periods. 
Comment 
The higher LDH and HBDH values in LVH negative compared -with LVH positive 
patients, especially during the first week, is in keeping with the hypotheses 
that AM produces myocardial cellular damage more readily than EFE. However, 
the lack of statistically significant differences, and the fact that the values 
in LVH positive patients were also well above the normal range, precluded the 
use of these enzyme estimations as a differential t~st between AM and EFE. 
Although the difference in CPK values between LVH negative and LVH positive 
patients were also non-significant, the fact that abnormally raised levels 
were obtained only in the LVH negative group, albeit less frequently, suggested 
that this test might be , more discriminating in differentiating AM from EFE. 
TABLE 10.2 Serum LDH values (u/L) at different times after presentation: 
Comparison of pati~without and with LVH on admission (Groups lA and 2A, 
respectively).~ 
TIME-PERIOD LDH VALUES (MEAN + -SEM) 
(DAYS) 1-2 3-7 8-14 15-21 
GROUP lA (60) (24) (18) (15) 
+1157.4 
-146.93 
+ 925.4 
-173.58 
+ 735.7 
-193.93 
+657.3 
-84.95 
GROUP 2A (21) (10) (5) (4) 
+ 850.2 
-127.84 
+687.3 
-82.97 
+699.2 
-98 .11 
+ 500.8 
-153.08 
t 
lA cf 2A 0.642 0.862 0.097 0.856 
Total number of patients in each group indicated in parentheses. 
u/L = international units per litre. 
>21 
(11) 
459.0 
!59,41 
(3) 
444.7 
:!:91,94 
0.115 
t = Statistical -evaluation by Student's t-test for unpaired samples. 
No significant differences demonstrated . 
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+ !IG 10:5 Se:um LDH values (mean -SEM) at different times after presentation, 
in patients with and without LVH on admission (Groups 2A and lA, respectively). 
(LDH = lactate dehydrogenase. No statistically significant differences 
demonstrated. Dashed line indicates upper limit of normal). 
TABLE 10.3 Serum HBDH values (u/L) at different times after preseqtation: 
Comparison of "patients without and with LVH on admission (Groups lA and 2A, 
respectively). 
+ 
TIME-PERIOD HBDH VALUES (MEAN -SEM) 
(DAYS) 1-2 3-7 8-14 15-21 
GROUP lA (54) (23) (21) (12) 
-
+ 677.7 
-113.58 
594.9 
!144.27 
455.9 
:99.76 
+364.1 
-48.08 
GROUP 2A (19) (10) (5) (3) 
+ 499.2 +331.7 + 383.4 + 421.3 
-128.03 -31. 91 -135.33 -105.79 
t 
lA cf 2A 0.835 1.187 0.335 -0.524 
Total number of patients in each group indicated in parentheses. 
u/L = international units per litre. 
>21 
(9) 
:;i\~ 
(3) 
+234.7 
-26.67 
1.060 
t = Statistical evaluation by Student's t-test for unpaired samples. 
No significant differences demonstrated. 
800 I 
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1-2 3-7 8-14 15-21 > 21 
TIME PERiOO ( DAYS ) 
+ FIG. 10.6 Serum HBDH values (mean -SEM) at different times after presentation, 
in patients with and without LVH on admission (Groups 2A and lA, respectively). 
(HBDH = hydroxybutyrate dehydrogenase. No statistically significant diffe-
rences demonstrated). 
TABLE 10.4 Serum CPK values (u/L) at different times after presentation: 
Comparison in patients without and with LVH on admission (Groups lA ~nd 2A, 
respectively) . ., 
(MEAN + TIME-PERIOD CPK VALUES -SEM) 
(DAYS) 1-2 3-7 8-14 15-21 
GROUP lA (43) (19) (16) (14) 
+151. 4 
-48.05 
+188.3 
-97.21 
+ 41.6 
-7.73 
+127.0 
-96. 21 
GROUP 2A (19) (11) (4) (2) 
+ 70.9 + 42.3 21.5 +75.0 
-21.87 -14 .11 !6.13 -5.00 
t 
lA cf 2A 1.088 1.317 1.256 0.198 
Total number of patients in each group indicated 1n parentheses. 
u/L = international . units per litre. 
>21 
(10) 
+ 41. 4 
-5.88 
(3) 
51.0 
!19 .50 
-0.659 
j 
t . = Statistical evaluation by Student's t-test for unpaired samples. 
No significant differences demonstrated. 
C PK 
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FIG. 10. 7 Serum CPK values 
in patients with and without 
(CPK = creatine kinase. No 
(mean !sEM) at different times after presentation, 
LVH on admission (Groups 2A and lA, respectively). 
statistically significant differences demonstrated). 
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2.5 COMPARISON OF PATIENTS WITH AND WITHOUT ST SEGMENT ABNORMALITIES 
Mean serum LDH, HBDH and CPK values in patients with and without ST segment 
abnormalities on ECG are denoted in Tables 10.5, 10.6 and 10.7, respectively. 
Mean LDH and HBDH levels were higher in all time-periods in patients with 
ST segment changes on ECG than in those without, except for the first time-
period in respect of HBDH. This predominance was statistically significant 
in the final time-period only for both LDH and HBDH. Mean CPK values were 
higher in patients with ST segment changes in the second, fourth and fifth 
time-periods, but none of the differences was statistically significant. 
2.6 COMPARISON OF SURVIVORS AND PATIENTS DYING 
Mean serum LDH, HBDH and CPK values in patients surviving or dying subse-
quently are noted in Tables 10.8, 10.9, and 10.10, respectively. 
Mean LDH levels were higher in patients dying than in survivors in the 
second, fourth and fifth time-periods, but only the latter difference was 
statistically significant. Mean HBDH and CPK levels were higher in survivors 
than in patients dying during the first four time-periods, but there were no 
statistically significant differences. 
DISCUSSION 
The large number of patients with elevated serum enzyme values in this series 
and the high levels reached in many cases indicate gross cellular derangement 
in patients with acute endomyocardial disease (EMD). Although the selected 
enzyme tests lack specificity for myocardial involvement, their measurement 
appeared to be of valu~ in several respects. 
In acute myocardial infarction serum LDH and HBDH levels are reported to rise 
TABLE 10.5 Serum LDH values (u/L) at different times after presentation: 
Comparison in.,patients with and without ST segment changes on ECG. · 
+ 
TIME-PERIOD LDH VALUES (MEAN -SEM) 
(DAYS) 1-2 3-7 8-14 15-21 
WITH (41) (17) (13) (9) 
ST ABNORMALITY + 961. 9 +1010.6 +. 808.0 
!1~~\~ -123.09 -232.31 -264.15 
WITHOUT (40) (17) (10) (10) 
ST ABNORMALITY 
!i~~\; 
700.3 623.4 +590.9 
!109. 63 !33,54 -87.22 
t-statistic -1.026 1.247 0.593 0.466 
Total number of patients in .each group indicated in parentheses. 
t = statistical comparison by Student's t-test for unpaired samples. 
u/L· = international units per litre. 
*If = difference statistically significant at p< 0-025. 
l 
I 
>21 
(8) 
+548.9 
-41.48 
(6) 
!~~~8~ 
* 2.638 
I 
TABLE 10.6 Serum HBDH values (u/L) at different times after presentation: 
Comparison inpatients with and without ST segment changes on ECG. 
(MEAN + TIME-PERIOD . HBDH VALUES -Sr:M) 
(DAYS) 1-2 3-7 8-14 15-21 >21 
WITH (42) (18) (14) (6) 
ST ABNORMALITY + 589.9 + 608.6 + 471.1 +413.3 
-101.61 -176.43 -147.46 -81.11 
WITHOUT (31) (15) (12) (9) 
ST ABNORMALITY 676.7 403.1 +407.9 +350.3 
!164.05 !76.71 -66.54 -48.37 
t-STATISTIC -0.472 0.998 0.369 0. 713 
Total number of patients in each group indicated in parentheses. 
u/L = international units per litre. 
t = statistical comparison by Student's t-test for unpaired samples. 
o = difference statistically significant at p<0,02. 
(8) 
+321.5 
-25.60 
(4) 
+198.0 
-20.83 
3. ll5° 
., 
TABLE 10.7 Serum CPK values (u/L) at different times after presentation: 
Comparison in patients with and without ST segment changes on ECG. 
-- -
TIME-PERIOD CPK VALUES (MEAN :!:sEM) 
(DAYS) 1-2 3-7 8-14 15-21 
WITH (34) (13) (10) (9) 
ST ABNORMALITY + 121. 2 + 170.1 +35.0 + 184.8 
-47.79 
-126.09 -7.04 -148.98 
WITHOUT (28) (17) (10) (7) 
ST ABNORMALITY +135. 5 +107.7 
:!:1i~3~ 
+ 37.9 
-49.51 -57.32 -12.34 
t-STATISTIC -0.177 1.242 -0.391 0.861 
Total number of patients in each group indicated in parentheses. 
u/L = international units per litre. 
t = statistical comparison by Student's t-test for unpaired samples. 
No significant differences demonstrated. 
I 
>21 
(7) 
50.3 
:!:s.85 
(6) 
+35.8 
-7.40 
1.227 
TABLE 10.8 Serum LDH values (u/L) at different times after presentation: 
Comparison in survivors and deaths. 
TIME-PERIOD LDH VALUES (MEAN :!:sEM) 
(DAYS) 1-2 3-7 8-14 15-21 
SURVIVORS (55) (29) (20) (15) 
1175.4 841.6 730.9 615.4 
:!:154.92 :!:143.99 :!:173.12 :!:84.36 
DEATHS (26) (5) (3) . (4) 
· 871.3 + 936.0 + 706.7 + 658.0 
:!:134. 96 -197.32 -229.30 -176.38 
t-STATISTIC 1.246 -0.263 0.052 -0.228 
Total number of patients in each group indicated in parentheses. 
u/L = international un its per litre. 
> 21 
(10) 
386.3 
:!:50.83 
(4) 
I 630.0 
:!:55 .68 
-2.747 ° 
t = s·tatistical comparison by Student's t-test for unpaired samples. 
o = difference significant at p<, 0. 02. 
. I . TABLE 10.9 Setum HBDH values (u/L) at different times after presentation: 
Comparison in surviv~and deaths. 
TIME-PERIOD 
(DAYS) 
SURVIVORS 
DEATHS 
t-STATISTIC 
1-2 
(50) 
723.8 
!128.62 
(23) 
416.0 
!42.57 
1.599 
HBDH 
3-7 
(28) 
+ 547.0 
-119.75 
(5) 
336.8 
!62.18 
0.730 
+ VALUES (MEAN -SEM) 
8-14 15-21 
(23) (12) 
+453.4 
-94.34 
+379.8 
-52.94 
(3) (3) 
354.3 
!79_53 !;~~9; 
0.371 0.191 
Total number of pati_ents in each group indicated in parentheses. 
u/L = international units per litre •. 
t = statistical comparison by Student's t-test for unpaired samples. 
No significant differences demonstrated. 
>21 
(7) 
!Z~\~ 
I (5) 
!i~~3~ 
-0.647 
TABLE 10.10 Serum CPK values (u/L) at different times after presentation: 
Comparison in survivors and deaths. 
TIME-PERIOD CPK VALUES (MEAN !sEM) 
(DAYS) 1-2 3-7 8-14 15-21 
SURVIVORS 
-
(42) (25) (17) (12) 
+134.4 
!~~\i 
+38.8 144.3 
-47.12 -7.47 !112.12 
DEATHS (20) (5) (3) (4) 
+110.6 +26.20 31.0 49.3 
-39.30 -4.32 ! 11. 36 !15.88 
t-STATISTIC 0.324 o. 771 0.417 0.478 
Total nu~ber of patients in each group indicated in parentheses. 
u/L = international units per litre. 
t = statistical comparison by Student's t-test for unpaired samples. 
No significant differences demonstrated. 
I 
>21 
1(10) 
+ 41.5 
r 7.75 
(3) 
+50.7 
, 0.67 
-0.628 
·-
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after 6 to 12 hours, reach a maximum of 3.3-3.5 times normal between 24 and 72 
I 
hours and return to normal after 7 to 20 days, the time course being slightly 
.d . h h 465 more rapi wit LDH tan HBDH. In inflammatory cardiac disease, these 
enzymes are only slightly raised unless myocardial damage is severe, in which 
465 
case enzyme elevation may be prolonged. 
In this series, mean LDH and HBDH levels were at t ·heir maximum of 2. 5-3. 4 
times normal when first measured during the initial 48 hours and decreased 
slowly thereafter, but mean LDH values had not returned to normal even after 
21 days. Hence, the enzyme response simulates that of acute myocardial in-
farction and the duration of abnormality indicates that myocardial damage in 
acute EMD may be extensive. 
The results for both LDH and HBDH were very similar and there appears to 
be no advantage in using the HBDH test, despite its theoretically greater 
specificity for heart muscle and reported reliability in monitoring progress. 465 
Although higher LDH and HBDH levels were reached in LVH negative than LVH 
positive patients, the differences were not sufficiently large to allow dis-
crimination between AM and EFE. In fact, the degree of abnormality found in 
LVH positive patients encouraged the belief that EFE was also associated with 
an "active" disease process. However, these enzymes are known to be elevated 
with acute liver congestion (not with chronic liver congestion or acute left 
ventricular failure); 65 and this could have provoked the immediate enzyme re-
sponse in both AM and EFE. 
Though less common, CPK elevation appeared to be more reliable in differen-
tiating AM from EFE since mean values remained normal in LVH positive patients. 
130 
However, this enzyme may also be raised by- skeletal muscle disease (associated 
viral myositis, possibly) and transiently by shock, 465 ,which is common in AM 
(se"e page 57 ) • 
The higher early serum enzyme values· in patients with ST segment abnormalities 
than in those without, suggested a greater degree of myocardial cell damage in 
the forn:ier patients, but the results were not conclusive. However, the sig-
nificantly higher levels of LDH and HBDH after 3 weeks in patients with ST 
abnormalities indicated that ST changes may herald long-standing myocardial cell 
damage. 
Serum enzyme estimations in the first three weeks after admission were of 
little value as a prognostic indicator of survival or death. However, signi-
ficantly higher levels of LDH after 3 weeks in patients dying later suggested 
that late enzyme analysis may be prognostically more helpful. This differs 
from the close correlation between serial changes in total CPK activity and 
1 1 . . d. l . f . 51,487 ear y acute morta ity in myocar ia in arction. 
The overall impression was that these serum enzyme estimations provided a 
useful adjunct to the ECG in diagnosing acute EMD. Further studies with more 
cardio-specific enzymes are required to validate the findings of this study. 
It is of interest that measurement of the CPK2 isoenzyme, i.e. the MB fraction, 
was recently shown to be an effective means of detecting papillary muscle 
. . . h . . . d . ff. . . . 388 necrosis in neonates wit transient tricuspi insu iciency. 
; 
CHAPTER 11 
VIROLOGICAL INVESTIGATION 
1. AIM 
Although confirmation of a viral aetiology for either AM or EFE was not a 
primary objective in this study, an attempt was made to identify viruses by 
direct culture or by serological means in as many patients as possible, to 
establish if there was any difference in the yield of viruses between LVH 
negative and LVH positive patients. 
2. METHODS 
Throat swab, urine, stool and blood specimens were collected within 48 
hours of admission whenever possible, and refrigerated in previously prepared 
media until conveyed to the laboratory of the Department of Bacteriology, 
Medical School, University of Cape Town. Direct culture was performed on 
all specimens,and complement fixing and neutralising antibody titres were 
measured in sera by standard techniques. Antibody titres were repeated in 
specimens obtained after 2 weeks whenever possible. 
3. MATERIAL 
A detailed list of the specimens submitted- for investigation in each patient, 
and the positive and negative results obtained, are tabulated in Appendix F. 
i' I. 
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The number of patients (and samples) tested in the clinical series (Groups 
1 and 2) for each specimen submitted for viral culture and/or serology, and 
the number of positives obtained in each instance, appear in Table 11.1. 
Including the J post-mortem patients (no's 126, 131 and 133), viral culture 
and/or serology was performed in 78 of the 136 cases · (57%) in Groups 1, 2 and 3. 
Investigations were not performed in many patients who died within hours of 
admission and in most Group 3 patients. 
4. RESULTS NUMBER OF POSITIVES 
4.1 TOTAL SERIES 
A virus was isolated by direct culture in 22 patients (from a single source 
in 19, and two different specimens in 3). Positive serology was obtained in 
6 patients, in 3 of whom the same virus was detected by direct culture, and in 
one (no 97) an adenovirus was grown from sputum culture and a serum antibody 
titre to measles of 1:1024 was detected. Hence, 25 viruses were detected in 
·24 of the 78 patients tested (30.8%). 
Comment 
This yield compares favourably with reported results among similar patients, 
such as the 32.1% positive yield of virus in black children with respiratory 
disease in the Johannesburg area between 1966 and 1972. 265 
In epidemic AM, where the yield is expected to be higher, the number of viruses 
isolated relative to patients studied has varied from 9 of 9 cases386 to 2 of 3372 
262 
and 1 of 3 cases. In sporadic AM, Berkovich et al reported positive virus 
. 1 . ' 8 f 12 1 d h. d · 255 b · d · iso ation in o se ecte cases. Hutc ins an Vie o taine negative 
results in 5 patients with AM or EFE studied post-mortem,and only 1 positive in 
357 a pre-mortem study. 
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4.2 COMPARISON OF LVH NEGATIVE AND LVH POSITIVE PATIENTS 
There were no statistically significant differences between Group 1 and 2 
patients by any classification, either in the total number of patients with 
positive results,;or in the number of positives for any particular specimen 
tested or for all the tests together. (Table 11.1) 
Similar numbers of patients were tested in Groups lA and 2A for each of the 
specimens sent for investigation. However, when patients were r~-allocated 
to form different groupings (see Chapter 4) ,there was a significantly larger 
number tested by blood culture and serology in patients LVH positive at any 
stage (Group 2C">lC, p<"0.005), and at the end of the study (Group 2T::::,.1T, 
p<0.025). This resulted in a preponderance of the total number of LVH posi-
tive patients tested (Group 2C)>- lC, p<0.025). 
This distribution might be expected to result in the number of positive 
results being over-represented in these groups but this was not so, partly 
because of the small numbers of positive results obtained from blood culture 
or serology (8 out of 56 patients, and 9 out of 68 specimens tested). 
Comment 
V. . l . . . - 1255,274,357 h h l . l irus iso ation in EFE is most unusua , sot at t ere ative y 
high yield in LVH positive patients in this study is suprising. According 
310 311 to Lerner and co-workers, ' the evidence is insufficient for a cause-and-
548 effect relationship, but Waterson points out that a high order association 
is rarely achieved. It is possible that these viruses caused intercurrent 
infections which precipitated the clinical presentat_ion of underlying EFE. 
5. RESULTS VIRUSES IDENTIFIED 
All viruses identified, in relation to the date of presentation and number 
of patients investigated, are noted in Table 11.2. _ 
A wide variety of viruses (9 in all) was detected. 
TABLE 11.2 Viruses identified in the total series (Groups 1, 2 and 3). 
in relation to date of presentation and number of patients investigated. 
NO IN-
YEAR NO OF VESTI- MONTH VIRUS ISOLATED CASE 
PATIENTS GATED 
1970 10 5 SEPTEMBER ECHOVIRUS (? TYPE) 
OCTOBER ECHOVIRUS TYPE 9 
DECEMBER MEASLES* 
1971 7 4 NIL 
1972 16 15 APRIL HERPES HOMINIS 
MAY HERPES HOMINIS 
OCTOBER CYTOMEGALOVIRUS** 
II ECHOVIRUS . 
. 
II COXSACKIE VIRUS A 
NOVEMBER COXSACKIE VIRUS B 
DECEMBER ENTEROVIRUS (? TYPE) 
1973 33 17 APRIL POLIOVIRUS TYPE 2 
JULY HERPES HOMINIS ** 
II ADENOVIRUS 
SEPTEMBER ADENOVIRUS 
OCTOBER ADENOVIRUS 
II RUBELLA* 
1974 37 26 FEBRUARY CYTOMEGALOVIRUS** 
MAY PARA INFLUENZA TYPE 3 
SEPTEMBER HERPES SIMPLEX 
NOVEMBER. ADENOVIRUS ; MEASLES* 
DECEMBER ADENOVIRUS 
1975 13 7 JULY COXSACKIE VIRUS B 
JULY PARA INFLUENZA TYPE 
1976 20 4 SEPTEMBER ENTEROVIRUS (? TYPE) 
* Virus detection by serology. 
** Virus detection by culture and serology. 
All other viruses were identified by direct culture. 
+ Virus detected post-mortem. 
3 
NO 
66 
51 
58 
52 
117 
2 
4 
36 
28 
54 + 
32 
120 
71 
94 
45 
6 
103 
14 
81 
97 
108 
104 
or 4 133+ 
27 
': \ 136 
Enteroviruses comprised 367. (9/25) of all viruses identified. 
The majority of viruses was detected in the second half of the year (20/25) 
which coincided with the maximum seasonal incidence of case presentations 
(see Chapter 5). Furthermore, despite the paucity of numbers of each type, 
certain viruses appeared to cluster together in time. For instance, echo-
virus was isolated in 2 cases in September-October 1970, Herpes hominis virus 
in 2 cases in April-May 1971, Coxsackievirus and an unidentified enterovirus 
in 3 cases in October-November 1972 (though the Coxsackieviruses appeared to 
be of two distinct types), adenovirus in 3 cases, coincident with a major 
outbreak of AM in July-October 1973, and adenovirus again in 2 cases in 
November-December 1974. 
5.2 COMPARISON OF LVH NEGATIVE~ LVH POSITIVE PATIENTS 
Frequency of isolation of specific viruses was assessed in LVH negative and 
positive patients on admission, since this classification coincided with the 
timing of virus investigations. (Table 11.3) 
Of the 9 enter~viruses, 8 occurred in LVH negative patients (Group lA) and 
only 1 in LVH positive patients (Group 2A). 
tributed between Group lA and 2A patients. 
Comment 
Other viruses were equally dis-
The enteroviruses (especially Coxsackievirus, 69 , 134 , 155 , 171 , 196 , 186 , 230 , 246, 
262,258,280,277,309,372,468,386,528,534,171 d l l h . 36,280,337 
an ess common y ec ovirus 
d 1 . . 237,267,391,520) ll . d f AM 562 d h . an po iovirus are we -recognise causes o , an t eir 
relative preponderance in suspected AM cases compared with suspected EFE patients 
in this· study comr ~ies with this experience. 
{: 
\ 
., 
TABLE 11.3 Viruses isolated in patients without (Group 1) 
and with (Group 2) LVH on ECG on admission (A). 
NUMBER ISOLATED 
VIRUS GROUP lA GROUP 2A (16) (9) TOTAL 
ENTEROVIRUSES 8 1 9 
COXSACKIE 2 1 3 
ECHO 3 0 3 
POLIO 1 0 1 
UNIDENTIFIED 2 0 2 
OTHER VIRUSES 8 8 16 
ADENO 2 3 5 
HERPES 2 2 4 
MEASLES 1 1 2 
CY TOME GALO 1 1 2 
PARA INFLUENZA 1 1 2 
RUBELLA 1 0 1 
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Many of the other viruses identified in this study have been reported to 
· · 1 d h d . 233 l 416 cause AM in iso ate cases, sue as a enovirus, meas es, b 11 10,11 rue a, 
H . 1 576,558 and 1 . 73,569 h 1 . h . b . 1 . erpes simp ex cytomega ovirus, t e atter aving een imp i-
cated in EFE as well. 529 There have been no previous reports of Herpe~ 
homininis or parainfluenzavirus being associated with either AM or EFE. 
CONCLUSION 
The association of virus infection with the clinic~l condition in this 
study is of a low-order, as defined by the stringent criteria of Lerner and 
·1 310 Wison. However, the concurrence of positive results with the maximum 
incidence of case presentations, the tendency for the same viruses to cluster 
together during these time-periods, and the correlation of enteroviruses with 
suspected AM, encourages the belief that these organisms were aetiologically 
significant, either as causative (AM) or precipitating (EFE) agents. 
In terms of the objective of this study, it is apparent that there was no 
significant difference in the overall yield of virus between patients with and 
those without LVH on ECG. 
Assuming that LVH positivity on ECG correlates with EFE, it may be concluded 
(i) that viruses play an aetiological role at the time of presentation in 
both AM and EFE, 
(ii) that enteroviruses are particularly associated with sporadic AM, and 
(iii) that a wide variety of other viruses may be causal in AM and precipi-
tant in EFE. 
CHAPTER 12 
NATURAL HISTORY 
The 123 patients in the clinical series were initially followed from the 
time of their admission after the onset of the study in June 1970 till December 
1976 (a study period of 6 years 7 months), at which point _patients were classified 
into LVH positive or negative groups for comparative purposes (see Chapter 4). 
No new cases were admitted to the study thereafter, but observation was maintained 
for a further 2 years 3 months (observation period), so that the total follow-up 
period was 8 years 10 months. 
The long-term progress of these patients is discussed under the following 
headings: 
(i) Review of classification, 
(ii) Duration of follow-up, 
(iii) Interim course and mortality, 
(iv) Final status. 
1. REVIEW OF CLASSIFICATION 
Patient allocations t o each group as at the end of the study period (December 
1976) were reviewed at the end of the follow-up period (March 1979). There was 
! ' 
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no change of group allocation in the A-type classification (LVH negative or 
positive on admission). Similarly, because no patient developed LVH for the 
first time after December 1976, the number of patients in Groups lC and 2C 
(LVH negative or ~ositive at any stage of the course) remained constant: 
However, the T-type classification required alteration because resolution of 
LVH after December 1976 occurred in 5 of the 27 LVH positive patients (no's 58, 
102, 103, 116, 121), resulting in their conversion from Group 2T (now 22 patients) 
to Group lT (now 101 patients). Since 18 of the Group 2T .patients died and 3 
have been transferred or lost to follow-up after 19 to 48 months (no's 97, 108 
and 118) there is only 1 patient (no 123) still being observed with persistent 
LVH (after 55 months). · This form of classification was therefore not used for 
comparing LVH negative and positive patients in this chapter. 
2. DURATION OF FOLLOW-UP 
The duration of observation till death or final clinical, radiological, and 
ECG examination for each patient is tabulated in Appendix G. The mean duration 
of follow-up in each group is noted in Table 12.1. The C-type classification 
was used to compare LVH negative with LVH positive patients since this included 
patients who developed LVH at any stage. 
2.1 CLINICAL 
During the total follow-up period, 32.5% (40/123) of patients died within 
1 day to 386 days after presentation. The 83 survivors were followed for 19 
days to 104 months. Of these, 2 were lost to follow-up early, 23 days and 19 
days after admission (case no's 38 and 93, respectively) and 5 patients (no's 
33, 73, 76, 79 and 118) were transferred to their referral centres for continua-
+ 
tion of management . 34 days to 19 months (mean of 6.4-3.27 months) after admission. 
TABLE 12.1 Duration (mean! standard error of mean) of Clinical, 
Radiological and Electrocardiographic Follow-up of survivors and 
deaths in patients without (Group 1) and with (Group 2) LVH at any 
stage (C). 
DURATION OF FOLLOW-UP 
PATIENT STATUS GROUP TOTAL lC 2C t SERIES 
(71) (52) (123) 
SURVIVORS (months) (51) (32) (83) 
CLINICAL + 41. 7 +50.3 -1-.426 45.0 
-3.95 -4.29 !2.96 
RADIOLOGICAL 31.5 
!3.53 
37.7 
'!4.42 
-1.092 33.9 
!2.76 
ECG +34.7 41.4 -1.083 +37.3 
-4.05 !4.46 -3.03 
DEATHS (days) (20) (20) (40) 
CLINICAL + 31.5 + 81.3 -1.923 + 56.4 
-15.07 -21.06 -13. 39 
RADIOLOGICAL +19.6 + 67.5 -2.300* 43.5 
-9.33 -18.65 :!:10.98 
ECG 19.6 + 65.4 -1.976 42.5 
!13.32 -18.97 !12.02 
Total number of patients in each group and sub-group indicated in 
parentheses. 
t = statistical evaluation by student's t-test for unpaired samples 
* = difference is statistically significant ~t P< 0.05 
All other differences are not significant. 
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The remaining 76 patients (91.6%) were fol~owed for 3 to 104 months with a 
+ 
mean of 48.7-5.59 months. 
~ 
There was no significant difference in mean duration of follow-up between 
LVH negative and LVH positive patients among survivors and deaths. (Table 12.1) 
Comment 
d d . h 1 h. f . h AM3oo There are few reporte stu ies on t e natura istory o eit er or 
EFE.87,533 476 · . Sellers et al followed 33. patients with clinical EFE for 2 
to 8 years, but the author has been unable to find a single detailed report 
h 1 h . f · h.ld and few· d 1 · 39 , 4o, 453 on t e natura istory o AM inc i ren, very in au ts. 
195 Greenwood et al retrospectively reviewed a 20 year experience of 161 
patients with primary myocardial disease (including chronic non-obstructive 
cardiomyopathy, AM and EFE). Although the mean duration of follow-up was 
55 months in the 104 survivors compared with 45 months in 80 survivors in 
the present series, the percentage observed for over 2 years was 40.4% (65/161) 
compared with 49.6% (61/123) in this study. 430 Recently, Ribierre et al 
reported their experience of "apparently primary acute heart failure" (inclu-
ding AM, EFE and COCM) in 61 infant survivors followed for a 5 to 20 year 
period. 
2.2 RADIOLOGICAL 
The duration from admission until the final chest x-ray was performed varied 
from 4 days to 95 months in survivors and from 1 day to 330 days in patients 
dying. The mean duration of observation among the latter patients was sig-
nificantly longer in LVH positive than in LVH negative patients (Table 12.1). 
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Comment 
This result confirms the more protracted course in patients with EFE. 
2.3 ELECTROCARDI-OGRAPHIC 
The duration from admission until the last ECG was performed varied from 2 
day~ to 96 months in survivors and from 1 day to 330 days in patients dying. 
There was no significant difference in mean duration of follow-up between LVH 
I 
negative and LVH positive patients among survivors and deaths (Table 12.1). 
3. INTERIM COURSE AND MORTALITY 
3.1 
(a) 
CLINICAL 
READMISSIONS 
In general, patients continued to improve after initial hospitalisation, but 
+ 22 · patients required readmission on 25 occasions 8 to 345 days (mean -SEM of 
+ ) . 
.81.6-17.0 days after discharge. Readmission was precipitated by cardiac 
decompensation (17 instances) - mainly due to failure to take medication (10) 
or pneumonia (3) - or by pneumonia itself (8). 
There was no significant difference between Group 1 and 2 patients in either 
type A or C classifications, in respect of the delay between admissions or the 
duration of admissions themselves (Table 12.2). However, the incidence of 
readmission was significantly greater statistically in LVH positive than in LVH 
negative patients on admission (Group 2A'),-1A, p.(,0.05). 
Comment 
This finding suggests that patients presenting with established EFE are more 
resistant to treatment and run a more protracted course than those with AM or 
those developing E~E (LVH) later. 
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(b) MORTALITY 
In addition to the 23 patients dying during the first admission (Appendix B 
and Table 7.5), and the 4 during readmission (Table 12.2), 13 died at home or 
~ 
were brought to hospital in a terminal condition. 
Actuarial survival curvesl7 , 97 , 2o4 , 35s for LVH positive and LVH negative 
patients in the type A and C classifications are depicted in Figures 12.1 and 
12.3. The percentage follow-up of survivors (number of patient-months observed 
divided by the total possible, including patients lost or removed358) up to the 
end of the follow-up period was 69.3%. 
It is apparent from Figure 12.1 that almost the entire fall in survival 
occurred during the first year after presentation. Only 1 patient (no 112) 
died after this period (at 13 month~). The survival curves of the LVH posi-
tive groups (2A and 2C) were approximately 107. lower than the LVH negative 
groups (lA .and lC) from 2 years onwards. 
More detailed survival curves for the first year are depicted in Figure 
12.2. Group 1 curves fell more acutely than Group 2 curves during the first 
month but showed little change after the second month. GFoup 2 curves dropped 
at a slightly slower rate but for a period of 3 months, to reach a lower level 
than Group 1 patients. 
Figure 12.3 details the survival curves during the first month and high-
lights the fact that Group 1 curves fell more rapidly than Group 2 curves, 
particularly during the first 48 hours. 
There was no statistically significant difference between Group 1 and 2 
patients in respect of the overall or early (<.l day) mortality rates in the 
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FIGS. 12.1-3 ACTUARIAL SURVIVAL CURVES in patients without (Group 1) 
and with (Group 2) LVH on admission (Groups lA and 2A) and at any stage 
(Groups lC and 2C) during the total period of follow-up (Fig. 12.1), 
the first year (Fig. 12.2), and the first month (Fig. 12.3). 
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total series. (Table 12.3). However, early deaths in relation to total 
mortality were significantly less frequent in patients who developed LVH at any 
stage than in LVH negative patients (Group 2C)'-1C, p.(0.01). 
Comment 
It may be concluded that long-term survival was slightly better in patients 
with AM than in those with EFE. However, AM patients ran a more fulminant 
course in the first months, and particularly in the first 48 hours, while 
mortality in EFE patients occurred mainly between 1 and 3 months. This is 
exemplified by the mean survival rates at 48 hours, 1 month, 3 months and 1 
year,respectively, of 86%, 79%, 75% and 71% in LVH negative patients (Group lC) 
and 96%, 89%, 69% and 63% in LVH positive patients (Group 2C). The mean sur-
vival rates at these times for the series as a whole were 90%, 83%, 72% and 68%, 
respectively. 
. . . d d . .d . 163, High mortality rates early in the course have been recor e in AM epi emics, 
171,262' 283 d . 12 f 13 f d. AM b d an in one report o proven cases o spora ic succum e 
within 1 month. 195 The majority of deaths in EFE have been reported to occur 
84 226 195 
within 2 years, 18 months or 1 year (17 of 20 proven cases) ·, but may be 
sudden and unexpected. 573 
3.2 RADIOLOGICAL 
The cardio-thoracic ratio (CTR) on admission and terminally, the maximum and 
minimum CTR during the course, and their timing after presentation, are presen-
ted in Appendix H. The mean admission, maximum, minimum and final CTR's are 
summarised in Table 12.4. 
(a) COMPARISON Bi....fWEEN SURVIVORS AND PATIENTS DYING 
There was no significant difference between survivors and deaths in admission 
TABLE 12.3 Overall and early mortality rates in patients without 
(Group 1) and with (Group 2) LVH on admission (A) and at any stage 
of the course (C). ~-
NUMBER OF PATIENTS 
MORTALITY GROUP 
x2 
GWUP 
RATE lA 2A lC 2C 
TOTAL SERIES (92) (31) (71) (52) 
OVERALL 28 12 0.396 20 20 
x2 
1.018 
EARLY* 10 2 0.135 10 2 2.506 
TOTAL DEATHS (28) (12) (20) (20) 
EARLY* 10 2 0.686 10 2 
Total number of patients in each group indicated in parentheses. 
*~l day 
x2 statistical evaluation by Chi-square analysis 
+ di.f ference significant at P< 0. 01 
6.944+ 
TABLE 12.4 Radiological Cardiomegaly. Comparison of admission, maximum, 
minimum and final cardiothoracic ratios in survivors and deaths. 
CTR % 
ADM MAX MIN FIN ADM cf MAX 
SURVIVORS +64.9 66.3 +53.8 +55.3 -1.794 
(83) -0.62 :!:o.54 
-0.45 -0.43 
+68.4 DEATHS +65.9 62.8 +65.6 -1.841 
(39) 0 -0.94 -0.96 :!:o. 77 -0.97 
t-statistic 
SURVIVORS -0.944 -1.977 -10,613dl -11.228~ 
cf 
DEATHS 
Number of patients in each group indicated in parentheses. 
'O No x-rays available in patient No. 39 
CTR% percentage cardio-thoracic ratio 
ADM on admission 
MAX - . maximum at any stage of the course 
minimum II II II II II II 
t-statistic 
MIN cf 
FIN 
** 
-2.308 
* -2.208 
MIN 
FIN final x-ray performed at end of follow-up or prior to death 
cf 
t 
* 
** 
dl 
compared with 
statistical evaluation by 
difference siinificant at 
II II II 
II 
" " 
t-test for 
p <.. 0. 05 
p<_0.025 
p ( 0.001 
unpaired samples 
ADM cf 
FIN 
12.145dl 
0.260 
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or in maximal heart size (though in the latter case the CTR was greater in 
patients who died, p<0.10,) 0.05). However, both the minimal and final 
CTR's were very significantly greater in patients dying than in survivors 
(p<:0.001 in each~case). 
Comment 
It is to be expected that the CTR in patients dying would remain large, 
and this finding is unlikely to reflect an intrinsic difference between these 
two patient categories. Heart size on admission is reported to be of no 
. . . . 225,339,506 f . 476 prognostic value in determining outcome, except or one series. 
(b) COMPARISON BETWEEN LVH NEGATIVE AND LVH POSITIVE PATIENTS 
Statistical analysis revealed no significant differences between LVH negative 
(Group lC) and LVH positive (Group 2C) patients in respect of mean admission, 
maximum, minimum and final CTR's. 
(c) COMPARISON BETWEEN ADMISSION AND MAXIMUM CTR's 
The mean maximum CTR was greater than the mean admission CTR among survivors 
and patients dying, but the differences were not statistically significan~. 
(d) COMPARISON BETWEEN MINIMUM AND FINAL CTR's 
The mean minimum CTR was significantly smaller than the mean final CTR among 
both survivors and patients dying (p-<.0.025 and<:0.05, respectively), though 
both mean values in survivors were within the normal range. 
Comment 
It was expected that patients dying would have larger hearts terminally but 
this finding in survivors was not anticipated and reflects the considerable 
variability of CTR in individual cases during the course, the final CTR being 
150 
larger than the minimum CTR in as many as 53 patients. 
(e) COMPARISON BETWEEN ADMISSION AND FINAL CTR's 
., 
There was a highly significant decrease in mean CTR from admission to the 
final films in survivors (p<.0.001), but no significant difference in patients 
dying. 
Comment 
The persistence of marked cardiomegaly (indicative of heart failure) despite 
d h . . . . d b h 22,195,225, a equate t erapy is a poor prognostic sign, as pointe out y ot ers. 
339,364 
3.3 ELECTROCARDIOGRAPHIC 
The ECG features throughout each patient's course is tabulated in Appendix D 
and discussed in detail in Chapter 9. 
4. FINAL STATUS 
Each patient's status at the last clinical, radiological, or ECG examination 
at the end of the observation period, or before death, is tabulated in Appendix 
G. The number of patients allocated to normal, probable normal and abnormal . 
categories is indicated in Table 12.5. 
4.1 CLINICAL 
Of the 83 survivors, 74 were clinically normal ; 5 patients were probably 
normal in that the LV apex was either slightly displaced but not prominent, as 
frequently seen in normal young children with distended abdomens, or slightly 
prominent in the normal position, as often seen in anxious patients. There 
• 
were .only 4 patients (4.8%) with definite LVH on palpation. 
; 
TABLE 12. 5 Final clinical, radiological and electrocardiographic 
status among survivors and deaths. 
NUMBER OF PATIENTS 
CONCLUDING SURVIVORS (83) DEATHS (40) 
STATUS N PROB .N AbN N PROB N 
CLINICAL 74 5 4 - -
X-RAY 55 19 9 3 1 
ECG 55 14 14 1 1 
Total number of patients in each group appears in parentheses. 
N = normal • 
PROB N = probable normal, as defined in sections 4.1, 4.2 and 4.3 
AbN = abnormal 
TABLE 12.6 · Cardiothoracic ratio (CTR) in control 
patients during inspiration and expiration. 
I CTR % 
NAME AGE INSPIRATION EXPIRATION (years) 
LA 8.0 44.6 50.5 
GL 11.0 49.3 53.2 
NA 9,5 46.7 50.5 
LH 7.0 42.9 41.1 
VN 7.0 50.0 55.7 
CA 6.5 47.8 54.4 
AB 9.0 43.7 44.6 , 
LB 8.0 46.0 54.9 
~AN 
-SEM 
8:25 
!o.53 
46.4 
!o.91 
+50.6 
-1.85 
AbN 
-
36 
38 
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4.2 RADIOLOGICAL 
In the final x-rays a normal CTR (less than 55%) was demonstrated 1n 42 of 
the 83 survivors. Hence, as many as 49.4% (41/83) of patients were 1n the 
abnormal range as "'defined (page 23 ) • 
Comment 
The interpretation of the CTR at any time was complicated by two factors. 
Firstly, the CTR varied considerably depending on the phase of respiration 
during exposure, the degree of abdominal distention present and the state of 
sedation or otherwise of the patient at -the time. In a control series of~ 
normal older children aged between 6! and 11 years (in whom these factors are 
even less likely to operate) the difference in CTR between inspiration and ex-
+ + piration was a mean -SEM of 4.7-0.937. (Table 12.6), so that incorrect classi-
fication was highly likely. For this reason patients ·with a CTR% between 55 
and 60% in the final films were regarded as probably normal. 
Secondly, wide fluctuations 1n CTR. were observed in many cases so that, 
despite the marked decrease in mean CTR between admission and final films in 
survivors (Table 12.4), mean maximum CTR during the course was greater than 
mean admission CTR and mean minimum CTR was significantly smaller than final 
CTR - see sections 3.2 (b) and 3.2 (c). For this reason patients with a 
final CTR% between 55 and 607. who had CTR's of under 55% 1n earlier films 
were regarded as normal. 
Revised status 
Of the 32 survivors with a final CTR of between 55 and 60%, 13 had a 
previous CTR of under 55%. Hence, of the 83 survivors, 55 were classified 
normal, 19 probably normal and 9 abnormal. 
Among the 40 patients who died, 1 was similarly reclassified normal and 1 
probably normal, giving final figures of 3 normal, 1 probably normal and 36 
abnormal (Table 12.5). 
! ' 
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4.3 ELECTROCARDIOGRAPHIC 
Details of the final ECG's are discussed in Chapter 9. Patients with 
minor ECG changes, including left or right axis deviation of the mean frontal 
QRS vector, prolo~ged PR interval, or decreased R/SVl ratio, were regarded as 
probably normal ; those with major changes such as atrial abnormality, LVH, 
ST-T wave changes or arrhythmias, were regarded as abnormal. On this basis, 
55 of the 83 survivors were normal, 14 probably normal and 14 abnormal. Of 
the 40 deaths, 1 was normal, 1 probably normal and 38 abnormal (Table 12.5). 
4.4 COMPARISON OF LVH NEGATIVE AND LVH POSITIVE PATIENTS 
Because of the varying LVH status during the course (see page 29 ), only 
the C-type classification (with or without LVH at any stage) was evaluated in 
comparing the final outcome. Probable normal patients were incorporated into 
the normal groups for this purpose (Table 12.7). 
There were no statistically significant differences in frequency of abnormal 
status, clinically, radiologically or on ECG between LVH negative and LVH posi-
tive patients, among survivors or patients dying. 
4.5 COMPOSITE RESULTS 
The combined final results are summarised in Figure 12.4. 
Of the 83 survivors, 61 ·were normal in all respects. 
Ten patients had ECG abnormalities only. In 3 of these (case no's 29, 59 
and 97) final ECG's were performed within 1 month of admission, but the patients 
were well 9 to 49 months later ; 2 patients (no's 52 and 93) were lost to follow-
up 6 months and 19 days after admission; and in 5 (case no's 48, 85, 95, 122 
and 123) ECG abnormali~ies persisted for between 12 and 65 months. 
Six patients ha~ radiological cardiomegaly only; 3 (case no's 11, 79 and 102) 
TABLE 12.7 Clinical, radiological and electrocardiographic status 
at end of stuay. Number of patients with residual abnormalities in 
Groups lC and 2C among survivors and deaths. 
NUMBER OF PATIENTS 
SURVIVORS DEATHS 
CONCLUDING GROUP 
x2 
GROUP 
STATUS lC 2C lC 2C-
(51) (32) (20) (20) 
CLINICAL - LVH 2 2 0.002 - -
X-RAY - C 5 4 0.001 16 20 
ECG - AbN 5 9 3.491 18 20 
Total number of patients in each group indicated in parentheses. 
C = cardiomegaly; AbN = abnormal 
x2 = statistical evaluation by Chi-square analysis. 
No significant differences demonstrated. 
lQ.IAL 
A 
SURVIVORS DEATHS 
83 (62·5°/o) 40 (37-5 °/o) 
COMPLETE~BESIDUAL 
RECOVERY ABNORMAL ITIES 
61 (49,6°/o) Total Series" =-12 Months· 
22 (17-9°/o) 11 (8·9°/o) 
10 ECG S 
6 RADIOL 3 
-2 CUN 
2 RADIOL + ECG 1 
RADIOL + CLIN 1 
1 RAOIOL•CLIN • ECG 0 
FIG. 12.4 FINAL OUTCOME. Number of patients 1n each category . 
. 
including patients lost to follow-up or transferred. 
+ follow-up of all parameters for at least 12 months. 
ECG= electrocardiographic abnormalities, RADIOL = radiological 
cardiomegaly, CLIN = clinical cardiomegaly (LVH). 
x2 
2.500 
0.526 
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between 1 and 8 months and 3 (case no's 21, 55 and 72) between 23 and 30 months 
post-admission. 
Clinical cardiomegaly alone was noted in two patients (no's 32 and 106) 26 
., 
and 8 months after presentation. 
Patient no 38 had clinical cardiomegaly and T wave flattening on ECG but 
was lost to follow-up after 23 days ; and 2 patients had radiological and ECG 
abnormalities at 31 and 28 months (case no 5) and 11 months and 7 days (case 
no 118). (The latter patient was clinically normal at 19 months but later ECG's 
were not available). 
Only 1 patient (no 108) had clinical and radiological cardiomegaly (after 32 
months) as well as ECG abnormalities (at 2 months - later ECG's not available). 
None of these 22 patients was symptomatic. 
Hence, where follow-up data was available in each parameter for at least 12 
months, only 11 (13.3%) patients had residual abnormalities - 5 on ECG only, 3 
on x-ray only, 1 clinically only, 1 clinically and radiologically, and 1 radio-
logically and on ECG (Figure 12.4). 
Of the 40 deaths, 35 patients had abnormalities of x-ray and ECG, 3 (case 
no's 17, 34 and 75) had ECG abnormalities alone, and 1 (case no 6) radiological 
cardiomegaly alone. 
normal ECG and x-ray. 
Patient no 2 was the onlf one to die with an apparently 
In summary, therefore, of the original 123 patients presenting with severe 
and acute endomyocardial disease (EMD), 32.5% died, 49.6% recovered completely, 
and 17.9% have residual abnormalities (8.9% after follow-up of all parameters 
for over 1 year). 
i' 
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5. DISCUSSION 
5.1 ENDOCARDIAL FIBROELASTOSIS (EFE) 
16 113 203 274 . EFE was considered to be almost uniformly fatal ' ' ' until reports 
· 60' · d. d h · 1 "bl 322 , 339 d h · in the 19 sin icate tat surviva was possi e, an tat asymptomatic 
cases with residual radiological and ECG abnormalities occurred. 353 , 532 Re-
cently, Hastreiter and Fisher226 claimed that only 14% of patients with EFE 
survived beyond 18 months of age, while Chen et a1 84 quoted a mortality rate 
(MR) of 44% in 132 cases diagnosed clinically and pathologically. Sellers et 
476 
al asserted that one-third of patients died, one-third had residual abnormali-
ties and one-third resolved completely. 
The overall . MR of patients with EFE in this study-. 38.7% (12/31) in those 
with LVH on ECG on admission and 38.5% (20/52) in those with LVH at any stage 
of. the course - coincides with the latter estimates, but the frequency of 
residual abnormalities after follow-up of all parameters for at least 12 months 
was very low - 12.9% (4/31) in patients with LVH on admission and 11.5% (6/52) 
in those with LVH at any stage. 
5.2 ACUTE MYOCARDITIS (AM) 
Although the MR in epid~mic AM is known to be high, 163 , 171 , 262 , 283 there is no 
report in the English literature of a large series of patients presenting with 
525 
sporadic AM (albeit on clinical grounds) comparable to the present one. The 
MR was 30.4% (28/92) in patients without LVH (ECG) on admission and 28.2% (20/71) 
in those without LVH at any stage. 
There is also very little information on the long-term outcome of survivors 
f 1 . . 11 d' d AM • d 1 39,40,199,453 d 1 . h'ld 43 o c inica y iagnose in au ts an even ess inc i ren. 
According to Gear and Measroch, 171 survivors of epidemic neonatal AM recover 
~ 43 
completely, but Berkovich et -al found abn~rmal cardiac signs 1 to 5 years 
i' 
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after presentation in 5 of 12 patients dia&!losed as sporadic AM on the basis of 
clinical and ECG evidence and positive virology. 
In the present~study, the frequency of residual abnormalities after follow-up 
of clinical, radiological and ECG parameters for at least 12 months was only 
7.7% (7/91) in patients without LVH (ECG) on admission and 7.0% (5/71) in those 
without LVH at any stage. ~ 
/ 
5.3 ACUTE ENDOMYOCARDIAL DISEASE (EMD) 
If one accepts that AM and EFE are 2 phases of one condition, i.e. acute EMD 
of infants and young children, then the overall frequency of abnormalities after 
follow-up of all parameters for at least a year was 8.9% (Figure 12.4). 
· This figure differs considerably from the 37.9% (61/161) incidence of residua 
195 
. in primary myocardial disease (PMD) in children quoted by Greenwood et al 
(58.7% of all survivors), of whom 51 patients had ST-T wave changes, 37 had 
radiological cardiomegaly and 21 clinical heart failure. .b. 1430 Ri ierre et a 
reported a slightly more favourable outcome for 61 survivors with "apparently 
primary acute heart failure" in infants under 30 months (including AM, EFE and 
COCM), followed for 5 to 20 years. Residua were found in 28 (45.9%) of whom 
22 had ECG and radiological abnormalities, 3 had persistent heart failure, and 
3 died .subsequently. 
The lower incidence of residua in the present series is probably due to the 
rigorous exclusion of patients with COCM wherever possible, and to the constant 
surveillance of patients who are being followed prospectively. This favourable 
outlook following a high early MR is in line with the opinion of Ribierre et ai. 430 
. 
. r 
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5.4 CONCLUSION 
It is therefore concluded that, despite the high early MR, the vast majority 
of patients with acute EMD (AM and EFE) surviving more than 1 year, and receiving 
adequate observation and treatment, will recover in time. 
; 
.This finding, and the fact that even those patients with residua are pro-
gressively improving, makes it very unlikely that either clinical AM or EFE is 
a significant aetiological factor in the development of idiopathic, chronic 
congestive cardiomyopathy (in children), contrary to the claims of some 
th 199,457 au ors. However, the possibility that sub-clinical viral infection 
may be pathogenetically important through some other mechanism cannot be dis-
counted. 
CHAPTER 13 
PATHOLOGY 
Autopsy results were available in a total of 37 patients, including 20 from 
the clinical series (Group 1 and 2), 13 from the autopsy series wfrh a short 
history (Group 3), an? therefore comparable with the former patients, and 4 
from the autopsy group with a long history (Group 4). (Appendix A). 
Of the 40 deaths in the clinical series, autopsy was not possible on reli-
gbous grounds in 6 instances, Moslem in 5 and Apostolic in l (case no's 3, 4, 
13, 17, 24 and 94), and because of death at home in 4 (case no's 6, 8, 47 and 
111). Permission for autopsy was refused in the remaining 10 patients (case 
no's 2, 16, 18, 49, 75, 91, 104, 107, 110 and 112). The clinical diagnosis 
of acute EMD was confirmed in all 20 patients who came to autopsy. The 
autopsy rate for all deaths was 657. (37/57). 
The cardiac and major non-cardiac findings in the 37 patients are listed in 
Appendix I and summarised in Tables 13.1 to 13.4. 
into groups according to the presence of 
Patients have been separated 
(i) the characteristic viral-type, mononuclear inflammatory cell 
infiltration, intercellularly in the myocardium, either diffusely 
f 11 . h . l 482 (. . ) or oca yin t e peri-vascu ar areas indicated by the letter M, 
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(ii) the typical features of EFE, i.e. a thickened, white or pale, 
opaque endocardial membrane with excessive collagen and elastic 
tissue on histology 497 , 515 (indicated by the letter F), or 
(iii) featyres of both (indicated as M+F). 
1. CARDIAC FINDINGS 
1.1 MORPHOLOGY 
All 15 patients with EFE were identified on macroscopic examination. The 
fibroelastotic endocardium was thick and obvious in the 7 patients classified 
F (grade 3+ in 2, and 2+ in 5) and in 6 of the 8 patients with M+F (graded 3+ 
in 1, and 2+ in 5). The features were less impressive in patient no 64, and 
in patient no 117 the endocardium was opacified but thin histology confirmed 
the presence of considerable collagen and elastic tissue (Appendix I). 
Generalised cardiac enlargement was noted in all groups, most conunonly in 
a 
patients .with M+F. (Table 13.1) The appearance of-pale, flabby heart, with 
small pericardial effusions (5 to 20 ml), congestion, and petechiae, was 
typical of patients with Mand unconunon in those with For M+F, though the 
difference in frequency between these groups was not statistica~ly significant · 
(Table 13.1). Mottling tended to occur in M+F patients as well as those with 
Malone. 
The single patient with pericarditis (case no 135) and the 2 with ante-
mortem thromboses in the left ventricle (case no's 62 and 129) all had Malone. 
Both patients with intrinsic mitral valve fibrosis and distortion (case no's 
138 and 140) had F alone and histories of long-standing. 
Left ventricular hypertrophy (LVH) and left atrial enlargement (LAH) were 
more frequent in the patients with F and M+F than in those with M, the diffe-
TABLE 13.1 Pathology. Frequency of macroscopic cardiac features in 
patients with paShological myocarditis (M), fibroelastosis (F), and 
both (M+F). 
NUMBER OF PATIENTS 
x2 MACROSCOPIC M M+F F TOTAL F 
FEATURES (22) (8) (7) (15) M cf TOTAL F 
ENLARGED 13 8 2 10 0.015 
PALE 7 1 1 2 0.804 
FLABBY 7 1 0 1 2.011 
PERIC. EFFUSION 8 1 2 3 0.494 
CONGESTED 8 0 1 1 2.812 
MOTTLED 12 3 1 4 1.803 
PETECHIAE 5 0 1 1 0.718 
Total number of patients in . each group indicated 1n parentheses. 
cf= compared with 
PERIC. = pericardial 
x2 = statistical evaluation by Chi-square analysis. 
No significant differences demonstrated. 
TABLE 13.2 Pathology. Frequency of cardiac chamber enlargement in 
patients with pathological myocar_ditis (M), fibroelastosis (F), and 
both (M+F). 
NUMBER OF PATIENTS 
x2 CHAMBER M M+F F TOTAL F 
HYPERTROPHY (22) (8) (7) (15) M cf TOTAL F 
LVH 10 7 6 13 4 .807 * 
RVH 6 3 5 8 . 1.254 
LAH 1 1 4 5 3.391 
RAH 2 1 1 1 :/: 
Total number of patients 1n each group indicated in parentheses: 
cf= compared with 
LVH = l_eft ventricula'r hypertrophy; RVH = right ventricular hypertrophy; 
LAH= left atrial enlargement; RAH= right_ atrial enlargement. 
x2 = statistical evaluation by Chi-square analysis. 
* = Difference significant at p<. O. 05, 
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rence being s.tatistically significant for LVH (p<0.05). (Table 13.2). 
CoIIDI1ent 
Macroscopic features in hearts of the M+F group tended to be similar to 
those in the F group and showed a similar propensity for left-sided cardiac 
chamber enlargement. 
1.2 HISTOLOGY 
Microscopically, evidence of myofibre· degeneration (loss of striations, 
vacuolization, and pyknotic nuclei), fragmentation (disruption of cell 
membranes) and necrosis (destruction of recognisable myocardial cell shape 
with presence of cell debris, hyalinization, and collagen deposition in the 
myocardium), was significantly more frequent in patients with M than in those 
with F and M+F (p<0.01). (Table 13.3). Furthermore, the severe degree of 
myocellular destruction (necrosis) was common in patients with M (11/22) but 
did not occur in patients with M+F (0/8). 
common in patients with F. 
By contrast, hypertrophy was more 
InflaIIDI1atory cell infiltration with mononuclear cells, mainly lymphocytes 
(Table 13.3), varied 1n intensity from diffuse and severe (3+) to patchy and 
moderately intense (2+), in 21/22 patients with Mand 5/8 with M+F. Focal 
and mild (l+) inflammation was observed in 1/22 patients with Mand 3/8 with 
M+F. Evidence of cellular infiltration was, therefore, somewhat less marked 
in the M+F group. 
· Correlation of the degree of myocardial destruction with the degree of 
inflaIIDI1atory cell infiltration (Figure 13.1) demonstrates the tendency for 
patients with M to hav~ ++or+++ cellular infiltration associated with severe 
destruction (necrosis), while patients with M+F tended to have+ or++ cellular 
infiltration with milder or no evidence of myocardial destruction. Occasional 
TABLE 13.3 Pathology. Microscopic cardiac features in patients 
with pathological rnyocarditis (M), fibroelastosis (F), and both (M+F) . 
., 
NUMBER OF PATIENTS 
x2 MICROSCOPIC M M+F F TOTAL F 
FEATURES (22) (8) (7) (15) M cl TOTAL F 
MYOFIBRES: 
DEGENERATION 8 2 2 4 
FRAGMENTATION 5 2 0 2 
NECROSIS 11 0 0 0 
~l ABNORMALITY . 17 2 2 4 7.359+ 
HYPERTROPHY 1 1 4 5 3.391 
INTERSTITIUM: 
LYMPHOCYTES 15 1 -
MONOCYTES 1 0 -
PLASMA CELLS 4 1 -
HISTIOCYTES 1 1 -
MONONUCLEARS 5 7 -
)1 ABNORMALITY 22 8 -
CONGESTION 8 2 2 4 0.068 
Total number of patients in each group indicated in parentheses. 
cf= compared with 
x2 = statistical evaluation by Chi-square analysis. 
+ = Difference significant at p<. 0. 01. 
. 
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FIG. 13.1 PATHOLOGY. Correlation of degree of myocardial cell 
destruction(+= degeneration; ++=fragmentation; +++=necrosis) with 
inflammatory cell infiltration(+= mild and focal; ++=moderate and 
patchy; +++=severe and diffuse). 
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patients with F had degenerative changes but no inflammatory cells (by defini-
tion). 
Comment 
The coexistence of features of both AM and EFE in· 21.67. (8/37) of patients 
is highly suggestive of a common aetiological factor. The fact that this 
group (M+F) manifests varying grades of pathology intermediate between AM with 
acute inflammation and myocardial necrosis at one end of the spectrum, and EFE 
with chronic endocardial fibroelastotic "reaction" and myocardial hypertrophy 
at the other, supports the contention that EFE may evolve from AM over a period 
Of . 255,467 ti.me. 
Further evidence in favour of this conclusion includes the high incidence 
of. interstitial myocarditis in patients with EFE reported by Fruhling et al, 166 
467 43 126 255 512 466 Schryer and Karnauchow and others ' ' ' ' (see page 9 for further 
details). Several of these authors166 , 255 also described necrosis (as in this 
study), fibrosis and even calcification in the interstitium, which refutes the 
f - d. f · b d · lf b555 d h 415 , 426 h d. 1 1.n 1.ngs o Wein erg an ~1.nune ar an ot ers tat myocar 1.a scars 
are absent in EFE. The disappearance of these features may be time-dependent 
d b h · d · 255 h f d . . 1 d . . . f as suggeste y Hutc 1.ns an Vie, w o oun tr1.v1.a or no myocar 1.t1.s 1. 
EFE persisted for more than 4 months. These authors also emphasized the 
gradation of pathological features, as found in the present series. 
2 • . NON-CARDIAC FINDINGS 
A summary of the major non-cardiac pathology appears 1.n Table 13.4. 
Pathological features of viral pneumonitis and/or bronchiolitis occurred 1.n 
78.4% (29/37) of the autopsy cases, and were equally common in patients with M, 
,. 
\: 
\ 
TABLE 13.4 Pathology. Non-cardiac findings in patients with 
pathological myocarditis (M), fibroelastosis (F) and both (M+F). 
NUMBER OF PATIENTS 
PATHOLOGY M M+F F TOTAL F x2 
(22) (8) (7) (15) M cf TOTAL F 
VIRAL PNEUMONITIS 17 7 4 11 
" BRONCHIOLITIS 8 3 2 5 
~ 1 ABNORMALITY 18 7 4 11 
BACTERIAL PNEUMONIA 4 0 3 3 
- PRIMARY 2 0 2 2 
- SECONDARY 2 0 1 1 
LYMPHOID HYPERPLASIA 18 6 4 10 
PULMONARY CONGESTION 10 5 4 9 
HEPATIC CONGESTION 16 0 4 4 
- FATTY CHANGE 12 4 4 8 
- CIRRHOSIS 0 1 0 1 
~l ABNORMALITY 16 5 7 12 
·RENAL CONGESTION 5 1 1 2 
- INFARCTS 2 ~ 0 0 0 
- ACUTE TUBULAR 1 1 0 1 
NECROSIS 
- ACUTE GLOMERULO- 1 0 1 1 
NEPHRITIS 
~l ABNORMALITY 9 2 . 2 4 
· cEREBRAL OEDEMA 7 2 0 2 
- INFARCT 1 0 0 0 
- MENINGITIS 1 2 0 2 
- ANOXIA 4 2 2 4 
~l ABNORMALITY 13 6 2 8 
SPLENIC CONGESTION 4 1 2 3 
- INFARCT 2 0 0 0 
)1 ABNORMALITY 6 1 2 3 
Total number of patients in each group indicated in parentheses. 
x2 = statistical evaluation by Chi-square analysis. 
No significant differences demonstrated. 
cf = compared with 
,. 
0.014 
0.026 
0.044 
0.083 
'f 
'f 
0.442 
0.283 
5.877 
0.111 
'f 
0.014 
0.083 
'F 
.J. 
T 
'F 
0.292 
0.804 
'f 
'F 
'f 
0.0001 
'f 
'f 
0.014 
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For M+F. Bacterial pneumonia was an occasional complication. 
Reactive lymphoid tissue (in lymph nodes, intestine or spleen) typical of 
viral infection was also common3occurring in 75.7% (28/37) of all cases, and 
was equally distributed in the three groups. 
Pulmonary, renal and splenic congestion due to heart failure occurred with 
similar frequency in the three pathological groups, though hepatic congestion 
was almost significantly more common in M than in groups with F (p< 0 .10, ;> 0. 05). 
Renal (2), splenic (2) and cerebral (1) infarction was limited to patients 
with Malone. 
Evidence of shock, i.e. acute tubular necrosis and cerebral oedema and anoxia, 
was observed in all groups. 
There were no statistically significant differences in frequency between the 
three groups for any of the pathological conditions noted in Table 13.4. 
Comment 
Although the pathological involvement of organs other than the heart is well-
known i·n AM 155,230,171,279,262,361 h. h . d 1 . l ·f , tis aspect as receive itt e, i any, 
attention in EFE. The striking feature in this study is the equal prevalence 
of viral-induced pathology (mainly pu\monary and lymphatic) in patients with 
AM (19/22), EFE (5/7) or both (7/8). It is tempting to c9nclude that this 
evidence "proves" a common viralaetiology in both conditions. In patients 
with AM, it is reasonable to assume that the current viral infection is 
aetiological. But it is difficult in patients dyi~g soon after presentation 
with AM plus EFE, and especially with EFE alone, to equate the acute inflammation 
in non-cardiac organs with the more chronic fibroelastotic process in their hearts. 
It is more probable that patients with (sub-clinical) AM develop EFE in the 
course of time, and that an intercurrent infection precipitates its clinical 
expression. 
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3. CORRELATION WITH CLINICAL FINDINGS 
Detailed clinical data was available in 20 autopsy patients. 
- 3.1 ECG 
LVH on ECG, defined according to RVl and SV6 voltages (see page 24 ), was 
present in 2 of 14 patients with M, 2 of 4 with M+F and 1 of 2 with F. If 
the R/SVl ratio is included as a criterion for LVH, the proportion of patients 
with LVH increases to 4/14, 3/4 and 2/2, respectively. Although these numbers 
are too small for accurate evaluation, the greater frequency of LVH in the M+F 
and F groups compared with the M group was just short of statistical signifi-
2 
cance (X = 3.117, P< 0.10) 0.05). 
Other ECG abnormalities were equally distributed in the 3 groups, except 
that pathological Q waves (3 patients) occurred in th~ M group only. 
The incidence of autopsy-proved fibroelastosis in LVH negative and positive 
patients, classified as in Chapter 4, was also assessed (Table 13.5). The 
T~type classification (LVH status at the end of the study period or pre-
terminally) was included, since this represented the ECG findings closest in 
time to the autopsy data. 
The incidence of F, relative to the total number of patients in each group, 
was almost significantly greater in Group 2A than lA (p<.O.l0>0.05), and 
significantly greater in Group 2T than lT (p<.0.005). Similarly, relative 
to the total PM's performed, F was almost significantly more frequent in 
Group 2A than lA and in Group 2C than lC (p<0.10 ;>0.05), and significantly 
more frequent in Group 2T than 1 T ( p < 0. 05) • 
TABLE13.5Frequency of autopsy-proved EFE in patients without (Group H 
and with {Group 2) LVH on ECG on admission (A), at any stage (C) or 
terminally (T). 
NUMBER OF PATIENTS 
CATEGORY GROUP 0 x2 GROUP
0 
x2 GROUP
0 
x2 
lA 2A lC 2C lT 2T 
TOTAL F 2 4 1 5 1 5 
RELATIVE TO: 
TOTAL PATIENTS 92 31 3.673 71 · 52 2.768 96 27 10.361d, 
TOTAL DEATHS 28 12 2.698 20 20 1. 765 22 18 2.567 
TOTAL PM's 14 6 3.277 11 * 9 3.117 12 8 4.375 
0 = 
F = 
x2 = 
* = 
di = 
Clinical groups defined as in Chapter 
pathological endocardial fibroelastosis alone (2) or with myocarditis (4) 
statistical evaluation by Chi-square analysis 
difference significant at p.(0.05 
11 11 11 P< o. 005 
Connnent 
The correlation of EFE with LVH on ECG supports the conclusion of several 
authors 226 , 302 , 364 , 476 that this is the most helpful diagnostic sign for EFE. 
In autopsy-proved cases, LVH has been found in 10 of 14, 195 17 of 21, 368 19 
of 21, 352 20 of 23, 476 and 19 of 20466 cases. 
The fact that this correlation is strongest when LVH is present pre-
terminally, rather than on admission or transiently during the course 
(i) indicates that EFE is closely related to concurrent LVH, and 
(ii) suggests that EFE itself may be mild and reversible, contemporaneous-
ly with resolving LVH. 
Mild or sub-clinical EFE is supported by the demonstration of EFE at autopsy 
548 in 3.4% of infants with overtly normal hearts. Serial endomyocardial 
biopsies would be required to prove the resolution of clinical EFE. 
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3.2 PNEUMONIA 
Although pneumonia was confirmed in all 6 cases diagnosed radiologically 
during life, there were 10 additional cases from the clinical series not 
previously diagnosed. 
Conunent 
This finding emphasises the high frequency of clinically undetected viral 
disease in the lungs in all groups. 
3.3 SHOCK 
Clinical shock was previously diagnosed in 8 of 14 patients with M, and 2 
of 6 with F (both with M+F). 
Conunent 
• The prevalence of shock in patients with pathological myocarditis coincides 
with the high frequency in those with clinical myocarditis (see page 57 ). 
3: 4 OTHER FINDINGS 
Elevated blood urea and/or urinary abnormalities were detected pre-mortem 
in 5 of 13 patients with M, and 2 of 6 with F. Cerebral abnormalities were 
observed clinically in 2 patients with Mand 1 with M+F. 
• 
CHAPTER 14. 
CONCLUSIONS. 
The relationship, if any, between AM and EFE has perplexed paediatricians, 
cardiologists and pathologists for generations. It appears that no previous 
study has evaluated their possible relationship by a comprehensive clinical, 
natural history and pathological study of these two conditions, prospectively 
and simultaneously, over the long-term. 
A project of this nature was undertaken in Cape Town over a period of almost 
9 years and the findings are reviewed in the preceding chapters. The results, 
which are coordinated in this chapter, lead to support of hypothesis A 
"that AM and EFE represent different phases of the same disease process," 
and rejection of hypothesis B, 
"that either AM or EFE evolves into idiopathic chronic congestive cardiomyopathy 
in children." 
VALIDITY OF LVH ON ECG AS AN INDEX OF CLINICAL EFE 
Without histological evidence from endomyocardial biopsy, differentiation of 
clinical EFE from AM d7pends on the presence of LVH on ECG. The reliability 
. . . . 144 195 349 352 368 466 476 
of this sign has been emphasised by many authors, ' ' ' ' ' ' and 
( 
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was confirmed in this study 1n the limited number of patients with both 
pathological EFE at autopsy and pre-terminal ECG data (page 167), 
HYPOTHESIS A. 
1, EVIDENCE OF A RELATIONSHIP BETWEEN AM AND EFE. 
Evidence that AM and EFE represent stages of a corrnnon disease process is 
derived from the following information: 
1.1 EPIDEMIOLOGY 
A preponderance of Cape coloured patients was found in both AM and EFE 
(Chapter 4). Both conditions were thus prevalent in the socio-economically 
deprived section of the community. 
The relative increase in the number of patients with clinical EFE in the 
summer months, following the predominance of AM in late winter and spring, and 
the marked increase of EFE within 3 to 12 months of a major outbreak of AM, 
provided strong evidence of a link between these two conditions. The pattern 
favoured a common viral etiology with the evolution of EFE in time in a pro-
portion of patients who survived the initial insult, but failed to resolve 
completely. 
1.2 SIMILARITIES BETWEEN CLINICAL AM AND EFE 
Those features which showed no significant differences between AM and EFE 
on statistical analysis, are noted in Table 14.1 • 
.. · (a) 
(b) 
SYMPTOMATOLOGY: Symptoms prior to presentation were remarkably 
similar in patients with either AM or EFE, and favoured a preceding 
viral infection (Chapter 7). 
CLINICAL SIGNS: Various clinical signs occurred with similar 
frequency, notably pyrexia, pneumonia, hepatomegaly, pulmonary 
venous congestion, gallop rhythm and apical systolic murmurs 
(Chapters 6 and 7). 
TABLE 14.1 Conditions statistically analysed - no significant 
differences between clinical AM and EFE. 
RACE 
* CONDITION 
SOCIO-ECONOMIC BACKGROUND 
SEX 
SYMP'f'OMS: 
URT INFECTION 
SWELLING 
MALAISE 
GASTROINTESTINAL 
SIGNS: 
PYREXIA 
PNEUMONIA (radiological) 
HEPATOMEGALY 
PULMONARY VENOUS CONGESTION 
GALLOP RHYTHM 
SYSTOLIC MURMUR 
INVESTIGATIONS: 
ELEVATED WHITE BLOOD COUNT 
ELEVATED BLOOD UREA 
POSITIVE BACTERIAL CULTURE 
POSITIVE VIRAL YIELD 
EVIDENCE OF INFECTION 
ECG: 
ARRHYTHMIAS 
CONDUCTION ABNORMALITIES 
FRONTAL QRS AXIS DEVIATION 
ATRIAL ABNORMALITIES 
PATHOLOGICAL Q WAVES 
ST SEGMENT ELEVATION 
T WAVE FLATTENING 
SERUM ENZYMES: LDH, HBDH, CPK (mean) 
TREATMENT 
NATURAL HISTORY 
DURATION OF FIRST ADMISSION (mean) 
- SURVIVORS 
DURATION OF FOLLOW-UP 
MORTALITY 
RESIDUAL ABNORMALITIES 
CLINICAL 
RADIOLOGICAL 
ECG 
PAGE 
33 
36 
36 
63 
65 
65 
65 
67 
67 
54 
56 
57 
58 
73 
74 
76 
82 
83 
92 
95 
95 
96 
107 
109 
109 
116 
77 
82 
140 
145 
150 
152 
153 
URT = upper respiratory tract; JVP = jugu_lar venous pressure; 
CNS= central nervous system; LDH = lactate dehydrogenase; 
HBDH = hydroxybutyrate dehydrogenase; CPK = creatine kinase. 
*omitting conditions with insufficient numbers of affected 
patients for statistical analysis. 
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(c) ROUTINE INVESTIGATIONS: Elevated white blood counts and elevated 
blood urea levels occurred with similar frequency in AM and EFE 
(Chapter 7). 
(d) EVIDENCE OF INFECTION: Various clinical and laboratory parameters 
suggesting viral infection were equally prevalent in AM and EFE 
(Chapter~8). 
(e) ECG: There was a similar incidence in both conditions of 
(f) 
(g) 
(h) 
(i) 
• 
arrhythmias, conduction abnormalities, frontal plane QRS axis 
deviations, atrial abnormalities, pathological Q waves, ST segment 
elevation and T wave flattening, on admission and throughout the 
follow-up period (Chapter 9). 
SERUM ENZYMES: The frequency of abnormally elevated serum LDH, 
HBDH and CPK enzymes, the mean values reached, and their pattern 
of behaviour during the 3 week period after admission, were all 
similar in AM and EFE (Chapter 10). 
VIROLOGY: The overall yield of viruses by direct culture and 
serology was similar in both conditions (Chapter 11). 
MORTALITY: Overall mortality and survival curves during the 
entire study were similar in both conditions (Chapter 12). All 
deaths occurred within the first 13 months. 
NATURAL HISTORY: Resolution of clinical, radiological and electro-
cardiographic abnormalities in survivors was the rule in both AM 
and, contrary to previous reports, in EFE (Chapter 12). 
1.3 COEXISTENCE OF PATHOLOGIES 
Autopsy evidence in this study revealed that pathological features of both 
AM and EFE coexisted in 21.6% of cases (Chapter 13). 
Non-cardiac pathology reflected heart failure and shock, but evidence of 
viral infection (mainly pulmonary and lymphoid) was particularly connnon and 
equally prevalent in AM and EFE. 
2. EVIDENCE OF THE BIMODAL PRESENTATION OF A COMMON ENTITY 
Evidence that AM and EFE represent two phases of a single disease process is 
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derived from the following: 
2.1 EPIDEMIOLOGY 
The uniform, non-seasonal, pattern of presentation of EFE, as compared with 
AM, implies a di{ferent mode of presentation (Chapter 5). 
2. 2 DIFFERENCES BETWEEN CLINICAL AM AND EFE 
Statistically significant differences, which favour a bimodal presentation, 
are noted in Table 14.2. 
(a) CLINICAL FEATURES: The greater frequency on admission of sinus 
tachycardia, elevated jugular venous pressure, oedema or a com-
bination of signs of heart failure in patients with AM reflect 
a more acute presentation than occurs in patients with EFE 
(Chapter 6). This is emphasised by the· fact that almost all 
patients (18/19) presenting with acute shock had clinical AM. 
The greater incidence of central nervous system abnormalities 
in AM is probably due to acute hypotension in some cases, and 
to a virus which is neurotropic as well as cardiotropic in 
others (Chapter 7). 
Conversely, the greater degree of radiological cardiomegaly 
on admission in patients with EFE ,coincides with their less 
precipitous mode of presentation and slower evolution of 
cardiomegaly before presentation (Chapter 6). 
(b) ECG: Apart from LVH, which separates clinical EFE from AM (by 
definition), ST segment depression and deep T wave inversion also 
occur significantly more frequently in patients with EFE, and pro-
vide further evidence of severe and probably long-standing left 
ventricular strain (Chapter 9). 
(c) VIROLOGY: Although the yield and range of viruses was similar 
in both AM and EFE, those viruses known to be causative agents 
TABLE 14.2 Conditions statistically analysed - significant 
differences between clinical AM and EFE, favouring a bimodal 
presentation. 
SIGNS: · 
* CONDITION 
HEART RATE () 95th percentile) 
OEDEMA 
ELEVATED JVP 
MULTIPLE SIGNS OF HEART FAILURE 
SHOCK 
CNS ABNORMALITIES 
INVESTIGATIONS: 
0 RADIOLOGICAL CARDIOMEGALY (mean CTR) 
ECG: 
LVH 
ST SEGMENT DEP~ESSION 
DEEP T WAVE INVERSION . 
NATURAL HISTORY: 
DURATION OF FIRST ADMISSION (mean) 
- DEATHS 
READMISSIONS 
SIGNIFICANT+ 
DIFFERENCE 
AM'>EFE 
. AM>EFE 
AM>EFE 
AM>EFE 
AM)'EFE 
AM>EFE 
EFE>AM 
EFE only 
EFE>AM 
EFE>AM $ 
AM<EFE 
EFE>AM 
JVP = jugular venous pressur·e; CNS = central nervou·s system. 
PAGE 
54 
56 
54 
56 
57 
67 
60 
102 
109 
110 
82 
143 
* omitting conditions with insufficient numbers of affected patients 
for statistical analysis. 
+ in incidence unless otherwise stated. 
o on admission. 
~ autopsy-proved cases. 
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. . . ( . )69,36,155,196,171,230,262,280,309,391, in myocarditis enteroviruses 
520, 528 were isolated only in patients with clinical AM. The 
viruses detected in patients with EFE are unlikely to be causative, 
but appear to be associated with intercurrent infections which 
provoke the clinical expression of underlying EFE (Chapter 11) 0 • 
(d) MORTALITY AND NATURAL HISTORY: The shorter duration in hospital 
before death in patients with AM (Chapter 7), and the more 
frequent readmission rate in patients with EFE (Chapter 12), 
emphasize the acute mode of presentation in the former, and the 
more protracted course in the latter patients. 
2.3 LVH VARIABILITY 
Although accurate and reliable as a means of detecting concurrent EFE (see 
above), this study revealed that LVH on ECG may fluctuate considerably at 
different times (see Classification - Chapters 4 and 12). LVH commenced after 
presentation in as many as 40% (21/52) of all patients with LVH, and resolved 
in almost all survivors after a variable period of up to 48 months (Figure 9.1). 
Hence, the underlying EFE may itself be transient and reversible. 
2.4 PATHOLOGY 
In those patients who had histqlogical evidence of both AM and EFE at autopsy 
(section A.3), there was a tendency for the fibroelastosis to increase as inflam-
matory cell infiltration and myocardial cell necrosis decreased, in keeping with 
a progression from AM to EFE 255 , 467 (Chapter 13). These patients comprised an 
intermediate spectrum between isolated AM at one end and pure EFE at the other, 
thus favouring different modes of presentation of the same disease process, 
depending on the stage of pathology reached. 
Comment 
Although resolution of the extensive fibroelastosis described at post-mortem 
177 
• 
226 by many authors seem~ inconceivable, the observed fluctuations of LVH, the 
interim grades of EFE found in this and other series,
166
,
255
,
512
,
467 
and the 
d f . 1 1 . f h 
565 
. d. h 
reporte presence o EFE in apparent y norma in ant earts, in icate tat 
lesser degrees of EFE do exist and may well be reversible • 
., 
The relatiyely 
good long-term outlook for patients with EFE, and the occurrence of mixed 
pathology in this series, suggest that these patients present in an earlier 
phase of EFE than most previously reported cases. 
In order to confirm the dynamic nature of .EFE, and the correlation of EFE, 
with LVH on ECG, serial endomyocardial biopsies would ~e required, but this 
procedure was considered ethically unjustifiable when this study conunenced in 
1970. . . 
. . . . . 
· . 107,290, 
Although experience with this technique in chi_ldren is growing, 
162
,
167
,
331
,
418
,
284
,
451
,
377
,
406 its usefulness remains controversial. 146 ' 330 , 407 
3. OTHER SIGNIFICANT DIFFERENCES BETWEEN AM AND EFE 
Statistically significant differences between AM and EFE, which are not 
attributable to different modes of presentation, are noted in Table 14.3. 
3.1 AGE-RELATED DIFFERENCES 
(a) 
(b) 
CLINICAL: The increased frequency of grunting respiration in EFE 
in response to respiratory infection or pulmonary venous congestion 
(Chapter 7) is thought to be age-related, since this phenomenon is 
peculiarly prevalent in young infants. 
ROUTINE INVESTIGATIONS: The more severe anaemia in AM (Chapter 7) 
is probably a function of time, since these .patients present at 
an older age and may have been iron-deficient for longer. 
3.2 AGE AT PRESENTATION 
The seemingly parad9xical finding that patients with EFE are younger at 
presentation than those with AM, despite the fact that EFE is considered to be 
' 
TABLE 14.3 Conditions statistically analysed - other significant 
differences between clinical AM and EFE. 
* 
SIGNIFICANT+ 
PAGE CONDITION DIFFERENCE 
AGE (mean) EFE<AM 37 
SIGNS: 
GRUNTING RESPIRATION EFE>AM 63 
INVESTIGATIONS: 
HAEMOGLOBIN (mean) AM<EFE 71 
*omitting conditions with insufficient numbers of affected patients 
for statistical analysis. 
. ( + TABLE 14.4 Age in months mean ~sEM) according to 
(i) 
(ii) 
AUTOPSY 
Pathology at autopsy and 
LVH on ECG. 
EFE 
C4t 
+ 4.3 
-7 .13 
EFE + AM 
(7) + 
+11.1 
-4.21 
LVH · AFTER 
AM 
(22) 
+15.8 
-3.36 
LVH FROM ONSET PRESENTATION NO LVH (31) (20) * 
ECG +11.8 +16.3 
--
-2.65 
-3.32 
. 
Total number of patients in each group indicated in parentheses. 
+ 4 patients with long histories (group 4) omitted. 
* patient no 123 aged 144 months at presentation is omitted. 
(71) 
+21.5 
-2.67 
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a consequence of myocarditis, requires further consideration. In order to · 
explain this phenomenon, it is postul~ted that the tendency to develop EFE is 
itself age-~elated, the younger infant being specially predisposed to this 
condition. 
; 
This view gains credence from 3 findings: 
(i) Patients with autopsy-proved EFE + AM are older than those with EFE 
alone, and younger than patients with AM alone (Table 14.4), sugges-
ting that the potential for conversion of AM to EFE diminishes with 
increasing age. 
(ii) Patients who develop LVH on ECG afte.r presentation . are older than those 
with LVH ab initio, and younger than patients who remain LVH negative 
(Table 14.4), suggesting that the rate of pathological evolution of 
(iii) 
EFE decreases with increasing age. 
Since the peak incidence of EFE is in early infancy it is likely that 
the precursor condition (AM) occurs in-utero in some cases, and this · 
is borne out by case reports of EFE (without other cardiac anomalies) 
at birth.113,159,222,223,270,347,381 
The younger age of patients wi~h EFE, presenting months after an outbreak 
of AM, may be explained as follows. At the time of the seasona.l outbreak of 
AM, the increased prevalence of cardiotropic viruses in the community results 
in an increased incidence of mild or inapparent viral infections in, inter 
alia, mothers in late pregnancy and neonates and young infants. Such sub-
clinical infections have been described in the perinatal period in relation 
t C k . B , 69,247,213,311,562
 
o oxsac ie viruses. If associated myocarditis remains 
sub-clinical, EFE may be initiated pre- or post-natally at this stage ~and become 
clinically manifest in ensuing months • 
. 
l l 
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4. PAT OGENESIS OF EFE 
From the above evidence, the pathogenetic course of EFE in relation to AM 
can be represented diagramatically as follows: 
A 
DIE SURVIVE 
~ EFE RECOVER 
~ DIE RESOLVE 
5. SUMMARY 
In summary, therefore, patients with AM and EFE simulate each other in terms 
of racial and socio-economic background, symptomatology, clinical presentation, 
evidence of infection, ECG abnormalities, enzyme responses, overall yield of 
viruses, mortality rate, and natural history, while pathological features of 
both coexist in over 20% of cases. Significant differences point to a bi-
modal presentation, with a more acute onset in AM, severe LVH and strain (ECG) 
in EFE, and a particular predisposition of the young infant to EFE. The 
t1ansition between AM and EFE may be observed pathologically, and is reflected 
electrocardiographically. 
• I Although largely circumstantial, this evidence favours the hypothesis that 
AM and EFE are different phases of a common clinical entity, i.e. acute EMD. 
HYPOTHESIS B. 
This hypothesis is rejected on the basis of the .natural history data. 
Recovery was the rule for patients with either AM or EFE who survived beyond 
1 year. Even in the 9% of patients with residual abnormalities after follow-
up of all parameters for at least 1 year, the tendency was towards progressive 
improvement. Not a single patient displayed the myocardial deterioration with 
.. 
f I 
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time acteristic of congestive cardiomyopathy (COCM). Further follow-up 
of the recovered patients is required to exclude late-onset COCM, but AM and 
EFE are unlikely to be significant factors in the aetiology of this condition 
in children. 
This evidence~contradicts the claim that COCM in children is part of a 
spectrum of primary myocardial disease (including AM and EFE) resulting from 
195 injury to cardiac muscle. It is argued that COCM should be regarded as 
a separate entity from acute onset EMD wherever possible, and not as a diffe-
d f . f . . 1 d. . 43o . h AM d rent mo e o presentation o a singe con ition int e same way as an 
EFE until further investigation establishes its aetiology. 
SPECULATION. 
The main purpose of this study was to establish whether a relationship 
existed between AM and EFE, and not to investigate the specific aetiology of 
either condition. However, from the above conclusions it is possible to 
derive a comprehensive theory for the pathogenesis of EFE,which incorporates 
several of the factors discussed in the introductory review. 
It is recognised that EFE may occur in infants with diverse conditions other 
than viral. Common to most is the possibility of (acute) cardiac dilatation 
pre- or post-natally. Probably because _the atrial and ventricular walls are 
still relatively thin, especially on the left side, the myocardium of the foetus 
and young infant appears to be specially predisposed to (acute) dilatation. 
In consequence, the individual responds to the (sudden) increase of myocardial 
and especially endocardial tension72 ' 254 by the deposition of elastin65 and 
f .b · 65 , 249 · 1· . h d'l . d d h i rous tissue, in an attempt to imit t e i atation an ecrease t e 
energy expenditure which is required to maintain cardiac function. In this 
353 
way, the normal cardiac output is usually maintained in the early stages . 
( '. 
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When the precipitating stimulus is removed, the endomyocardial pathology may 
progress to cause the death of the patient or, if less extensive, may resolve 
in time. 
. . 96 48 394 255 Hence, EFE is essentially a non-specific pathological reaction ' : ' ' 
254 d. d. 1 . h d. 1 d . 46 7 to severe car iac i atation, rather tan to myqcar ia egeneration or 
to a product of viral metabolism. 313 , 477 Such endomyocardial distention may 
b d b 1 . l . l . 48,255,446 e cause y mu tip e aetio ogies. Although particularly prone to 
. 1 109 develop in the foetus and young infant, ' in whom AM is a common precursor, 
EFE does occur in adolescents 25 •483 •526 , 460 and adults 254 ,ZOl,Z89 subjected to 
similar haemodynamic stress, but is pathologically less extensive. 153 
1 1 . . . l . . 167,327,328 U trastructura studies of EFE in endomyocardia biopsy specimens, 
389 reported recently be Neustein et al, encourage the belief that EFE is a 
reactive phenomenon following stimulation of smooth muscle cells. These cells 
undergo proliferation, 153 •475 and then transformation into fibroblasts 444 via 
· d. 1 · ·d 11 d d · d 1 · 445 d 11 interme iate eiomyoi ce s, an pro uce increase e astin an co agen. 
A difference in elastic fibres between congenital and acquired EFE 153 could 
not be evaluated. 
It is possible that a similar response to dilatory stress in early gestation 
may lead to the development of EFE, with interruption of further growth and 
maturation resulting in the so-called contracted variety of EFE, usually with 
associated left-sided cardiac anomalies. 
These concepts are purely derivative and require further investigation, but 
it is believed that an approach which is mutually inclusive, rather than 
exclusive, of the wide array of conditions associated with EFE is more likely 
to solve the aetiological and pathogenetic mysteries of acute EMO in infants 
and children. 
'While from the bounded level of our mind, 
Short views we take, nor see the lengths behind, 
But more advanced, behold with strange surprise 
New, distant scenes of endless science rise! 
An Essay on Criticism. 
Alexander Pope. 
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\ APPENDIX D. 
ECG ABNORMALITIES 
KEY TO ABBREVIATIONS (with limits of normality) 
(ST) = SINUS TACHYCARDIA (beats/minute) (PR+) = PROLONGED PR INTERVAL (seconds) 
< 3 months : >190 <. 1 month :;>.0.12 
3 to< 12 months : >180 1 to< 12 months : >0.14 
12 to<36 months : >160 12 to< 60 man ths : >0.15 
36 to< 60 months : >140 60 to <96 months : >0.16 
)60 months : >120 ~96 months :)0.17 
(LAD) = LEFT AXIS DEVIATION 
(<lower limit) 
(RAD) = RIGHT AXIS DEVIATION 
()upper limit) 
Normal limits 
7 days to< 1 month 
1 to <3 months 
3 to< 12 months 
12 to< 60 months 
60 to< 96 months 
~96 months 
00 -
20° -
20° -
00 -
-20° -
00 ... 
160° 
120° 
100° 
100° 
100° 
80° 
(Pla) = LEFT ATRIAL STRESS (Pra) = RIGHT ATRIAL HYPERTROPHY 
Bit°id or notched P waves 
in lead 2, Vl and/or other 
leads. 
(Q) ·· = PATHOLOGICAL Q WAVES 
)>2 nnn x)0.03 seconds - any lead 
Peaked P waves in lead 2 or 
right chest leads; 
< 12 months 
12 to< 36 months 
~36 months 
:>2.5 nnn 
: >3.0 mm 
:>2.Snnn 
or>S nnn x)0.02 seconds - leads I, AVL, Vl-6 
(T+) = DEFINITE T ABNORMALITY 
T waves inverted 
and/or flattened (< 1 mm) 
and/or biphasic 
in both VS and V6 
,: 
(T!) = SUSPECTED T ABNORMALITY 
T waves inverted 
and/or flattened (<. 1 mm) 
and/or biphasic 
in one of VS or V6 
(ST+) = ST SEGMENT ELEVATION (ST-) = ST SEGMENT DEPRESSION 
(SVl) 
> 2 nnn - limb leads 
and/or>3 nnn - praecordial leads 
OR 
.>1 nnn with coved ST segment 
- limb leads 
and/or>2 nnn - praecordial leads 
with other abnormalities 
(i.e. Q, Tor LVH) 
= LVH by~ voltage in Vl {RV6) = LVH by~ voltage in V6 
<6 months 
~ 
°':>' 6 months 
>20 mm 
> 25 nnn 
< 1 month : >20 nnn 
1 month to <6 months : )'25 nnn 
~6 months >30 mm 
(R/S) = Suspected LVH by R/S ratio in Vl 
(N) = 
(RVH) = 
(BVH) = 
(ARY) = 
(VPS) = 
(APS) = 
(WPW) = 
. 1 to <36 months 
36 to <60 months 
)60 months 
NORMAL 
: .(0. 25 
:< 0.20 
: < 0.10 
RIGHT VENTRICULAR HYPERTROPHY 
BIVENTRICULAR HYPERTROPHY 
ARRHYTHMIA 
VENTRICULAR PREMATURE SYSTOLE 
ATRIAL PREMATURE s·YSTOLE 
WOLF-PARKINSON-WHITE SYNDROME 
----- ---------·----------· 
CASE ECG ABNORMALITIES AND NO TIMING OF ECG AFTER ADMISSIOI'! 
Id Id Id 2m 3m 7m 12m !Sm IBm 21m 26m 29m 
I PR+ - - N N N N N N N N N . ., 
-
RAD -
P.la P.la P.la 
Q Q Q 
T+ T+ T+ 
ld 3d Sd D 
2 RAD RAD RAD I P. la - -
- ST+ -
Id Id Sd 7d 9d 16d 21d 23d 24d 28d 37d 41d D 
3 Q - - - - - - - - - - -
- - - - - -
ST+ ST.f - ST+ - -
- -. - - -
- ST- ST- - - - -
t+ T+ T+ T+ T+ , T+ T+ T+ T+ T+ T+ T+ 
ld 2d 3d Sd Bd lld D 
4 - - - - PR+ 
RAD RAD RAD RAD RAD RAD 
- - - -
ST+ ST+ 
- ST- ST- ST- ST- -
T+ T+ T+ T+ T+ T+ 
- - RVH RVH - BVH 
- - - -
RV6 -
ld 4d IOd 19d lm , 2m 2.Sm 3m 3.3m 3.Sm 4m 4.3m , 6m 7.Sm 7.Bm 
s ARY ARY ARY ARY ARY - - ARY ARY ARY ARY - N ARY ARY 
- - - - - -
PR+ - - - - PR+ - -
(LAD) (LAD) (LAD) (LAD) (LAD) - - (LAD (LAD) (LAD) (LAD) - (LAD) (LAD) 
- (ST+) (ST+) (ST+) (ST+) - - - - - - - - -
(ST-) (ST-) (ST-) (ST-) (ST-) - - (ST- (ST-) (ST-) (ST-) - (ST-) (ST-) 
T+ T+ - T+ T+ T.+ - - - - - - - -
RV6 
'\ 
CONT. Bm B.Sm 12m ISm 19m 28m 
ARY ARY ARY ARY ARY ,\RY 
{~AD) (LAD) (LAD) (LAD) (LAD) (LAD ) 
(ST-) (ST-) (ST-) (ST-) (ST-) 
8d !Od 24d D I 
6 ,· T+ - - l 
2d Sd 13d 3m 4m Sm 9m 15m 17m 59m. 
7 P.la P.la P. la - P. la N N N N N 
T+ + T- T+ T+ T+ 
-Id Id 2d 3d 8d !Od lm D 
8 
- - - ST - - -
P.la P.la - - - - -
- -
ST+ ST+ ST+ - -
T+ T+ T+ T+ T+ T+ T+ I 
... 
I 
! 
- - ~--------·------ ---.>...----- ----· ------ '----- - - --- ---
-,-. 
' ,, 
I 
Id 4d IOd I Id 12d 17d 18d 
9 ARY ARY ARY ARY ARY ARY ARY 
- - - - T+ T+ T+ 
- - - - - - -
- - - - - - -
39d D 
. ARY 
T+ 
-
ld 9J 3m 6m Jim I Sm J 8ru 
10 LAD LAD LAD LAD LAD LAD !..AD 
P.la P.la P.la - - - -
P.ra - - - - - -
T+ T+ T+ T+ T+ T+ . T+ 
ld ld 2d 3d Sd 6d 14d 
II - ARY - ARY ARY - -
- - P.la - - P. la P.la 
ST+-.. - ST+ - - ST+ ST+ 
ST- - - .: - - -
T+ T+ - - - - -
ld Sd 14d 4m Sm 9m 171'1 
12 - - LAD LAD LAD LAD -
P.la P.la - - - - -
-ST+ ST+ - - - - -
- - SVI - - - SVI 
Id D 
13 P. la 
ST+ 
7d D 
14 P. la 
T! 
Id 6d 14d Im 4m 
15 ST - - - ST 
- - - - RAD 
- P.la - P. la -
+ + T+ T- T- - -
I ' 
-Id D 
16 + T-
Id Id 3d 3d 4d 6d 7d 
17 - S'f - - - - -
- - - - - - -
Q - - - - - -
ST+ ST+ ST+ - - - -
ST- ST- - - - - -+ T+ T+ T+ T- - - -
R/S - R/S R/S R/S R/S R/S 
I 
!._ 
_. ------ ----- - ---· · ---~-- --- --·--- --- -
19d 21,d 
ARY ARY 
- -
- -
- -
22m 
LAD 
-
-
-
Im 
N 
29m 
N 
IOd 12d 
- -
- -
- -
- -
- -
- -
R/S R/S 
---- ·-
,._ 
--- -------
I 
' 
25d 26d 27d 31d 33d .JSd 
ARY ARY ARY ARY ARY ARY 
- - - - - -
SVI SVI - - SVI -
- RV6 - RV6 - -
I 
' 
Im 2m t.w 6m 9m D 
- - - - -
- - - - ARY 
- - - - -
- - - -
ST+ 
- - - - ST-
-
.. 
- - -
R/S R/S R/S R/S -
. 
- ------- -·- ·- ---- ---
"\ 
, I 
' . 
' } 
·---· -
.. 
Id Id 3m Sm 7m D . 
. 18 ST - - - -
LAD LAD LAD LAD -
P.la - P.la - P. la 
- - -
Q -
-
ST+ - - -
-
ST- - - -
T+ - - T+ T+ 
-
SVI SVI SVI SVI 
-
- - - RV6 
Id Id D 
19 - ST 
- RAD 
- P. la . 
- P.ra 
'- ST+ 
T+ T+ 
R/S -
)d . 16d 26d 2.2m 2.Sm 2. 6m Sm 7m 16m 37m 42m 45m Slm SSm 
20 - LAD - - \.., -
-
- N - - - - - -
- - -
- - - - - -
PR+ PR+ PR+ PR+ 
- - -
P. la - - - - P. la - - - -
- - - -
- - -
- ST+ - - - -
.T+ T+ T+ T+ T+ T+ T+ T+ T+ T+ T+ T+ -
- - -
R/S R/S - - - R/S - - - -
Id 14d JSd 2Sd 1. Sm I. Sm 2. Sm 4. Sm 27m 33m 
21 · RAD RAD RAD RAD RAD RAD RAD RAD RAD RAD 
- - - -
- - - -
PR+ PR+ 
+ + + T+ T+ T+ T+ . T- T- T+ T- T+ -
Id 2d Sd 9d 16d 2m 40m 
22 RAD - - - - - N 
- P. la P.la P.la P. la P.la '\ 
T+ T+ T+ T+ T+ T+ 
- SVI SVJ SVJ SVJ SVJ 
- R/S - - - -
Id 7d IS<l I . Sm 2.Sm 6m Sm I Im 13m 17m 19m 22m 25m 2Sm 63m 
23 - - - - - - - - - - N N N PR+ N + 
r+ T+ T+ T- T+ T+ T+ T+ T+ T+ -
- SVJ SVI - - - - - - - -
R/S R/S R/S R/S - R/S R/S R/S R/S - -
Id D 
24 T+ 
R/S 
Id Id 2d JOd 17d 2m 7m IOm 13m 22m 25m 29m 35m SOm 6:i.m 
25 ST - - - N . N N ST N N N N N N N 
I ST+ ST+ - - -
I T+ T+ T+ T+ -
! 3d 6d IOd 4m 30m 
! 26 P. l a P. l a P. la - N j 
: s:r+ - - -
! T+ 
-
T+ 
-
... 
' 
- - - R/S 
Id Id id 4d 6d 8d 20d 
27 PR+ - - - - - -
LAD. - LAD LAD LAD LAD LAD 
P.la P. la P.la P.la P.la P. la P.la 
- - - ST+ - ST+ -
T+ T+ T+ T+ T+ T+ T+ 
- - - - - - R/S 
Id D 
28 ST 
RAD 
T+ 
Id 2d 
29 P. la -
+ T- T+ 
ld D 
30 P.la 
+ T-
R/S 
Id 3d 5d II d 4m 8m I Im 
31 ST - - - N N N 
- - - -
P.la P. la P. la P.la 
T+ - - T+ 
. 
CONT. 40:n 46m 52m 60m 72m 
N N - N N 
PR+ 
Id 2d 3d 4d 7d 9d 15d 
32 - - - - - - -
P.ra - - - - - . -
- P.la P.la P.la P.la - P. la 
- - - - Q Q Q 
ST+ ST+ ST+ ST+ ST+ ST+ ST+ 
ST- - -
- - - -
T+ T+ T+ T+ T+ T+ T+ 
R/S R/S - - R/S - R/S 
CONT. 15m 21m 26m 
- - PR+ 
P.la - -
-
T+ 
-
ld 15d 25d 2m 6I!' 
33 RAD - - - N 
P.la P. !a P.la -
P.ra - - -
Q - - -
ST+ ST+ ST+ ST+ 
- ST- ST- ST-
T+ T+ T+ T+ 
- SVI SVI -
- R/S - -
t~ 
~ . . 
·- -----
--- --
--·- --· - ·- -~ ---.__ ... 
Im 1.3m 
- -
LAD LAD 
P.la P.la 
ST+ ST+ 
T+ 
-
R/S -
I 
/ 
14m 19m 
N N 
21d lm 
- PR+ 
- -
P.la P.la 
Q Q 
- -
- -
T+ T+ 
- -
.. 
- ·--- --
.. 
.. 
1. 8m 9m 
- N 
LAD 
-
-
-
. 
R/S 
-
72m 25m 28m 31m 32m 
- N N N N 
PR+ 
-
-
1.2m 2m 6m 9m )Om 
- LAD RAD N -
-
- - -
P. la - P.la P.la 
Q Q Q -
- - - -
- - - -
1'+ T+ 
- -
- - - -
- ----~.-- - -- -~---
· - -
33m 
N 
J lr:1 
-
-
P.la 
-
-
-
-
-
~---··· 
I 
\ 
. 
l j 
.i 
i 
J 
l 
i 
' ' i 
I 
-· 
- ·--
-·· .. . -
- ---
... 
ld D 
34 ST 
. 
., 
P.la 
ST+ 
T+ 
R/S 
Id D 
35 ST 
Q 
ST+ 
ST-
T+' 
Id Id 2d 3d 6d 7d 8d 13d Im I . 7m -Sm 9m 12m !Sm 18m 
36 - RAD - - N N N - N N - N N N N 
-P~la - - - - -+ T+ T+ T- - - -
-
- SVJ SVI - -
- - - -
RV6 RV6 
.. 
CONT. 20m 23m 27m 32m 3Sm 38m 44m I 77m 
N N N N N I 
. N N N 
Id D 
37 ST 
Q 
ST- -
T+ 
R/S 
Id 3d 9d 
38 T+ T+ T+ 
Id D 
39 ST 
RAD "\ ' 
P.la -
T+ 
-
Id Sd 8d I Id 3m Sm Sm I Sm 21m 
40 ST - - - N N N N N 
RAD - RAD RAD 
- P. la - P. la 
-
ST+ - -
T+ T+ - T+ 
Id Id 2d I .Sm !Om 16m 19m 22m 2Sm 28m 34m 40m 82m 
41 ST - - - N N - - - - - - N 
RAD RAO RAD - - - - - - -
P.la P. l a P. la P.la - - - - - -
T+ T+ T+ T+ T+ - - - - -
- - R/S R/S R/S R/S R/S R/S .R/S R/S 
-
i____: ----· --- - - .____ ---- -~ --- -·- ---- · ·- - --
- - -- • • L.,_____ . _ _ ---
-- -
I I . 
I 
2d 3d 4d 6d 9d 2m 
: 42 ST - - - - -
- - - - - PR+ 
RAD RAD RAD RAD RAD RAD 
- - ·- - - -
- P.la P.la P.la P.la P.la 
Q Q Q - Q 
-
T+ T+ T+ T+ T+ T+ 
Id Im Sim 70m 
43 RA~ RAU N N 
T-
-
.. 
Id Id 2d 4d 8d IOd 
44 ST ARY - -
- -
RAD - - - - -
- - - - - LAD 
·- ST+ ST+ ST+ ST+ ST+ 
' T+ T+ T+ T+ T+ T+ 
R/S - R/S R/S R/S R/S I 
I 
CONT. 32m 38m I 60m 
- - N 
R/S R/S 
Id Id Sd 7d 12d 2.Sm 
, 45 
.. 
- ST 
- - - - S'r 
I ST+ ST+ - -
- -
- ST- - - - -
T+ 
- T+ T+ 
- T+ 
- SVI SVI SVI SVI -· 
; 
! Id 2d 3d 8d 9d lld 
46 · ST - - - N -
I RAD - - -
-
j - - LAD LAD LAD 
i 
- ST+ - ST+ 
-
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APPENDIX G 
DURATION OF FOLLOW-UP AND OUTCOME 
Key: Clinical - A= alive, N = normal, (N) = probable normal, D = dead, 
/=no further follow-up or transferred 
+ X-ray - N = normal, -N = probable normal (CTR 55% to<:60%), 
C = cardiomegaly (CTR) 60%) 
ECG - N ~ normal, "N" = minor changes, i.e. residual QRS axis deviation 
or increased R/SVl ratio, Ahn= persistent LVH, atrial abnormality, 
ST-T wave changes or arrythmias 
ON DIG= duration, (x) intermittent, /=patient discontinued treatment 
d = days, m = months - = treatment continuing 
CASE DURATION OUTCOME 
NO CLINICAL X-RAY ECG CLINICAL X-RAY ECG ON DIG 
1 50ml 25m 29m A-N N N 15m 
2 49d 42d 5d D N "N" 42d 
3 45d 37d 41d D C Abn 45d 
4 13d 9d lld D C Abn 13d 
5 43m 31m 28m A-N C Abn 43m-
6 164d 53d 24d D C N 5m 
7 59m 49m 59m A-N :tN N 31m 
8 46d 44d lm D C Abn 46d 
9 39d 39d 39d D +c Abn 39d 
10 30ml 14m 22m A-N :-N "N" 24m 
11 3ml 27d lm A-N +c N 3m-
12 29ml 18m 29m A-N -N N 9m 
13 26d 21d ld D C Abn 26d 
14 8d ld 7d D +c Abn 8d 
15 12m/ 12m 4m A-N -N "N" 6m 
16 2d ld ld D +c Abn 2d 
17 268d 6m 9m D -N Abn 9m 
rs 210d 7m 7m D(>270d) C Abn 9m 
19 ld ld ld D C Abn ld 
20 76m 53m 58m A-N N "N" (43m) 
21 32m 23m 32m A-RVH* C "N" 16m 
22 80m 80m 40m A-N N N (14m) 
23 63m 29m 63m A-N N N 25m 
24 ld ld ld D C Abn ld 
25 63m 29m 63m A-N N N (35m) 
26 31m 31m 31m A-N +N N 31m 
27 lOm/ 7m 9m A-N -N N lOm-
28 ld ld ld D C Abn ld 
29 9ml 9m 2d A-N !N Ahn 29d/ 
30 4d 2d ld D +c Ahn 4d 
31 72m 52m 72m A-N· -N N 31m 
32 26ml 23m 26m A-LVH + "N" 26m--N 
33 6m/+ 6m 6m A-N N N 6m-
34 ld ld ld D N Abn ld 
35 ld ld ld D C Abn ld 
36 77m 77m 77m A-N N N 44m 
37 ld ld , ld 
.D +c Abn ld 
38 23d/ 23d 9d A-LVH -N Abn 23d/ 
39 ld - ld D - Abn -
40 21m 21m 21m A-(N) N N 2lm-
CASE DURATION OUTCOME 
NO CLINICAL X-RAY ECG CLINICAL X-RAY ECG ON DIG 
41 82m 65m I 82m A-N N N 25m 
42 37ml 32m 37m A-N N "N" llm 
43 70m 59m 70m A-N N N • Sm/ 
44 70m ., 70m 60m A-N N N 35m 
45 64m 64m 64m A-N N. N 31m 
46 39ml 6m 31m + 39m-A-N -N N 
47 60d 48d 48d D C Abn 60d 
48 35m 30m 30m A-N N Ahn 34m 
49 68d 38d 35d D C Ahn 68d 
50 36m 33m 36m A-N !N N 33m-
51 92m 50m 92m A-N N N 29m 
52 6m/ 26d 4.5m A-N !N Abn 6m-
53 65m 53m 65m A-N + 20m -N N 
54 70d 63d 2m D C Ahn 70d 
55 30ml 30m . 5.5m A-N C "N" 2m/ 
56 9ml 7m 8m A-N C N 9ml 
57 21m/ 7m 6m A-N N N 9m 
58 104m 43m 72m A-N N "N" 54m 
59 49m 49m 30d A-N !N Abn -
60 96m 93m 96m A-N N N 48m 
61 64m 64m 53m A-N N N 31m 
62 22d 19d 19d D C Ahn 22d 
63 ld ld ld D · c Abn ld 
64 ld ld ld D C Abn . ld 
65 60m 60m 60m A-N N N 8m/ 
66 95m 95m 93m A-N N N 14m 
67 59m 40m 59m A-N N N 29m 
68 ld ld ld D C Ahn ld 
69 31m 30m 23m A-(N) N N (32m) 
70 70m 52m 70m A-N +N N 28m 
H 70m 33m 56m - A-N -N N (25m) 
72 28m 24m 24m A-(N) C N 16in 
73 2m/+ 29d 2m A-(N) !N "N" 2m-
74 40m 12m 12m A-N N N 2m/ 
75 7d ld 3d D !N Abn 7d 
76 4m/+ 3m 3m A-N !N N 4m 
77 88m 88m 76m A-N + (65m) -N N 
+ 78 71m 71m 44m A-N -N N 16m/ 
79 34d/+ 30d 6d A-N N "N" 34d-
80 63m 39m 63m A-N +N N 27m 
81 14m 6d 17d A-N -N N 9d/ 
82 16m/ 13m 8m A-N N N 16m 
83 52m 13m llm A-N !N N 20m 
84 73m 49m 60m A-N N N 22m 
85 33m 13m 12m A-N + Ahn 38d/ -N 
86 56m 30m 46m A-N !N "N" 50m 
87 57m 32m 57m A-N +N N 35m 
88 24m 24m 24m A-N -N N lOm/ 
+ 89 18m 7m 14m A-N -N N 18m 
90 18m l?m 18m A-N N N 10m 
. 
CASE DURATION OUTCOME 
NO CLINICAL X-RAY ECG CLINICAL X-RAY ECG ON DIG 
91 72d 66d 66d D +c Ahn 72d 
92 40m 14m 40m ·A-N -N N 15m 
19d/ A-(N) + Ahn .19d/ 93 4d 6d -N 
64d 1.- 48d 1.6m Ahn 64d 94 D C 
95 65m 65m 65m A-N ·N Ahn 3ml 
96 ld ld ld D +c Ahn ld 
97 47m 3m 20d A-N -N Ahn 3m-
.. 98 84m 84m 84m A-N N "N" 14m 
99 62d 2m 14d D C Ahn !3od/ 
100 65m 23m 53m A-N N N 23m 
101 26d 24d 8d D C Ahn 26d 
102 18m 8m 16m A-N +c N 18m-
103 51m 41m 51m A-N -N N 4lm-
104 152d 4m 4m D +c Ahn (Sm) 
105 78m 56m 68m A-N -N N 68m 
106 8m/ 54d 8m A-LVH N N 8m/ 
107 41d 20d 5d . D C Ahn 25d 
108 32m/ 32m 2m A-LVH C Abn 32m/ 
109 ld ld ld D C . Ahn ld 
110 216d 6m 6m D C Ahn 7m 
111 42d 40d 40d D C Abn 42d 
112 386d llm llm D - C Ahn (13m) 
113 55m 46m 55m A-N · N "N" 27m 
114 58m 58m 58m A-N N N (20m) 
115 53m 33m 53m A-N N N 27m 
.116 61m 61m 59m A-N N N 25m/ 
117 71d 25d 2.2m D C Abn 71d 
118 19m/+ llm 7d A-N C Ahn 19m-
119 9d 7d 3d D C Ahn 9d 
120 68m 68m 32m A-N +N N 20m 
lZl 52m 35m 52m A-SM0 -N "N" (33m) 
122 22m/ 22m 22m A-N N Ahn (13m) 
123 55m 55m 55m A-N N Ahn 2ml 
* Clinical signs of atrial septal defect. 
~ Transferred to referral centre (Richmond, Transkei, . Posmashurg, Namaqualand and 
Transkei,respectively). 
o Apical systolic murmur of trivial mitral incompetence. 
' -
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21 
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APPENDIX H . 
CARDIOTHORACIC RATIO 
The admission, maximal, minimal and final cardio-
thoracic ratio (as a p~rcentage) for each patient, and the 
time after prese~tation when obtained. 
NO. OF 
ADMISSION MAXIMAL MINIMAL FINAL X-RAYS 
61.0 61.0 - 0/A 49.4 - 25m 49.4 - 25m 9 
64.2 66.7 - 10d 54.6 - 42d 54.6 - 42d 5 
65.0 66.9 - 36d 62.5 - 37d 62.5 - 37d 7 
71.6 71.6 - 0/A 68.2 - 9d 68.2 - 9d 3 
77. 2 77.2 - 0/A 59 .4 - 13m 61.0 - 31m 7 
54.3 63.3 - 10d 54.3 - 0/A 60.9 - 53d 7 
60.8 63.5 - 9m 57.4 - 49m 57.4 - 49m 6 
84.7 84.7 - 0/A 62.7-lld 73.0 - 44d 7 
67.9 67.9 - 2d 63.1 - 10d 65.5 - 39d 4 
61. 7 63.3 - 51d 54.2 - 9d 58.3 - 14m I 1 
63.1 68.8 - 4d 57.0 - 7d 60.6 - 27d 13 
65.6 65.6 - 0/A 57.3 - 18m 57.3 - 18m 7 
62.1 67.2 - 21d 62.1 - .0/A 67.2 - 21d 5 
66.3 66.3 - 0/A 66.3 - 0/A 66.3 - 0/A I 
57.4 61. 2 - 5d 56.7 - 12m 56.7 - 12m 5 
64.7 64.7 - 0/A 64.7 - 0/A 64.7 - 0/A 1 
58.9 58.9 - 0/A 54.4 - 17d 56.8 - 6m 5 
68.2 79.7 - 7m 68.2 - 0/A 79.7 - 7m 5 
66.9 66.9 - 0/A 64.3 - ld 64.3 - ld 1 
59.6 68.9 - 70d 49.7 - 53m 49.7 - 53m 22 
62.5 64.9 - 10m 61.1 - 10m 61. 9 - 23m 6 
72.8 72.8 - 0/A 52.9 - 80m 52.9 - 80m 4 
65.9 65.9 - 0/A 50.0 - 29m 50.0 - 29m 6 
67.9 67.9 - 0/A 66.4 - ld 66.4 - ld 2 
73.2 73.2 - 0/A 51.4 - 25m 52.9 - 29m 7 
75.0 75.0 - 0/A 53.2 - 31m 53.2 - 31m 4 
60.4 60.4 - 0/A 58.0 - 34d 58.7 - 7m 5 
60.3 60.3 - ld 60.3 - ld 60.3 - ld 1 
57.8 66.2 - 12d 55.0 - 12d 55.6 - 9m 9 
59.5 62.5 - 2d 59.5 - 0/A 62.5 - 2d 3 
66.2 66.2 - 0/A 54.4 - 4m 56.9 - 52m IO 
61. 2 61.2 - 0/A 59.1 - 23m 59.1 - 23m 2 
64.6 64.6 - 0/A 54.4 - 6m 54.4 - 6m 4 
60.1 60.1 - 0/A 51.6 - ld 51.6 - ld 2 
69.2 69.2 - 0/A 69.2 - 0/A 69.2 - ld 1 
75.0 75.0 - 0/A 51.8 - 30m 54.8 - 77m 15 
60.9 60.9 - 0/A 60.9 - 0/A 60.9 - ld 1 
61. 7 61.7-0/A 50.7 - 4d 57.l - 23d 4 
* - - - - -
56.6 61. 2 - 5d 53.6 - 21m 53.6 - 21m 4 
62.8 63 • .3 - 28m 51.0 - 65m 51.0 - 65m 16 
7.3. 2 73.2 - 0/A 53.2 - 32m 53.2 - 32m 2 
CASE NO. OF 
NO ADMISSION MAXIMAL I MINIMAL FINAL X-RAYS 
43 56.4 56.4 - 0/A 49. 2 - 37m 52.9 - 59m 6 
44 61.1 63.9 - Sm 53.7 - 70m 53.7 - 70m 7 
45 62.2 65.6 - 12d 52.6 - 64m 52.6 - 64m 5 
46 63.1 
. 
63.1 - 0/A 56.3 - 6m 56.3 - 6m 5. 
47 65.6 65.6 - 0/A 61.7 - 48d 61. 7 - 48d 3 
48 57.9 64.5 - 4m 52.6 - -30m 52.6 - 30m 15 
49 63.9 63.9 - 0/A 61.3 - 38d 61. 3 :.. 38d 4 
50 74.7 78.5 - 15m 59.5 - 33m 59.5 - 33m I I 
51 61.3 64.5 - 40d 48.7 - 50m 48.7 - 50m I I 
52 56.4 63. 3 - lld 49.1 - 12d 57.2 - 26d 7 
53 64.5 64.5 - 0/A 57.6 - 58d 59.0 - 53m 3 
54 67.3 69.2 - 63d 67.3 - 0/A 69.2 - 63d 2 
55 68.5 68.5 - 0/A 60.0 - 30m 60.0 - 30m 2 
56 70.9 70;9 - 0/A 58.9 - 7m 58.9 - 7m 4 
57 51.5 56.8 - 17d 51.5 - 0/A 52.3 - 7m 7 
58 63.7 66.9 - 64d 52.4 - 43m 52.4 - 43m 15 
59 62.1 68.4 - 30d 59.9 - 49m 59.9 - 49m 5 
60 56.7 56.7-0/A 50.8 - 81m 50.8 - 93m 2 
61 68.0 68.2 - 80d 53.2 - 64m 53.2 - 64m 9 
.. 
62 60.4 70.5 - 14d 58.9 - 2d 61.5 - 19d 6 
63 67.4 67.4 - 0/A 67.4 - 0/A 67.4 - 0/A 1 
64 71. 9 71.9 - 0/A 68.5 - ld 68.5 - ld 2 
65 71. 2 71.2 - 0/A 49.7 - 58m 50.8 - 60m 5 
66 63.1 63.1 - 0/A 49.2 - 78m 52.8 - 95m 3 
67 65.8 65.8 - 0/A 46.2 - 40m 46.2 - 40m 8 
68 67.7 67.7 - 0/A 67.7 . - 0/A 67.7 - 0/A 1 
69 72.0 72.0 - 0/A 49.7 - 30m 49.7 - 30m 8 
70 59.3 61. 7 - 6d 52.2 - 52m 52.2 - 52m 7 
71 60.0 62.9 - 6m 56.0 - 12m 56.8 - 33m 9 
72 68.3 68.3 - 0/A 60.4 - 24m 60.4 - 24m 9 
73 64.6 64.6 - .0/A 59.6 - 29d 59.6 - 24d 6 
·74 61. 9 63.5 - 28d 54.1 - 12m 54.1 - 12m 8 
75 59.1 59.1 - 0/A 59.1 - 0/A 59.1 - 0/A 1 
76 60.8 60.8 - 0/A 48.2 - 9d 59.8 - 3m 7 
77 63.0 64.5 - 51d 53.3 - 70m 55.1 - 88m 8 
78 65.1 65.1 - 15d 47.8 - 44d 56. 7 - 71m 9 
79 63.4 66.5 - 2d 58.8 - 21d 61.5 - 30d 7 
80 59.4 59.6 - ld 50.6 - 80m 50.6 - 80m 8 
81 64.3 64.3 - 0/A 55.6 - 6d 55.6 - 6d 4 
82 63.5 64.6 - 25d 53.4 - 13m 53.4 - 13m 8 
83 73.9 73.9 - 0/A 50.3 - llm 55 .6 - 13m 9 
84 67.8 67.8 - 0/A 50.0 - 19m 54.7 - 49m 3 
85 67.8 67.8 - 0/A 55.3 - 7d 57. 9 - 13m JO 
86 56.'9 62.2 - 2d 53.3 - 10m 55.5 - 30m 7 
87 62.0 65.6 - 3m 51. 7 - 22m 52.9 - 32m 6 
88 66.3 66.3 - 0/A 56.7 - 38d 57.7 - 24m 5 
89 66.9 69.7 - 41d 55.7 - 7m 55.7 - 7m 7 
90 64.4 64.4 - 0/A 50.0 - 0/A 51.5 - 18m 3 
91 57.8 72.0 - 43d 57.8 - 0/A 68.6 - 66d 9 
92 62.9 63.3 - 6m 53.0 - Sm 57.1 - 14m 6 
93 67.8 07.,8 - 0/A 57.3 - 4d 57.3 - 4d 3 
CASE 
NO ADMISSION MAXIMAL MINIMAL 
94 72.1 72.1 - 0/_A 61.1 - 21d 
95 66.4 66.4 - 0/A 54.9 - 65m 
96 68.3 68.3 - 0/A 68.3 - 0/A 
97 59;4 59.4 - 0/A 49.6 - 43d ., 
98 65.7 66.9 - ld 47.1 - 84m 
99 68.1 69.4 - 2m 68.1 - 0/A 
100 69.2 69.2 - 0/A 52.6 - 23m 
101 68.6 68.6 - 0/A 67.9 - 24d 
102 71.9 71.9 - q/A 59.3 - 21d 
103 62.2 62.7 - 2d 58.4 - 41m 
104 70.2 70.9 - 4m 55.8 - 3m 
105 71.9 71.9 - 0/A 53.2 - 44m 
106 56.0 56.3 - 40d 50.8 - 9d 
107 61.3 62.8 - 9d 60.0 - 20d 
108 70.7 75.2 - 8m 69.7 - 4m 
109 63.8 63.8 - 0/A 63.8 - 0/A 
110 68.7 78.7 - 6m 67.7 - 27d 
111 57.6 68.2 - 4d 57.6 - 0/A 
11_2 78.3 80.0 - 11m 69.2 - Sm 
113 62.2 62.2 - 0/A 47.9 - 11m 
114 71.3 71.3 - 0/A 54.1 - 57m 
115 72.6 72.6 - 0/A 48.3 - 27m 
116 69.2 70.6 - 6m 54.6 - 61m 
117 68.4 68.4 - 0/A 62.4 - 25d 
118 79.3 79.3 - 0/A 61.1 - 11m 
119 71.5 71.5 - 0/A 65.2 - 3d 
·120 68.9 68.9 - 0/A 51. 4 - 12m 
121 67.8 67.8 - 0/A 56.3 - 35m 
122 67.2 67.2 - 0/A 51.1 - 16m 
123 55.1 64.8 - ld 53.6 - 55m 
.. 
d = days; m = months; 0/A = on admission. 
* a No x-ray taken (see page 
. . 
.,. 
NO. OF 
FINAL X-RAYS 
64.6 - 48d 5 
54.9 - 65m 6 
68.3 - 0/A 1 
55.2 - 3m 10. 
47 .1 - 84m 12 
69.4 - 2m 2 
52.6 - 23m 6 
67.9 - 24d 2 
62.1 - 8m 9 
58.4 - 41m 6 
70.9 - 4m I 3 
55.3 - 56m 14 
53.9 - 54d 6 
60.0 - 20d 3 
71.1 - 32m 4 
63.8 - 0/A 1 
78.7 - 6m 8 
62.3 - 40d 4 
80.0 - 11m 5 
53.7 - 46m 4 
54.1 - 57m 11 
51. 9 - 33m 8 
54.6 - 61m 17 
62.4 - 25d 2 
61.1 - 11m 5 
69.1 - 7d 3 
52.4 - 68m 9 
56.3 - 35m 3 
53.5 - 22m 3 
53.6 - 55m 5 
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STATISTICS 
The following statistical methods were extensively used throughout the 
treatise. 
1. CHI-SQUARE TEST (X2) 
For testing the significance of differences between expected and observed 
frequencies. Since only 2 frequencies were compared in all instances, the 
so-called 2x2 fo~mat was applied, i.e. 
. 2 
(be - ad) k, 
efgh 
where a,b, and c,d are the variables, and e,f,g,h and k are the 
totals, in the following table 
a C e 
b d f 
g h k 
Yates's correction was applied in all analyses, whereby 0.5 was added to each 
compartment less than expected, and subtracted from each compartment greater than 
2 the expected value. X tables were consulted, at 1 degree of freedom, to assess 
probability (p) of significance. 
2. STUDENT'S T-TEST FOR UNPAIRED DATA 
For testing the significance of differences of means of 2 unpaired series of 
data. 
The t-statistic was derived as follows, 
t = (X - X) / SE 1 2 
------------------------------
where SE= 
Student's t tables were consulted at (N1 - 1) + (N2 - 1) degrees of freedom 
to assess probability (p) of si$nificance. 
VARIANCE RATIO TEST was applied to confirm that standard deviations of the 
2 populations were not significantly different. 
3. LI~ AR REGRESSION (Chapter 10 only). 
9 JAN 1980 
Line of identity correlating 2 sets of paired samples was derived from 
the formula, 
y =Ax+ B, 
where B = ~xy ~x) (:ii') 
n 
2x2 - ~)2 
.n 
4. CORRELATION COEFFICIENT (Chapter 10 only). 
The correlation coefficient was derived from the formula, 
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